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Abstract 
The complex nature of upper limb function presents a challenge for rehabilitation 
following neurological injury.  Some patients, with relatively mild injury, have potential 
to recover useful function such as the ability to use the hand to hold and manipulate 
objects (active function).  Others with more severe injury will continue to have a non-
functional upper limb, and may require assistance from another person (or their own 
non-affected arm) to care for the affected limb (passive function).  The aim of this thesis 
was to develop and evaluate a self-report upper limb measure of active and passive 
function – the Arm Activity measure (ArmA) for use in focal spasticity management.   
 
A systematic review demonstrated that no suitable measure was available, but provided 
possible items for inclusion in the ArmA.  Patient-selected items were also included 
from goal setting for spasticity intervention.  A modified Delphi consultation was 
undertaken to reduce the number of items, followed by item confirmation with a larger 
group of clinicians and pilot testing with patients and carers.  The resulting twenty-item 
measure has two sub-scales of ‘active’ and ‘passive’ function. 
 
Two inter-linked studies were undertaken, firstly to evaluate the psychometric 
properties of the ArmA, and secondly to undertake a hypothesis-generating cohort 
investigation of the course of functional changes following spasticity intervention.   
 
Internal consistency evaluated by Cronbach’s alpha was >0.85 for both sub-scales.  
Kappa coefficients for test-retest reliability were >0.90.  Mokken analysis demonstrated 
unidimensionality for both subscales (Item H >0.5 for all items).  Expected convergent 
and divergent relationships were seen with comparison measures (rho 0.5-0.63).  The 
passive function sub-scale was responsive to change following spasticity intervention.  
In the cohort study, spasticity initially reduced following intervention and then 
increased again.  Passive function improved and was maintained despite the increase in 
spasticity. 
 
Adequate psychometric properties were demonstrated for the passive function sub-scale 
although further evaluation is indicated, particularly for the active function sub-scale. 
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because of the upper motor neurone syndrome contributing 
to limb stiffness. 
Deterministic Matching exactly of the functional form of the item 
characteristic curve to the Guttman model.   
Effect size The ratio of the mean difference to the standard deviation 
of baseline scores.   
Environmental factors 
 
Environmental factors make up the physical, social and 
attitudinal environment in which people live. 
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Feasibility The property of an outcome measure indicating it is suitable 
for routine clinical use. 
Generalisability The extent to which findings (from a study) can be 
generalised (or applied) to real-life. 
Guttman scaling Items are arranged in an order so that an individual who 
agrees with a particular item also agrees with items of lower 
rank-order.  
Health outcome  The effect of intervention in relation to the achievement of 
an intended health goal.   
Homogeneity The unidimensionality of a set of items. 
Idiographic Term to describe measures that are developed from the 
perspective of the individual. 
Impairments 
 
Impairments are problems in body function or structure such 
as a significant deviation or loss. 
Internal consistency Refers to the interrelatedness of a set of items. 
Interpretability The degree to which qualitative meaning can be assigned to 
quantitative scores. 
Interval Interval data are data that have an equal distance between 
measurement points, but with no absolute zero.  For example 
temperature in degrees Celsius. 
Item Characteristic 
Curve 
Describes the relationship between a latent trait and 
performance on an individual item. 
Likert scale A response scale usually with between five and seven points 
used in questionnaires e.g. strongly agree, agree, undecided, 
disagree, strongly disagree. 
Measurement Quantification of an observation against a standard. 
Minimal important 
change 
The smallest difference in score in the domain of interest 
which patients perceive as beneficial and would mandate, in 
the absence of troublesome side effects and excessive cost, a 
change in the patient’s management. 
Muscle weakness Reduced muscle power as a result of the upper motor 
neurone syndrome. 
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Nominal Data that is simply placed into categories and can therefore 
be counted but not measured. 
Nomothetic Measures, which are useful in describing a population as a 
whole. 
Ordinal Ordinal data are data placed in rank order.  For example, 
most preferred food to least preferred food.   
Participation Involvement in a life situation. 
Participation 
restrictions 
Problems an individual may experience in involvement in 
life situations. 
Passive function Where a task is carried out on the affected upper limb by the 
individual using the unaffected upper limb or by a carer e.g. 
cleaning the palm of the hand or armpit, cutting fingernails 
or positioning the arm. 
Physical therapy Physical interventions used in rehabilitation practice to 
affect the physical state. 
Physiotherapy The health profession of physiotherapy, using interventions 
often of a physical nature to positively affect people in need 
of rehabilitation or physical management. 
Probabilistic The probabilistic version of the Guttman curve allows small 
variations from the model, but requires that data still largely 
conform to the model. 
Real-life To evaluate function in the context of everyday activities. 
Ratio Ratio data are data that have an equal distance between 
measurement points and have an absolute zero.  For example 
height or weight. 
Responsiveness The ability of an instrument to measure a meaningful or 
clinically important change. 
Reliability The degree to which a test measures the same attribute each 
time it is used.   
Self-report Self-administered and Patient Reported Outcome Measures 
(PROMs). 
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Sensitivity The ability of an instrument to measure change in a state 




The proportion of actual positives correctly identified by a 
test when compared against actual outcome. 
Spasms Sudden involuntary, and often painful, movements.  
Precipitated by passive stretch, but may also be triggered by 
peripheral, noxious and visceral afferents. 
Spasticity Disordered sensory-motor control, resulting from an upper 
motor neurone lesion, presenting as intermittent or sustained 
involuntary activation of muscles. 
Spastic dystonia Abnormally increased muscle tone present at rest. 
Specificity The proportion of actual negatives correctly identified by a 
test when compared against actual outcome. 
Standardised response 
mean 
The ratio of the mean change (in a single group) to the 
standard deviation of the change scores. 
Stochastic Allowance for some variability in the shape of the Item 
Characteristic Curves functional form.   
Unidimensionality The degree to which all items in a measure evaluate aspects 
of the same construct.   
Validity The degree to which a test measures what it is intended to 
measure.   
Ecological Validity The degree to which the results in a study reflect the 
activities that actually occur in real-life. In addition, 
ecological validity is associated with generalisability.  
Face validity The degree to which the test looks as though it is measuring 
what the test is supposed to measure. 
Concurrent validity  The comparison of the new measure with an existing gold 
standard measure both applied at the same time. 
Construct validity The degree to which a test measures the theoretical ideas 
underpinning a particular topic. 
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Content validity The degree to which the test measures the overt 
manifestations of the theory.  
Positive predictive 
value 
The proportion of those identified by a test that actually have 
responded to intervention.  
Negative predictive 
value 
The proportion of those not identified by a test that have 
actually not responded to intervention. 
Predictive validity The degree to which responses to the test can predict future 
behaviour or events. 
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Chapter 1 Introduction  
 
1.1 Clinical context  
This thesis arose from a clinical challenge in the field of neurological rehabilitation.  
The challenge involved the management of spasticity in the hemiparetic upper limb and 
measurement of outcome in a manner meaningful to patients and their carers.    
Guidelines for the management of upper limb spasticity have highlighted the 
importance of measuring the impact of interventions at the level of improved function 
and care needs (Royal College of Physicians 2002; Royal College of Physicians et al. 
2009).  However, a need has been identified to re-conceptualise measurement of upper 
limb function from the perspective of patients and carers. 
 
The manipulative function of the hand and arm is an ability, which sets humans apart 
from other primates.  Humans use the upper limb for a wide range of complex activities, 
which include different combinations of grasping, twisting, pulling, pushing, reaching 
and lifting.  The wide range of movement at the shoulder and elbow allow the 
positioning of the hand optimally for manipulation, and humans have developed a high 
level of fine motor control.  Because of this complexity, when control of upper limb 
movement is lost, it is difficult to restore.  
 
Neurological damage to the brain, for example as a result of stroke or trauma, typically 
leads to paralysis or weakness of the opposite side of the body (hemiparesis), which 
may be partial or complete.  In the early stages after injury, the affected limbs are often 
flaccid (low-toned paresis), but after a few weeks muscle tone may start to return and 
can lead to the development of muscle over activity or ‘spasticity’.  Spasticity will often 
have unwanted effects, such as pain and result in secondary problems such as muscle 
stiffness and contracture.  Even if return of active movement occurs, spasticity may still 
interfere with the fine motor coordination required for highly skilled tasks.   
 
The complex nature of upper limb function presents a particular challenge for 
rehabilitation following neurological injury.  Some patients, with relatively mild injury, 
have the potential to recover useful ‘active function’ of the hand and/or arm (see Box 
1.1).  Others with more severe injury will continue to have a non-functional upper limb, 
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and may require assistance from another person (or from their own non-affected arm) to 
care for the affected limb, for example to maintain hygiene, dress or support the arm.  
This has been called ‘passive function’ (see Box 1.1). 
 









When evaluating the success of rehabilitation interventions such as spasticity 
management with botulinum toxin (BTX), the diversity of presentation poses a major 
challenge for outcome measurement.  A further challenge arises from the need to 
evaluate function in the context of everyday real-life activities, as opposed to simply 
what is possible to observe during a clinic attendance.  Self-reported outcome measures 
are gaining popularity as a means of capturing the impact of intervention for the 
individual in the context of their normal lives (Greenhalgh et al. 2005).  They also offer 
the possibility to obtain follow-up information at a distance, and avoid unnecessary 
clinic visits. 
 
This thesis centres on the development and initial evaluation of a self-report outcome 
measure for assessing both active and passive function in the hemiparetic upper limb – 
the Arm Activity measure (ArmA).  The ArmA is then applied as an outcome measure 
in the context of a focal intervention for upper limb spasticity using botulinum toxin 
(BTX) and physical therapy (PT) interventions (see Glossary). 
 
This introductory chapter will: 
 Present a framework for describing the impact of health conditions at different 
levels of patient experience – the World Health Organisation (WHO) 
International Classification of Functioning Disability and Health (ICF). 
Active function: Where a functional task is performed by active movement of the 
individual’s affected limb e.g. to reach for, grasp or manipulate objects. 
 
Passive function: Where a task is carried out on the affected upper limb by the 
individual using the unaffected upper limb or by a carer e.g. cleaning the palm of the 
hand or armpit, cutting fingernails or positioning the arm. 
(Sheean et al. 2010)  
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 Describe the effects of upper limb hemiparesis and the upper motor neurone 
syndrome in terms of that framework. 
 Provide a brief overview of the clinical challenges in management and 
rehabilitation of the hemiparetic upper limb as it relates to the focal management 
of spasticity. 
 Describe the physical interventions applied in rehabilitation of the upper limb, 
which have specifically been related to spasticity management. 
 Explore the various measures currently used to assess the outcome of 
interventions within the activity level of the ICF. 
 Examine the extent to which the existing literature has or has not demonstrated 
functional gains from such intervention, and explore some possible reasons for 
this. 
 
1.2 Consequences of neurological damage 
The International Classification of Functioning, Disability and Health (ICF) published 
by the WHO in 2001 can be used as a classification system to describe the 
consequences of neurological damage (WHO 2002).  A further development of the 
original International Classification of Impairments, Disabilities and Handicap (ICIDH) 
(WHO 1980; WHO 2002) resulted in the ICF which classifies the consequences of 
disease as; impairment to body structure and physiological function, activity limitations 
(previously termed disability) and participation restrictions (previously termed 
handicap).   
 
The ICF provides a model to describe the impacts of a health condition on a) the body, 
b) ability to perform activities, and c) participation in society within the context of 
personal factors relating to the individual and the environment in which they live and is 
shown in Figure 1.1 (WHO 2002; Stucki et al. 2007).   
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(WHO 2002)  
 
Application of the ICF provides a basis for rehabilitation practice and research with a 
standardised language to discuss the impact of disease incorporating participation, 
activity, and body systems.  The World Health Assembly approved the ICF in 2001 and 
referred to rehabilitation in a resolution in 2005 (Stucki et al. 2007).  The ICF has been 
widely used in rehabilitation practice and Stucki and colleagues have proposed that it 
provides a common framework to describe rehabilitation outcome, which is useful to 
both clinical practice and research (Stucki et al. 2007).  It offers a common language to 
both communicate and describe the wider impact of disease processes.  The category of 
activity is particularly important in rehabilitation where the primary outcomes of 
intervention are functional, and measurement at this level of the ICF is therefore 
needed.  Table 1.1 shows examples of some of the common problems experienced by 
people with neurological damage affecting the upper limb, categorised using the ICF. 
Health Condition 






Body Structure & Function                                  Participation 
 (Impairments)              (Disability)   (Handicap) 
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Table 1.1 Upper limb problems experienced by people with neurological damage 
ICF domain Problems experienced 
 





















Difficulty with caring for the limb: 
 Maintaining hygiene 
 Cutting fingernails 
 Dressing 
 
Unable to use the upper limb for active tasks: 
 Lifting, carrying 
 Reaching 
 Manipulating objects 






Loss of employment 
Inability to engage in leisure activities 
 
 
Whilst it is useful as a conceptual framework, the ICF contains some terminology that 
can be confusing.  The ICF uses the term ‘activity’ to describe the impact of impairment 
on function for an individual.  The term ‘function’ can be confusing in the context of the 
ICF because it is primarily used to refer to the ‘function of the body’ rather than 
activity.  However, in common parlance function is principally used to describe activity.  
For the purposes of this thesis, the term function is used when referring to activity or 
aspects of activity unless otherwise specified.  The ICF will be used as a conceptual 
framework to assist in understanding the context for measurement of upper limb 
function in hemiparetic individuals undergoing treatment for focal spasticity who have 
diverse presentations and goals.   
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1.2.1 Upper limb problems after stroke and brain injury 
Upper limb impairment after central nervous system damage includes muscle weakness, 
spasticity, poor co-ordination and often sensory impairment (Geyh et al. 2004).  Such 
impairments can result in functional restrictions to many activities of daily living (ADL; 
also see Glossary), such as washing, dressing or eating.  Up to 70% of patients with 
stroke admitted to hospital, are identified to have arm weakness (Nakayama et al. 1994) 
and 60% have a “non functional” arm (Wade et al. 1983).  Between 50% and 70% have 
long-standing restriction in arm function (Wade et al. 1983; Nakayama et al. 1994). 
 
The upper motor neurone syndrome 
The group of motor impairments resulting from damage to the central nervous system 
are termed the upper motor neurone syndrome (UMNS) (Thompson et al. 2005; 
Stevenson and Jarrett 2006).  The UMNS is divided into positive and negative features 
(Pandyan et al. 2005; Thompson et al. 2005).  Positive features are those characterised 
by muscle over activity and negative features by under activity (see Table 1.2).  
  
Table 1.2 Positive and negative features of the UMNS 
Positive features Negative Features 
Spasticity Muscle weakness 
Spastic dystonia Loss of dexterity 




Associated reactions  
(Pandyan et al. 2005; Thompson et al. 2005) (See Glossary) 
 
The positive features of the UMNS are individually defined as follows:  Spasticity as a 
clinical problem is often challenging to define and to manage (Pandyan et al. 2005; 
Thompson et al. 2005) but is characterized by involuntary muscle over-activity (see 
next section).  Spastic dystonia is increased muscle activity at rest presenting as 
abnormal postures, such as the constantly clenched fist (Thompson et al. 2005).  Co-
contraction is needed for many normal movements, but becomes abnormal if both 
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agonist and antagonist contract with similar force and prevent movement (Stevenson 
and Jarrett 2006).  Associated reaction, refers to involuntary activity of a body part, 
which occurs in response to voluntary movement elsewhere (Stevenson and Jarrett 
2006).  In patients with hemiparesis, this commonly occurs when the person is walking 
and the affected arm progressively flexes at the elbow.  Clonus is a rhythmic pattern of 
contraction occurring at a rate of several times per second and can also occur with a 
sudden stretch to muscle (Stevenson and Jarrett 2006).  Clonus is a positive feature of 
the UMN syndrome, which is not often a primary concern for management, particularly 
in the arm, but may be associated with other positive features. 
 
Spasticity 
Spasticity presents in a variety of ways depending on the size, location and age of the 
lesion, and may have associated unwanted effects such as pain, deformity and impaired 
function (Burke et al. 1988).  Data on the prevalence of spasticity are varied, but it has 
been reported in 38% of patients at 12 months after stroke (Watkins et al. 2002), 
although Sommerfeld and colleagues reported prevalence as low as 19% at 3 months 
after stroke (Sommerfeld et al. 2004).  Spasticity has been defined by Lance in 1980 as:  
 
“...a motor disorder, characterised by a velocity-dependent increase in tonic 
stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from 
hyper-excitability of the stretch reflex as one component of the upper motor 
neurone syndrome” (Lance 1980).  
 
However, the SPASM consortium, a European thematic network to develop 
standardised measures of spasticity (Pandyan et al. 2005), have more recently proposed 
a broader definition: 
 
“Disordered sensory-motor control, resulting from an upper motor neurone 
lesion, presenting as intermittent or sustained involuntary activation of muscles” 
 
This broader definition incorporates the positive features of the UMNS, but still 
excludes the negative features and biomechanical changes to muscle and associated 
structures.  The authors argue that, in so doing, it is more clinically relevant.   
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Unfortunately, there remains no consistent and universally accepted definition of 
spasticity in use by researchers and clinicians.  In practice, some clinicians and 
researchers refer to spasticity as hyperactive stretch reflexes, while others discuss a 
clinical presentation, which incorporates hyperactive stretch reflexes, other aspects of 
the UMNS as well as biomechanical changes to muscle and connective tissue.  
However, for the purposes of this thesis the broader SPASM definition of spasticity will 
be used. 
 
If spasticity is not managed effectively, affected muscles adopt a shortened position 
with corresponding contribution to abnormal limb and trunk posture (Barnes 2003).  
This may result in soft tissue shortening and biomechanical changes in the contracted 
muscles (Pope 2002).  Resistance to passive movement in muscle (following 
neurological insult) may be due to spasticity, thixotropy or contracture (Vattanaslip et 
al. 2000).  Thixotropy is stiffness in muscle, which is dependent on the history of the 
limb movement (Vattanaslip et al. 2000).  If muscle is not moved, there is a tendency 
for it to become stiffer and therefore more resistant to movement.  If movement is not 
undertaken for long periods of time contracture will also develop.  Contracture 
represents physical shortening of the muscle and other soft tissues around the joint (e.g. 
joint capsule), with loss of passive range of movement, which is irrespective of 
thixotropy or spasticity (Vattanaslip et al. 2000).  However, contracture may also cause 
some stiffness towards the end of range of movement.  Prevention of contracture and 
minimisation of thixotropy are therefore important in management of an immobile 
hemiparetic upper limb. 
 
In addition, spasticity may also be painful for two reasons.  First the over activity of the 
muscle itself can be painful (similar to ‘cramp’) because of the strength and duration of 
contraction (Stevenson and Jarrett 2006).  Second, the resulting mal-alignment can 
cause pain by adversely stressing interconnecting muscle tissue and joint structures 
(Thompson et al. 2005).  Figure 1.2 shows the clinical impact of arm spasticity at the 
shoulder, elbow, wrist and hand. 
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The left arm is extended and adducted at the shoulder, flexed at the elbow, supinated at 
the forearm, with the fingers flexed into the palm of the hand. 
 
Figure 1.3 represents the relative contributions of the positive features of the UMNS 
and biomechanical changes seen in the clinical presentation. 
 

























Chapter 1 Introduction 
 33 
1.2.2 Management of spasticity in the hemiparetic upper limb 
Clinical management should address spasticity where it is causing harm to the patient’s 
care provision; function, pain or risk of further deterioration exists, but should not treat 
spasticity indiscriminately without the possibility of meaningful benefit (Bhakta 2000b; 
Barnes 2003; Thompson et al. 2005).  For example, the implication of spasticity in the 
hand may be in leading to contracture in the long finger flexors.  The resulting difficulty 
in cleaning the palm of the hand may lead to maceration of skin tissue in the palm.  Risk 
of secondary contracture and damage to the skin would warrant intervention to prevent 
this and management of spasticity is indicated.  In contrast, if spasticity is present as a 
symptom without other adverse effects then intervention is not warranted. 
 
At a clinical level, treatment will often be concerned with management of spasticity and 
other features of the UMN syndrome such as spastic-dystonia, co-contraction, and 
associated reactions (Stevenson and Jarrett 2006).  The combined intervention package 
will also address other issues, such as joint range of movement (passive or active 
function) and task retraining (active function) (Thompson et al. 2005).  In some patients 
who have active function goals, the negative UMN feature of weakness, will be the 
main issue addressed by both task training and specific strengthening (Thompson et al. 
2005).    
 
Spasticity may be focal (localised to a specific anatomical area affecting one or two 
muscle groups), regional (affecting the whole limb e.g. arm) or generalised (affecting 
the whole body) (Bergfeldt et al. 2006; Royal College of Physicians et al. 2009).  The 
main approach to management has often been passive stretch, which is thought to both 
maintain structural length of muscle and inhibit expression of spasticity through an 
inhibitory effect on the stretch reflex (Thompson et al. 2005). 
 
The evidence for physical interventions to manage contracture and muscle shortening is 
limited.  The aim of such intervention is to counteract the dominant posture, which may 
lead to muscle and soft tissue shortening if unchecked.  Passive movement, active 
movement or interventions such as splinting or casting can achieve muscle stretch.  The 
possible advantage of splinting or casting is that they produce stretch of a longer 
duration than manual passive movement alone (Stevenson and Jarrett 2006; Lai et al. 
2009).   
Chapter 1 Introduction 
 34 
 
However current reviews have not supported splinting and casting applications in the 
upper limb for maintaining muscle length particularly in the acute period immediately 
following insult (Katalinic et al. 2010; Tyson and Kent 2010).  The primary sources of 
evidence in the reviews included all patients with a paretic limb, the majority of whom 
would not normally be considered for splinting intervention particularly acutely.  The 
lack of difference between the intervention and control groups is therefore not as 
surprising as it first seems.  In addition, an acknowledged weakness of a number of the 
included studies was that patients often did not receive the intended splinting dosage 
(Lannin and Herbert 2003; Lannin et al. 2007).  The majority of trials reviewed in both 
of these systematic reviews were examining patients in the more acute phase after 
stroke and therefore differences may be seen in patients in a more chronic state.  The 
effectiveness, methods and dosage required with physical interventions of this type are 
yet to be adequately identified and may also contribute to changing views on 
effectiveness (Katalinic et al. 2010).   
 
Physical interventions may be sufficient to inhibit the development of contracture in 
muscle and soft tissue in some cases of upper limb spasticity (Stevenson and Jarrett 
2006; Lai et al. 2009), although this is yet to be clearly demonstrated by research studies 
(Katalinic et al. 2010; Tyson and Kent 2010).  However in moderate to severe 
spasticity, pharmacological treatment may be needed to support an effective 
management programme as an adjunct to physical intervention such as splinting 
(Stevenson and Jarrett 2006).  For focal spasticity the pharmacological intervention of 
choice is intramuscular botulinum toxin (BTX) injection (Royal College of Physicians 
2002; Royal College of Physicians et al. 2009).   
 
Generalised spasticity interventions will weaken all muscles, not just those that have 
spasticity.  Therefore, focal interventions may also be desirable when: 
a) Weakening of other muscles may lead to adverse consequences, such as trunk 
weakness effecting sitting balance, dysphagia or weakening respiratory muscles.   
b) Muscle activity is wanted in opposing muscle groups to re-educate movement 
resulting in active function improvements.   
Focal interventions are therefore particularly useful in these circumstances and the 
measurement of the functional effect of such intervention is a particular focus of this 
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thesis.  Figure 1.4 summarises the overall management strategy and is adapted and 
updated from the Royal College of Physicians guideline document (Royal College of 
Physicians et al. 2009).   
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Generalised and segmental interventions are included but ‘greyed out’ to emphasis the 
focal interventions, both physical and pharmacological, of interest in this thesis. 
 
Botulinum toxin (BTX) intervention for focal spasticity 
Focal interventions such as BTX have an advantage over systemic interventions in 
targeting specific muscles and are therefore less likely to increase weakness in other 
muscles (Stevenson and Jarrett 2006; Royal College of Physicians et al. 2009).  In the 
minority of patients receiving spasticity intervention where improvement in active 
function is possible, reducing spasticity may restore a more normal balance of motor 
control and, in combination with task practice, may lead to improved active function.   
 
BTX is a neurotoxin which acts by blocking transmission pre-synaptically at the 
neuromuscular junction (Barnes 2003; Dressler et al. 2005).  The toxin is produced by 
Clostridium botulinum and strains of the bacterium have been identified as producing 
seven distinct toxins labelled A–G (Hambleton and Moore 1995).  Toxin-A is the 
serotype that has been developed into a therapeutic agent and widely applied in clinical 
practice and research (Elia et al. 2009; Royal College of Physicians et al. 2009).  Other 
serotypes have also been developed for use and botulinum toxin-B is available, but is 
less frequently applied in management of spasticity in the upper limb due to its shorter 
duration of action (Davis and Barnes 2000; Brashear et al. 2004). 
 
BTX is used to manage spasticity by relaxing targeted muscles, inducing paralysis or 
partial paralysis.  Reduction of spasticity allows stretching techniques such as splinting 
to reduce any biomechanical component affecting muscle and connective tissue length.  
The BTX itself is only effective in reducing the neurogenic component of spasticity 
(Royal College of Physicians 2002; Royal College of Physicians et al. 2009).  There are 
therefore two key pre-requisites for the successful use of BTX in management of 
clinical spasticity: 
 
 There must be a significant component of muscle spasticity, which can be reduced 
 An appropriate programme of stretching including splint application, passive 
stretching program or movement re-education to maintain muscle length for passive 
function or retrain active function must follow injection (Royal College of Physicians et 
al. 2009). 
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Reduction in spasticity or other positive features of the UMN syndrome does not 
directly lead to functional improvement (Bakheit 2004a).  It may allow passive function 
change to occur, by improving the ease of carrying out care tasks, because muscles and 
joints become easier to move.  In some cases, active function may be improved by 
enabling muscle stretch and thereby facilitate re-education of movement (Royal College 
of Physicians 2002; Royal College of Physicians et al. 2009; Wissel et al. 2009).  
Alternatively, active function may potentially improve if spasticity is masking selective 
control.  However reducing spasticity alone is unlikely to lead to improvement in 
function in the absence of other intervention (Sheean 2001; Royal College of Physicians 
et al. 2009).   
 
Elia and colleagues conducted a recent systematic review and meta-analysis of BTX 
intervention for post stroke spasticity (Elia et al. 2009).  They concluded that: 
 “Botulinum toxin A reduces upper limb spasticity in patients post stroke, but the 
improvement in functional ability remains to be established.  This gap needs to be filled 
by new studies to assess the effect of BTX in the context of multidisciplinary patient 
management” (p 801). 
 
There are a number of possible reasons for the failure to demonstrate functional 
improvement in clinical trials: 
a) Lack of appropriate concomitant therapy to maximise the functional 
improvements (in many studies concomitant interventions are poorly described). 
b) Failure to specify in advance the types of gains (passive or active) that are likely 
to be achievable – which will vary from patient to patient. 
c) Lack of suitably focused measures to capture the gains that occur (passive and 
active). 
d) Measuring at the wrong time points.  Functional changes may take longer to 
develop than improvements in spasticity, because they depend on both reduction 
of spasticity and improvements resulting from physical interventions. 
e) In the case of active function, failure to identify appropriate patients who may 
benefit. 
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Functional improvement following BTX is therefore not universally accepted and 
requires further exploration.  In addition, the application of physical interventions (such 
as splinting) in combination with BTX, the specific roles these interventions have and 
the resulting improvements achieved also need more investigation. 
 
Physical therapy (PT) intervention in combination with BTX 
PT is used in this thesis to describe physical intervention used in rehabilitation practice 
to affect the physical state and is not used to refer to a profession.  A small number of 
studies have explored the use of PT interventions in combination with BTX.  The 
following section will describe the key findings of these studies. 
 
In many studies of BTX intervention (discussed subsequently in Section 1.3), physical 
interventions are not included or described and the focus for evaluation is on reduction 
in spasticity rather than functional outcome.  Some studies have attempted to evaluate 
the influence of physical interventions in this context.  Giovannelli and colleagues 
demonstrated in a single-blind randomised controlled trial of patients with multiple 
sclerosis, that patients who received physiotherapy in combination with BTX had a 
significantly greater reduction in spasticity measured on the Modified Ashworth Scale 
(MAS) than those receiving BTX alone (Giovannelli et al. 2007).  Unfortunately, the 
study did not evaluate functional outcome.  In addition, the specific PT interventions 
used in this study were not described and other limitations included a small sample size, 
incomplete blinding and measurement bias.  Despite the limitations of this study, it 
provides indicative support for a combination of BTX and PT intervention rather than 
BTX alone.   
 
Other studies have attempted to explore specific PT interventions used in combination 
with BTX.  Hesse and colleagues conducted a small randomised, double-blind, placebo-
controlled trial investigating BTX in combination with functional electrical stimulation 
(FES) (Hesse et al. 1998).  Four groups were compared; BTX, FES, BTX + FES and no 
intervention.  Spasticity was measured using the MAS.  They also measured limb 
position and difficulties encountered by the patient or carer in performing care tasks 
(passive function) such as cleaning the palm, cutting finger nails and putting the 
affected arm through a sleeve.  Improvements were most prominent for spasticity 
reduction in the group who received combined BTX and FES.  Of the functional tasks, 
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only ‘cleaning the palm of the hand’ showed significant improvement, which occurred 
in both the BTX + FES group and the FES only group.  These results suggest that 
specific PT intervention such as FES may have a role in combination with BTX, but 
also that FES in some cases may be an effective management alone, to improve passive 
function at least in some patients.   
 
Carda and Molteni (Carda and Molteni 2005) compared BTX and strapping with BTX, 
splinting and electrical stimulation.  Both groups showed significant reductions in 
spasticity (as measured by the MAS), but a significantly greater reduction was identified 
in the BTX and strapping group.  Again, this study used MAS as the primary outcome 
measure and did not attempt to measure functional outcome in any way.  This study had 
significant limitations in the way in which intervention (strapping, splinting and 
electrical stimulation) was applied (with between group differences), control of bias 
(provision of intervention and measurement by the same clinician) and lack of blinding.  
Findings are therefore of more interest because of the questions they raise rather than 
the conclusions that can be taken forward and applied to practice. 
 
All these studies had limitations in evaluation of these physical interventions including 
study design, limited sample size and lack of blinding.  Overall, findings provide very 
limited evidence that focal PT interventions (such as splinting, strapping and FES) 
should be considered in conjunction with BTX in the management of spasticity and 
associated positive features of the UMN syndrome.  Interventions used often need to be 
tailored to the specific needs of individual patients, which makes evaluation more 
challenging (Ashford and Turner-Stokes 2006; Ashford and Turner-Stokes 2008; 
Turner-Stokes et al. 2010).  The trials of physical interventions used in combination 
with BTX have often focused on treatments that are easily available, rather than 
interventions, which may be more optimal.  Further work is required to identify the 
most effective interventions, as well as dose requirements and methods of application, 
before recommending clear strategies for clinical practice. 
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1.3 Measurement of upper limb function following focal spasticity intervention 
with botulinum toxin 
The ICF can be used as a system to classify measures of rehabilitation outcome.  As 
discussed in Section 1.2, the four broad classifications of the ICF describe the impact of 
a health condition on the person.  Each of these classification categories contains sub-
classifications called domains.  An example of a domain would be self-care; the ability 
to care for oneself.  Within each domain, further classifications are provided, which 
have numeric codes.  These classifications are termed category codes (Australian 
Institute of Health and Welfare 2003).  Outcome measures can be mapped onto and then 
evaluated against these classifications, to identify the areas of the ICF, which they 
measure (Poissanta and Mayob 2004).  Environmental factors can also be recorded as 
being either barriers to, or facilitators of, a person's activity (Australian Institute of 
Health and Welfare 2003).  The ICF and more commonly its precursor the ICIDH have 
been used as reference frameworks in the development of a number of upper limb 
measures of activity.  For example the Frenchay Arm Test (DeSouza et al. 1980), which 
measures upper limb activity in the clinic setting. 
 
Global measures of function are widely used to measure improvement in self-care.  
Examples include the Modified Barthel Index (Wade and Collin 1988) and Functional 
Independence Measure (Keith et al. 1987).  However these measures are often 
unresponsive to changes following focal intervention particularly in the upper limb, 
because localised changes, may be lost amongst the larger number of unchanging items 
(Granger et al. 1993).  Conversely many of the specific measures e.g. Nine Hole Peg 
Test (Wade 1992b) or Action Research Arm Test (Carroll 1965) used to evaluate 
improvements in the upper limb, do not represent what patients do during a ‘normal’ 
week because they evaluate function in the context of a clinical examination rather than 
the normal environment (Jones 1990).   Playford emphasises that many standardised 
measures, even if designed for specific anatomical areas such as the upper limb, do not 
capture how patients actually perform functionally and are often not reflective of the 
aims of intervention (Playford 2008). 
 
The framework given by the ICF provides a basis for the exploration of function at the 
level of activity.  Section 1.3.1 will explore the meaning of activity for patients 
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undergoing rehabilitation and will then address the need and possible methods of 
assessment of activity in clinical and research environments. 
  
1.3.1 Assessment of activity  
Assessing activity has two broad challenges, which are: 
a) What exactly should be measured (i.e. what constitutes the activity of interest)? 
and  
b) How should the activity be measured?   
Activity is, by definition, very broad and therefore difficult to define.  However, in the 
upper limb, related to focal spasticity intervention, this becomes easer to identify in 
terms of active and passive function.   
 
Measuring activity in a clinical context also requires a balance between the accuracy of 
information obtained and the practicality of collecting the data.  Three broad methods 
exist for the collection of activity data: 
 Firstly, the observation of activity in the everyday environment,  
 Secondly, observations of a proxy task such as that performed in a clinic 
situation and  
 Thirdly, self-report of activity in the everyday environment.   
 
Each method has different ‘trade-offs’ between the representative nature of the data 
produced and practical restrictions in measurement.  The following section will briefly 
explore activity analysis, measurement in the clinic environment and then focus on self-
report measures.   
 
Direct observation of activity over a 24 hour period would be the most accurate way of 
determining what an individual actually does, but it is very time consuming and 
impractical for most clinical situations.  Deconstruction of an activity (termed “activity 
analysis”) identifies the demands of the activity including what activity, where was it 
performed, how often, how quickly and with what (Blake and Fritz 1996).  Activity 
analysis requires either direct observation of the activity or methods such as video 
recording the tasks performed.  It provides an accurate measure of function in the day-
to-day environment (Blake and Fritz 1996).   
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Activity analysis has three principal limitations.  
 Firstly, it is time consuming because an observer must be present with the 
individual or to review the video recording.    
 Secondly, it is expensive to undertake, because of the cost of the observer’s 
time.   
 Thirdly, the presence of the observer may influence the function being 
performed.   
These limitations result in activity analysis, while being a useful research tool, being 
impractical to apply in clinical practice.   
 
Observation of a proxy task in the clinic environment is used in many existing upper 
limb outcome measures, for example the Frenchay Arm Index (DeSouza et al. 1980).  
Such measures require patients to complete standardised tasks, thought to be 
representative of the activities performed.  Proxy measures applied in a clinic setting 
circumvent some of the problems of activity analysis (Berglund and Fugl-Meyer 1986; 
Wade 1992b; Blake and Fritz 1996; Alon et al. 1998; Lagalla et al. 2000), but may not 
be representative of everyday performance.  They are usually more practical to apply, 
but will still have time costs to clinicians, carers and patients. 
 
One approach to address some of these limitations is the use of self-report measures, 
which are also referred to as ‘self-administered’ and ‘Patient Reported Outcome 
Measures’ (PROMs).  ‘Self-report’ means that the patient (and in some cases the carer) 
report on the activities, or aspects of them, that they have carried out in the home 
environment.  This approach is more representative of real life, but carries the risk of 
inaccurate reporting.  Self-report measures have the advantage of reporting on events 
that the clinician is not able to observe and are possibly less time consuming and 
expensive.  In addition, reporting over longer periods than a single assessment point in 
the clinic reflects activity performed over this whole period, rather than at only one 
clinic appointment, which enhances ecological validity.   
 
The use of self-report measures is commonly assumed less time consuming for 
clinicians.  However, patients with cognitive and communicative impairments may have 
considerable difficulty independently completing the measure.  Strategies are available 
to evaluate this ability in these patient groups and identify when simple questionnaire 
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completion may still be possible with support (Turner-Stokes and Jackson 2006).  Other 
methods are also available to support those who may be unable to complete 
questionnaires due to communication impairment or milder cognitive limitations 
(Jackson et al. 2006).  In practice, a combination of completion by patient and carer may 
be the most accurate form of feedback for care tasks particularly when both parties are 
involved in the process.  Self-report measures do not avoid the problems inherent in all 
questionnaires, such as the time costs in data entry and dealing with missing data. 
 
In summary, while activity analysis provides a gold standard measure of activity 
function, it is impractical for routine clinical practice due to time and cost constraints, 
which apply even in research.  This thesis attempts to balance the need to measure 
activity in an ecologically valid manner, while ensuring feasibility (see Glossary) and a 
reduced burden for routine clinical practice.  The following section explores measures 
applied in the evaluation of BTX intervention.  Measures, which are patient focused or 
self-report, are then explored in more detail. 
 
1.3.2 Patient and carer report in upper limb spasticity intervention 
The case for appropriate measures to evaluate passive function has been made by 
Sheean (Sheean 2001) and is supported by the work of Bhakta (Bhakta et al. 1996; 
Bhakta et al. 2000a) and Brashear (Brashear et al. 2002; Brashear et al. 2004).  These 
authors have attempted to identify patient reported methods to measure passive function 
outcomes following BTX intervention.  Passive function has been evaluated in a small 
number of studies (Bhakta et al. 2000a; Brashear et al. 2002).  However there is an 
identified gap in the measures available for the assessment of passive function in the 
hemiparetic upper limb, combined with a need to measure everyday performance in 
passive and active function. 
Many of the trials of BTX intervention have used the MAS as the primary or sole 
outcome measure (see Table 1.3).  To characterise existing approaches to evaluation, 
the literature is presented in Table 1.3, showing measures used to evaluate outcome in 
trials of BTX intervention for management of spasticity.  When PT interventions are 
mentioned, these are also presented, however descriptions are often limited.  In addition, 
intervention and outcome are also described. 
Chapter 1 Introduction 
       44 
Table 1.3 Outcome measures in trials of BTX for upper limb spasticity 
Author 
Year 


















Not measured Significant improvement in spasticity and 
physician and patient Global Assessment of 
Response at 4 and 6 weeks. 












by passive range of 
motion (ROM) exercise, 
splinting and casting as 
clinically indicated.  
MAS 
Range of Movement 
(ROM) 
Not measured Significant improvement in spasticity and 
ROM in the distal upper extremity. 












Pain (initial VAS) 
Upper limb Function  items 
identified by patients (e.g. 
hygiene, dressing, standing & 
walking balance) 
Significant improvement in MAS and ROM. 
Reported functional improvement in 14/17. 
Safe and effective treatment for reducing 
spasticity. 
(Hesse et al. 
1998) 
PC-RCT of 
BTX plus FES 
N=24 
Four groups 
6 in each 
Stroke 
Dysport 1000u into 6 




3 functional tasks (palm 
hygiene, cutting finger nails, 
and arm through sleeve) 
BTX and FES showed significantly greater 
reduction in difficulties with palm hygiene, 
with trend towards lower spasticity. The 
study had insufficient power.  










Dysport 500,1000 or 
1500 










Patient report items (palm 
hygiene, cutting finger nails, 
and arm through sleeve)  
Rivermead motor assessment 
(arm scale-RMA) 
BTX A reduces spasticity (MAS) over 16 
weeks (all doses). 
Optimal dose 1000U Dysport 
Intervention safe. 
No difference on RMA or Barthel Index 
between groups. 
Trend towards effect on functional tasks.  





Design Subjects Intervention Outcome Measures Findings 
Impairment Activity 


















Pain (Numeric scale) 
8-item Patient Disability Scale* 
4-item Carer Burden Scale* 
Significant improvement in patient disability 
at weeks 2-6, but reducing by week 12. 
Improvement in carer burden maintained at 
12 weeks. 
Significant reduction in spasticity at 2 weeks 
but not maintained to 6 and 12 weeks. 
Some improvements in ROM. 
No group differences in strength or pain. 
(Richardson 
















Rivermead Motor Assessment 
(RMA - arm, trunk and leg 
scales) 
9-hole peg test,  
10m walk 
Significant improvements in MAS, ROM, 
problem severity and RMA in treatment 
group. 
Goal attainment achieved in both groups. 















Global assessment scale 
Upper body dressing time 
Frenchay Arm Test 
Reduction in spasticity and increased ROM 
in wrist and fingers at 6 weeks – lost by 12 
weeks. 
No change in disability, but improvement on 
patient global assessment. 











ROM (Four point 
scale) 
Pain (Four point 
scale) 
 
Patient report items (palmar 
hygiene, cutting finger nails, 
and arm through sleeve) 
Goal Attainment Scaling (GAS)  
Global benefit. 
Barthel Index (BI) 
Significant reduction in spasticity up to 16 
weeks. 
Significant improvement in elbow ROM at 
16 weeks and global assessment of benefit. 
Tendency for patient reported items to show 
benefit – not formally analysed. 










Flexible dose regimen 
Wrist/fingers 
MAS Disability Assessment Scale 
(DAS) 
Global Assessment Scale 
Significant treatment effects on spasticity, 
functional ability (DAS) and global 
assessment. 
 





















Measure (FIM)  
Global Assessment SF-36 
Dose dependent reduction in spasticity but 
did not translate into improved function or 








Dose not specified 
Group 1: BTX + 
Strapping 
Group 2: BTX + 
Splinting and FES 
MAS  Both groups improved significantly; but 
group 1 had significantly better reductions in 
spasticity than group 2 (MAS). 










elbow, wrist & 
fingers) 
ROM 
 Significant improvements in all measures in 
intervention group, apart from shoulder 
spasticity, which was unchanged. 
(Giovannelli 






Upper limb 100U 
Lower Limb 100-300U 
Passive exercise and 
stretching (Experimental 
Group) 
MAS  Significant reduction in spasticity, both 
groups. 
Greater effect in the experimental group. 






Dysport 250u Pectoralis 






Shoulder range of 
movement 
 Significant reduction in shoulder spasticity 
(MAS). 
No significant change in shoulder pain 
(VAS). 






Dysport 500u Pectoralis 
Major for shoulder pain 
Fixed regimen 
TENS for 6 weeks 
Pain (VAS) 
MAS 
Shoulder range of 
movement 
 Significant reduction in shoulder pain 
following BTX administration. 
Improved external rotation. 














(20u each into FCU, 
FCR, FDS, FDP) 




Barthel Index Euroqol EQ-5D Significant reduction in MAS at wrist and 
fingers. 
No difference detected with Barthel Index 
and Euroqol. 






Up to 5 treatments of 
(200-400 units) of 
botulinum toxin-A 
(BOTOX® wrist, finger, 
thumb, and elbow flexors) 
Divided into high and 
low dose groups. 
MAS 1) Disability Assessment Scale 
(DAS) 
2) Stroke Adapted Sickness 
Impact Profile (SA-SIP30). 
3) Visual Analogue Scale from 
European Quality of Life-5 
(EQ-5D) 
Significant improvement in DAS – patients 
principal therapeutic target and spasticity at all 
time points, but not for low dose at the elbow 
(<250 units) and not for thumb at 12 and 24 
weeks (<250 units). 
Significant changes in SA-SIP30 from 
baseline (total score). 












(EMG) measure of 
upper limb associated 
reaction. 
Goal attainment scale using 
10-point categorical scale for 
daily activities. 
Significant improvement in biomechanical 
measure of associated reaction. 
No significant reduction of the interference 
of associated reactions with daily activities 
reported by patients. 







Repetitive task practice 
(60 mins per day) 
FES (Ness H200 system) 
 
MAS Chedoke-McMaster 
Assessment (CMA) at baseline 
for group allocation to; high 
‘function’ group; lower 
‘function’ group 
Action Research Arm Test 
(ARAT) 
Motor Activity Log (MAL)-28 
MAL-5 
Primary and secondary outcomes improved 
significantly over the 12-week intervention 
period. 
No differences between groups for ARAT 
and MAS. 
High function group predicted by CMA had 
significantly better MAL-28 outcomes than 









Group 1; Botulinum toxin 
(Xeomin®) 
 (median 320 units) wrist 
and finger flexors. 
Group 2; placebo group 
MAS Disability Assessment Scale 
(DAS) 
Global assessment of outcome 
Significantly higher proportion of 
experimental group responders (> or = 1 point 
on MAS) at 4 weeks. Significant results for 
experimental group until week 12 in patient’s 
principal therapeutic target (DAS), global 
disability and some care tasks. 





Design Subjects Intervention Outcome Measures Findings 
Impairment Activity 




Follow-up at 1 
and 14 weeks 
N=30 
Stroke 
All patients received 
BTX-A, heat, education, 
mobilisation, passive and 
active range of movement 
stretch, proprioceptive 
neuromuscular facilitation 
and therapeutic exercise. 
Experimental group: 
elbow extension using 
Dynasplint® 
1. Elbow active range 
of motion. 
2. MAS 
 Percentage difference improvements in both 
measures in both groups were seen.  Greater 
changes were seen in experimental group 
however; significant difference between the 









BOTOX® 300-400U with 
a therapy programme or 
placebo with a therapy 
programme. 
MAS 
Deep tendon reflexes 
Passive and active 




Klein-Bell Activities of Daily 
Life scale 
MOS-36 Item Short-Form 
Health Status Survey 
 
Significant difference from control in MAL 
(quality of movement sub-scale). 
No difference on other measures. 
Both groups showed reduction in MAS at 6 








Dysport (750-1000u) or 
placebo 
Distal upper limb 
muscles 










Assessment of Quality of Life 
(AqoL) 
Modified Motor Assessment 
Scale (MMAS) 
GAS 
8-item Patient Disability 
Scale* 
4-item Carer Burden Scale* 
Rating global benefit 
Intervention and control groups did not differ 
according to primary outcome (AQoL). 
Significant improvements for GAS, MAS 
and improved global benefit. 





parallel group  
Review at 3, 




1. Botulinum toxin-A 
(BOTOX®) plus oral 
placebo 
2. Tizanidine plus 
intramuscular 
placebo 
3. Intramuscular and 
oral placebo 
MAS Wrist flexor, 
elbow and fingers 
 
DAS 
Modified Frenchay Scale 
 
BOTOX® produced a significantly greater 
reduction in MAS than Tizanidine or placebo 
at 3 and 6 weeks. 
 
DAS showed a significant improvement in 
cosmesis at 6 weeks. 





Design Subjects Intervention Outcome Measures Findings 
Impairment Activity 










1. 50 Units 
2. 20 Units 
 
MAS DAS At four weeks (post injection) 
1 point or greater reductions in DAS and MAS 
for both groups. 
Difference between responders and non-
responders in groups for DAS.  10.6% greater 
response in group 1 (50 units). 
(Cousins et al. 
2010) 






(BOTOX®) – dosing 




1. Half dose 
2. Quarter dose 
3. Placebo 
1) Spasticity (sEMG) 
2) Grip strength 
(JAMAR 
Dynamometer) 
3) Isometric muscle 
strength – elbow and 
wrist 
Action Research Arm Test 
(ARAT) 
 
No benefit treatment over control in whole 
group analysis. 
Sub-group analysis (no active function 
ARAT, baseline), both active groups 
improved compared to control (effect size 0.5 
– quarter dose and 0.6 half dose groups). 









Group 1 high dose (200-
240 units); Group 2 high 
dose placebo group; 
Group 3 low dose (120-
150 units); Group 4 low 
dose placebo group 
MAS Disability Assessment 
Scale (DAS) 
Significant difference for mean difference 
(area under curve) groups 1 to 2 (high dose). 
No difference groups 3 to 4 (low dose). 
 
Significant difference noted in DAS at weeks 
6, 8 and 12 groups 1 and 2 (High dose). 
 





Design Subjects Intervention Outcome Measures Findings 
Impairment Activity 







Dysport (up to 1000u) 
4 Week therapy 
programme (placebo 
group received therapy 
programme only) 
 
2 Therapy programmes: 
1) ARAT (0-3) -
Stretching 
2) ARAT (4-56) -






9-hole peg test 
Barthel Index 
Motricity Index (MI) 
Patient report items (palmar 
hygiene, cutting finger nails, 
and arm through sleeve) 
 
(Participation measures also 
recorded: 
Stroke Impact Scale 
European Quality of Life-5 
Dimensions 
Oxford Handicap Scale) 
No significant difference on primary outcome 
(ARAT). 
MAS reduced at 1 month in experimental 
group, but not 3 or 12 months. 
Change in strength (MI) at 3 months. 
Significant improvement in patient report 
items. 




Review at 1, 6 
and  6 months. 
N=32 
Stroke 
 Dysport® 1000u elbow 




received CIMT with 
graded tasks, verbal 
feedback and a 
behavioural contract for 5 
hours/ day for 3 months. 
 
Control group received 
conventional 
(neurodevelopmental) 
therapy for 2 hours/3 




Both groups demonstrated significant 
improvement in spasticity (MAS) 1 and 3 
months following injection. 
 
Significant difference between experimental 
and control group for elbow, wrist, and finger 
spasticity at 6 months post injection. 
 
Significant difference in MAL (amount of use 
score) and ARAT at 3 and 6 months.  
 
Key: *Now known as the Leeds Arm Spasticity Impact scale (LASIS) – see Systematic Review; Chapter 5 for more information; PC = placebo controlled; RCT = randomised 
controlled trial. 
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Many of the trials addressing focal spasticity intervention with BTX have demonstrated 
significant improvements in the MAS (see Table 1.3).  However the use of MAS alone 
is inappropriate because it does not reflect the primary aim of intervention (Bakheit 
2004a).  The reason for implementing the intervention is usually functional and often 
passive function (Bakheit 2004a).  An option suggested by Bakheit is using the ICF as a 
model to interpret the goals of intervention and matching the outcome measures to goals 
at the activity level of the ICF.  Using the ICF as a model to interpret goals has already 
been applied in spasticity management (Turner-Stokes et al. 2010). 
 
A relatively small number of the trials presented in Table 1.3 attempt to evaluate active 
and passive function.  Where studies have applied measures of global disability or 
function these have not shown significant change e.g. (McCrory et al. 2009).  However 
when specific measures of disability/function or goal attainment have been applied, 
significant improvements in passive function have been demonstrated in some cases (for 
example studies by Bhakta and colleagues (Bhakta et al. 2000a) and Turner-Stokes and 
colleagues (Turner-Stokes et al. 2010)).   
 
The remainder of this section describes the different patient focused methods used to 
evaluate functional outcome following focal spasticity intervention using BTX.  The 
methods discussed are: the use of patient report on upper limb items (including the 
Leeds Adult Spasticity Impact Scale - LASIS), the Disability Assessment Scale (DAS), 
use of a composite measure of function and Goal Attainment Scaling (GAS). 
 
Patient report - upper limb function items 
Specific items thought to represent upper limb passive function have been used in some 
studies to measure functional outcome and are discussed in the following section.  
Three upper limb function items have been used in trials evaluating BTX intervention in 
a study by Hesse and colleagues (Hesse et al. 1998) and another by Bakheit and 
colleagues (Bakheit et al. 2000).  The three items used were: 1. putting the arm through 
a sleeve, 2. cleaning the palm and 3. cutting fingernails.  Each item is scored on a five-
point Likert scale from “no difficulty” to “not able to do the activity”.  The items are 
presented as a structured interview in the spasticity clinic setting.  In the study by 
Bakheit and colleagues, improvement was demonstrated in the MAS, but was not 
shown in these functional items (Bakheit et al. 2000).  However in a small study, Hesse 
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showed a significant reduction in difficulty with palmar hygiene (Hesse et al. 1998).  
Use of these patient reported items demonstrates some potential for them to register 
meaningful change following focal spasticity intervention. 
 
Leeds Adult Spasticity Impact Scale (LASIS) 
The LASIS has been developed as a more extensive measure of patient and carer 
reported functional outcome following BTX intervention for spasticity (Bhakta et al. 
1996).  Bhakta and colleagues undertook a preliminary evaluation of the impact of BTX 
treatment on disability caused by upper limb spasticity after stroke (Bhakta et al. 1996).  
In the literature, the measure is not referred to as the LASIS, but has been identified as 
such following contact with the author.  A component of this study was the 
development of an ‘item bank’ following open interviews with patients to identify 
which care tasks were most important to them.  The resulting measure has two sub-
scales a Patient Disability Sub-scale and a Carer Burden Sub-scale.  The Patient 
Disability Sub-scale assesses the patient difficulty in cleaning the palm, cutting 
fingernails, putting the paretic arm through sleeves, cleaning under the armpit, cleaning 
around the elbow, standing balance, walking balance and ability to perform a home 
exercise programme.  The Carer Burden Sub-scale is used if a carer is involved, to 
assess cleaning the palm, cutting fingernails, dressing and cleaning the armpit.  The 
items are scored either by the patient (Patient Disability Score) or carer (Carer Burden 
Score) on a scale between “no difficulty with task” to “unable to do task”.  The LASIS 
was delivered as a structured interview, based on the respondent’s report on the 
preceding 7 days.  Both sub-scales were summed and divided by the total number of 
completed items to give a separate Patient Disability Score and Carer Burden Score.   
 
Bhakta and colleagues conducted a further study using this measure to investigate 
whether reduction in spasticity after BTX treatment translates into reduction in 
disability and carer burden (Bhakta et al. 2000a).  Changes in Patient Disability Score 
occurred from 2 to 6 weeks but were not sustained to 12 weeks and changes in Carer 
Burden Score occurred by 6 weeks and were sustained at 12 weeks.   
 
Disability Assessment Scale (DAS) 
Brashear and colleagues (Brashear et al. 2002) developed the DAS, a measure of 
“functional impairment” associated with spasticity.  Although it contains similar items 
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to those used by Bhakta and colleagues, it is scored by clinicians after a combination of 
interviewing and observing the patient. The measure assesses hand hygiene, dressing, 
limb position, and pain.  All items are scored using a Likert scale.  Each item is scored 0 
- no disability, 1 – mild disability (noticeable but does not interfere significantly with 
normal activities), 2 – moderate disability (normal activities require increased effort 
and/or assistance), or 3 severe disability (normal activities limited).  Brashear and 
colleagues (Brashear et al. 2002) undertook reliability testing and established the 
reliability of DAS and MAS in the same study.  The DAS primarily addresses distal 
upper limb function, particularly of the wrist and hand.  Although it includes an item on 
dressing, which will necessarily include shoulder movement, proximal movement of the 
arm is not fully addressed.   
 
Brashear and colleagues (Brashear et al. 2002) then used DAS in a randomised 
controlled trial to evaluate if BTX reduced disability in persons with spasticity of the 
wrist and fingers after stroke.  They concluded that intramuscular injection of BTX 
reduced spasticity of the wrist and finger muscles (according to MAS) and that 
disability in patients was also shown to decrease (according to DAS).  Patients in the 
intervention group in this study showed a statistically significant improvement of at 
least one point on the DAS compared to the control group at six weeks after injection.   
 
Strengths and limitations of LASIS and DAS 
The scoring of LASIS and DAS are not truly ‘patient report’, because completion is 
undertaken by the clinician.  Both measures are administered as structured interviews, 
with the addition of observation in the case of the DAS.  However, the findings from 
evaluation of LASIS and DAS support the view that changes in disability and carer 
burden, following focal spasticity intervention, can be detected using patient or carer 
reported information.  Although the changes in DAS were small, the results also 
indicate that BTX intervention for wrist and finger spasticity leads to functional 
improvement measured using patient reported information.  Existing clinician-rated 
measures may detect change, but are insufficiently specific to fully characterise the 
improvement. 
 
Both LASIS and DAS have limitations in terms of the incomplete evaluation of their 
scaling properties.  The measurement properties of both of these measures have not 
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been confirmed.  In order to undertake arithmetic manipulations to derive a total score, 
evaluation of measurement scaling properties is needed (also see Chapter 3; page 63).  
Before this, it is also necessary to confirm that a single dimension or construct is being 
measured or to identify the dimensions corresponding to sub-scales within the tools.  
Given that LASIS contains passive function items, but also some active function items 
it is possible that more than one sub-scale is needed or the rationalisation of items to 
form a single scale from a measurement perspective.  Further work is therefore required 
in these measures before they are widely used in research and clinical practice. 
 
In general, self-report arm function measures have addressed distal function as the 
primary concern.  However, there is a need to ensure that measurement of upper limb 
function includes the contribution of the proximal upper limb in addition to distal and 
whole arm function. 
 
Composite measure of function 
The following section describes an approach taken to measuring function using a 
composite measure of function in a secondary analysis.  A meta-analysis by Francis and 
colleagues (Francis et al. 2004) using data from two trials by Bakheit and colleagues 
(Bakheit et al. 2000; Bakheit et al. 2001) was undertaken using two composite scores.  
The aim of the study was to attempt to extract the data most relevant to the intervention 
and combine this, whilst excluding irrelevant items (e.g. non upper limb items of the 
Barthel Index).  A composite spasticity score was generated, which comprised MAS 
scores from elbow, wrist and finger flexors and a composite functional score used three 
items from the Barthel index; feeding, dressing and grooming combined with the three 
other functional items (cleaning palm, cutting fingernails and putting the arm through a 
garment sleeve).   
 
For the majority of patients in the meta-analysis change in function occurred at the same 
time as maximal change in spasticity at 4 weeks following intervention.  Improvements 
were primarily seen in passive function.  However, for a minority of patients, maximal 
functional change appeared to follow on at some time after maximal change in 
spasticity.  The reason for the delay in these patients is unclear, but these findings may 
suggest that other factors such as time for PT intervention to have an effect is important 
in producing functional changes. 
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The authors suggest that future studies should have multiple time points and apply two 
primary outcome measures, a measure of spasticity (impairment) and a measure of 
function (activity).  They also suggest using a measure of goal attainment such as GAS 
because of the diverse nature of the aims of treatment.  Some limitations of the methods 
are identified, such as summing of scores in both the spasticity and functional indices, 
which may not be considered appropriate by some because of the non-parametric 
quality of the data.  In addition, the functional index incorporates items from the Barthel 
index, which are active function (grooming, feeding and dressing), with the additional 
items likely to be passive function (cleaning the palm, cutting fingernails and putting 
the arm through a sleeve).  It is therefore questionable whether these scores should be 
summed when they come from different constructs.  Finally, the authors also concede 
that the time points used in the two studies included for meta-analysis were further apart 
than is ideal and that the exact time of change in spasticity and function may have been 
missed.   
 
Goal Attainment Scaling 
The Goal Attainment Scaling (GAS) approach attempts to evaluate the attainment of 
patient agreed goals of intervention rather than use a standardised set of measurement 
items.  GAS is an individualised method, first introduced in the 1960s by Kiresuk and 
Sherman (Kiresuk and Sherman 1968).  It is a system of evaluating achievement of the 
goals of intervention set by the patient and clinical team before the commencement of 
treatment.  The method therefore provides both a quantification of individual goal 
outcome and qualitative information about the specific goals set.  It is therefore an 
evaluation of expected goal achievement, dependent on the patient’s ability to change 
and the clinical team’s ability to predict that change.  Because of its individualised 
approach, it does not provide a standardised outcome for comparison and therefore can 
not replace standardised measures. 
 
Improvement in GAS is rated from –2 to +2.  The expected target of achievement is set 
by the patient and treating team, before any intervention and given a value of 0.  
Outcomes less than expected are given values of –1 or –2 and more than expected +1 or 
+2.  It is recommended by the originators of the method, that a ‘T-score’ is produced 
(Kiresuk and Sherman 1968).  The ‘T-score’ is a total score of the composite outcome 
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of all the goals set for an individual patient (see Appendix 3).  The validity, reliability 
and responsiveness of GAS have been evaluated in rehabilitation (Malec 1999) and 
upper limb focal spasticity intervention (Ashford and Turner-Stokes 2006; Turner-
Stokes et al. 2010). 
In the context of spasticity management GAS was shown to provide a sensitive measure 
of change for a given individual (Ashford and Turner-Stokes 2006; Turner-Stokes et al. 
2010).  However, limitations have been identified in using the standard GAS approach 
which relate to a) comparison of scores between individuals or groups and b) data 
obtained being ordinal rather than interval, undermining the validity of the calculation 
of the T score (Tennant 2007).   
Comparing GAS scores between different individuals or groups is in fact comparing 
outcome in different constructs in almost every case.  However, proponents of GAS 
would identify the construct as ‘goal attainment’ or ‘achievement of expectation’, rather 
than relating to specific functional items.  Nevertheless to carry out GAS group 
comparison from a mathematical perspective, would require the confirmation of 
unidimensionality.  This leads on to the second issue that scaling is also different in 
every case, even though the same structure is used and data are therefore at best ordinal 
(although this is usually not tested).  In a simulated evaluation of GAS comparing a 
linearised, interval scale version of GAS produced by Rasch analysis, with the normal 
ordinal format, Tennant (2007) found that significant differences occurred with change 
scores at the extremes of the scale.  This means that doubt is cast on the judgement of 
significant change using ordinal GAS scores, particularly at extremes of the scale.  
However, this is not entirely unexpected and suggests that less difference is evident in 
the middle of scale. 
Item banking has been proposed as a method of using items identified by GAS for 
unidimensional constructs within rehabilitation, using item response methods such as 
Rasch analysis to ensure the interval properties of the data (Tennant 2007).  Tennant has 
suggested that similar goals are often generated within rehabilitation because of the 
limited options for improvement that are provided by the rehabilitation team.  However, 
patients can have very individual and specific goals for their rehabilitation, which may 
not always be contained in an item bank.  The item-banking approach could be applied, 
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but would raise the criticism that pre-defined items limit the range of goals and hence 
the patient centred strength of the approach.   
In the area of focal intervention and particularly upper limb function, due to the nature 
of intervention being focused in an anatomical area, the goals are likely to be even more 
focused than rehabilitation in general.  Therefore, upper limb function may provide an 
ideal area for construction of an item bank for evaluation of focal spasticity outcome in 
clinical practice and research.  Unfortunately, items to evaluate passive function 
improvement are still limited and will require further work before an item bank can be 
considered. 
The GAS method currently provides a system of recording goal achievement, which 
may be used to complement standardised measures in clinical practice.  However, for 
measurement, appropriate standardised measures, with clear psychometric properties 
will be required (see Chapter 3).  Goal attainment scaling provides a possible source of 
measurement items from goal setting to be included in development of standardised 
measures or possibly item banks in due course.  Items identified may then be compared 
with existing items from the literature and mapped onto the International Classification 
of Functioning, Disability and Health (WHO 2002) to confirm the domains being 
assessed in each case. 
1.4 Summary 
 Botulinum toxin A reduces upper limb spasticity in patients post stroke, but the 
improvement in functional ability remains to be established (Elia et al. 2009).   
 Possible reasons for the failure to demonstrate functional improvement include: 
a) Lack of appropriate concomitant therapy to maximise the functional 
improvements (in many studies concomitant interventions are poorly 
described). 
b) Failure to specify in advance the types of gains (passive or active) that are 
likely to be achievable – which will vary from patient to patient. 
c) Lack of suitably focused measures to capture the gains that occur (passive 
and active). 
d) Measuring at the wrong time points.  Functional changes may take longer to 
develop than improvements in spasticity, because they depend on both 
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reduction of spasticity and improvements resulting from physical 
interventions. 
e) In the case of active function, failure to identify appropriate patients who 
may benefit. 
 Performance measures are applied in the clinic setting and may provide a 
measure of activity, but currently only record active function and not passive.   
 Performance measures also do not reflect how the person undertakes activities in 
their normal environment and may lack ecological validity. 
 Examination of current measures used to evaluate BTX and combined PT 
intervention may provide possible tools or items as a starting point to evaluate 
functional outcome. 
 Self-report measures are able to record function occurring outside of a test 
environment in the patient’s own setting.  While having limitations, they may be 
useful in evaluating functional (passive and active) outcome following focal 
upper limb spasticity interventions.   
 Goal attainment scaling may provide a useful adjunct to evaluate clinical goal 
achievement, but can not replace the requirement for psychometrically robust 
measurement.  The analysis of individual goals may provide a possible method 
for identifying items for inclusion in the development of outcome measures. 
 It is essential in the development of tools, that evaluation of the measurement 
scaling properties of these instruments is undertaken as part of the process.   
 
The studies reported in this thesis address a poorly understood problem; that of the 
optimal way of measuring function in the upper limb, which represents patients 
everyday activity, following focal interventions (BTX and PT) for spasticity 
management.  To begin with, current measures used for this purpose are identified and 
critically appraised and the need for development of a new tool established.  Following 
this, the development of a new measure of active and passive function is described.  
This development entails a series of sub-studies to generate possible items, develop the 
measure and then test its psychometric properties.  Evaluation of feasibility in the 
clinical setting is also described and discussed.  The following broad hypotheses will be 
tested during the development and evaluation process. 
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Hypotheses 
1. Measurement items relevant to upper limb active and passive function can be 
identified from literature and clinical practice sources in a systematic manner. 
2. Development of a draft measure from an initial large number of items can be 
achieved using consultation-based item selection methods with clinicians, 
patients and carers. 
3. Items that capture upper limb function in the context of botulinum toxin and 
physical interventions for spasticity can form a robust measurement system so 
that the sub-scale scores can be summed to provide a single summary statistic. 
4. The resulting measure can be used to demonstrate improvement in passive 
function following treatment of upper limb spasticity using BTX and PT 
intervention. 
 
The objectives associated with these hypotheses are explained in chapter 2. 
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Chapter 2 Aim and Objectives 
2.1 Aim of the research programme 
The aim was to identify, modify or develop and then psychometrically evaluate a self-
report measure of function suitable for evaluating the impact of spasticity management 
intervention on the upper limb.  Key principles were the assessment of real-life 
performance and feasibility for use in routine practice following focal spasticity 
interventions in the hemiparetic upper limb.    
 
2.1.1 Module 1 – Evidence synthesis – literature and clinical practice  
Specific objectives (see Hypothesis 1) 
1. To identify standardised outcome measures of active and passive function used to 
assess outcome following focal intervention in the hemiparetic upper limb, which 
reflect ‘real-life’ function. 
 
2. To identify candidate items for inclusion in a measure of upper limb function for use 
following focal spasticity interventions, in the hemiparetic upper limb. 
 
A systematic review was undertaken to determine the nature and scope of current self-
report measures to evaluate active and passive function in the hemiparetic upper limb.  
This served to highlight gaps in existing forms of measurement.   
 
The systematic review was then used to identify existing measures and measurement 
items that could be included in adaptation or development of a new measure.   
 
In addition, an analysis of goal setting for upper limb spasticity intervention was 
undertaken to identify additional items for inclusion not present in existing measures.   
This approach ensured patient and carer involvement at an early stage of measure 
development and constituted new and original work to underpin the ecological validity 
of the resulting measure.   
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2.1.2 Module 2 – Development of the measure  
Specific objectives (see Hypothesis 2) 
3. To develop a self-report measure to assess both ‘active’ and ‘passive’ function in the 
hemiparetic upper limb following focal rehabilitation interventions. 
 
4. To confirm face and content validity by investigating item relevance for 
professionals (content), patients and carers (face and content). 
 
Development of the Arm Activity measure (ArmA), a self-report measure of difficulty 
in arm active and passive function, is undertaken informed by the findings of module 
one.  The structure and scoring is based on measures identified during the systematic 
review.  Item reduction using modified Delphi consultation technique is undertaken, 
initially involving a group of clinicians, followed by further refinement and 
confirmation in a much larger group of clinicians and pilot testing by patients and 
carers.  The criteria for the ArmA development are presented in Box 2.1. 
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2.1.3 Module 3 – Psychometric evaluation of the measure  
Specific objectives (see Hypothesis 3 and 4) 
 
5. To evaluate the reliability, internal consistency, construct validity, 
unidimensionality and ordinal scaling of the Arm Activity measure (ArmA) – a 
measure of difficulty in active and passive function. 
 
6. To evaluate the responsiveness and feasibility of the measure when using it to assess 
outcome following spasticity intervention in the upper limb. 
 
7. To apply the ArmA in measuring change in passive and active function following 
spasticity management intervention. 
 
Psychometric evaluation of the ArmA also incorporated a cohort study of spasticity 
management using botulinum toxin and physical interventions in the hemiparetic upper 
 
The proposed measure needs to meet the following criteria: 
 
1. Clinical relevance - applicable in the hemiparetic upper limb 
2. Include items measuring both: 
a. Active function 
AND 
b. Passive function 
3. Assessed in a manner reflective of ‘real life’ function 
4. Practical to apply in everyday clinical practice 
5. Valid and reliable for upper limb function evaluation 
6. Have established dimensionality of the sub-scales 
7. Have established scaling and measurement properties of the sub-scales 
8. Responsive to change occurring as a result of intervention 
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limb.  The main psychometric properties examined were; test-retest reliability, internal 
consistency, construct validity, responsiveness to change and feasibility. 
 
The cohort study examined the relationship between change in function and spasticity 
following focal spasticity intervention.  Although the main purpose of the study was the 
psychometric evaluation, the cohort study presented an opportunity to explore this 
important clinical issue and make a preliminary contribution to knowledge in this area. 
 
Passive function was addressed, but not active function because change in this sub-scale 
was expected in only a minority of participants undergoing spasticity management.  The 
utility of ArmA was tested during the cohort study addressing the following hypothesis.   
 
Cohort study null hypothesis: Improvement in passive function measured by the ArmA 
at 8 weeks following BTX and PT intervention will not be maintained above baseline 
levels as the effect of the BTX on spasticity decreases. 
 
Each module of the thesis builds on the work from the preceding module.  Before 
addressing the need for a new measure of arm function, Chapter 3 presents the 
theoretical concepts important in the evaluation and development of clinical outcome 
measures.  Chapter 4, through the systematic review, then identifies strengths and 
limitations of existing measures and highlights the need for a measure of active and 
passive function in the hemiparetic arm. 
 
Figure 2.1 provides a diagrammatic view of the modules within this thesis. 
 
Chapter 2 Aims and Objectives  
 64 
 
Figure 2.1 Structure of research programme 
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Chapter 3 Theoretical issues in measure development  
 
The development of a new psychometric measure typically involves a number of stages 
and different approaches or strategies may be used in this process.  Broadly speaking, a 
precise conceptualisation of the area to be evaluated is needed followed by 
consideration of how best to undertake measurement.  A process of development is 
required to develop and then test the tool to ensure that it is actually evaluating the 
concept (often referred to as ‘construct’, ‘dimension’ or ‘trait’) of interest.  If the tool is 
to be used for measurement, it is essential that it comprises a scale along which changes 
in the construct can be measured.  It is also important that the resulting measure is 
practical for use; including being feasible for patient and carer completion if self-report 
is required. 
 
The following chapter will explore what ‘measurement’ means for constructs such as 
active and passive function.  The approaches to understanding evaluation of such 
constructs are then discussed with reference to classical test theory (CTT), latent 
variable methods (LVM) and item response theory (IRT).  Methods for evaluating the 
properties of measurement tools are then considered and related to the approach taken in 
this thesis. 
3.1 Measurement 
Measurement is a widely used term that has been defined in a number of different ways 
depending on the underlying theoretical concept on which it is based.  Two broad 
theoretical approaches can be identified and both of these have further sub-categories.  
The two theories discussed below are: the ‘Classical Theory’ and the ‘Representational 
Theory’.  Different definitions have also been applied in information theory and 
quantum mechanics but these are not discussed here due to their limited relevance to 
this thesis. 
 
3.1.1 The classical definition 
The classical definition, which is the accepted standard in the physical sciences, defines 
measurement as determination or estimation of ratios and quantities (Michell 1990).  
The 19
th
 century physicist Kelvin gave the following summary: 
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“when you cannot measure what you are speaking about and express it in numbers, your 
knowledge is of a meagre and unsatisfactory kind; it may be the beginning of 
knowledge, but you have scarcely, in your thoughts advanced to the stage of science” 
(Thomson 1891). 
 
However this definition of measurement can be traced back much further in history to 
Aristotle and Euclid (Michell 1990).  Aristotle deemed quantity to be one of the 
fundamental categories of reality and divided it into ‘discrete’ and ‘continuous’.  
Discrete quantities were defined as categories or natural numbers (e.g. number 2, was 
thought to be common to all pairs of things), and were essentially descriptive.  
Continuous quantities were called ‘magnitudes’ and were intended to designate 
variables such as length, time or weight.   
 
In the 1920’s the classical theory was further clarified by Campbell, who described two 
types of measurement: fundamental and derived (Campbell 1920).  Fundamental 
measurement requires that the physical world relates directly to physical addition, for 
example putting ‘rods’ end to end in a straight line.  Therefore, the addition of (in this 
case) rods in the physical world has similar properties to the addition of numbers in the 
more abstract condition.  Derived measurement is defined by the relationship of a 
variable, which may not be directly seen or measured to fundamental quantities, which 
can be measured (e.g. the ratio of mass to volume is a derived measure for a substance’s 
density).  This led to the possibility of a more representational approach to 
measurement.   
 
The concept of ‘additivity’ is an essential part of the classical theory of measurement.  
Additivity is seen as the ability to combine numbers (add them together), because they 
represent addition in the physical world.  Additivity is considered so important, because 
without additivity it is not possible to have ratios of magnitudes and without ratios of 
magnitudes there is not measurement (Michell 1999).  However, Campbell modified the 
classical theory to allow numbers to ‘represent’ relationships in the physical world.  
This resulted in using numbers and the relations between them to represent empirical, 
non-numerical relations of order and addition. 
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3.1.2 The representational definition 
The representational theory defines measurement as “the correlation of numbers with 
entities that are not numbers” (Nagel 1931).  The work of Campbell led to other 
theorists considering this new perspective on measurement and taking it a step further 
(Stevens 1946).  Stevens defined measurement as:  
“the assignment of numerals to objects or events according to rules” (Stevens 1946; 
Stevens 1951; Stevens 1959) 
 
Stevens identified four principal types of measurement (nominal, ordinal, interval and 
ratio), although he also acknowledged others such as log-interval scales.  These scales 
were defined in the following manner: 
 
 Nominal (also known as categorical) scales assign items to a category and are a 
description.  For example gender or employment status.   
 Ordinal scales place items in rank order, but do not describe the degree of 
difference between points on the scale.  For example, most preferred food to 
least preferred food.  The numbers assigned indicate an order, but do not have 
true numerical value. 
 Interval scales, place items in rank order and have an equal distance between 
measurement points on the scale, but with no absolute zero.  For example, 
temperature measured in Celsius.  Numbers have relative value in this instance, 
but not necessarily absolute value. 
 Ratio scales, meet all the requirements of interval scales, but also have an 
absolute zero.  For example height or mass. 
 
This resulted in Stevens taking representational theory to the point where it allied with a 
closely related concept of operational theory.  In both representational theory, according 
to Stevens, and in operational theory, “any precisely specified operation for making 
consistent numerical assignments to things is measurement” (Michell 1990).  
Therefore, measurement is defined by the method (e.g. the questionnaire) rather than an 
external absolute (e.g. an object with mass in the physical world) as is assumed with the 
classical definition.  Measurement based on Stevens' model became known as ‘classical 
test theory’ (CTT), which should not be confused with the classical model of 
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measurement and therefore in one sense is unhelpful terminology.  It is also strange that 
a model that is comparatively recent is given the ‘classical’ label and may relate to its 
wide acceptance as a working definition (Lord and Novack 1968).  Methods utilised in 
Stevens’ model will be further explored under classical test theory (page 72). 
 
Stevens definition was widely accepted in psychology from an early stage (Lorge 1951; 
Green 1954), but has also been widely criticised because of its entirely operational 
nature (Michell 1999; Borsboom 2005; Borsboom 2006).  Michell (1990) has said that 
in his view; Stevens’ definition is mistaken because “it confuses two quite different 
practices: measurement (e.g. magnitude in the classical sense) and numerical coding 
(e.g. discrete quantities in the classical sense)”.  Measurement is seen by authors such 
as Borsboom (2005) and Michell (1990) as specifically related to magnitude 
representing the real world and should not include the assignment of numbers to 
categories.  However, Stevens’ model does provide a system to attempt to organise 
information from variables that are not so easy to define and evaluate as those in the 
physical world. 
 
Measurement in common language is often associated with the application of 
measurement procedures or its operationalisation.  However, for such applied 
procedures to be considered measurement, in the view of some authors, they must relate 
to an underlying attribute (Kline 2000c).  Haig and Borsboom give the following 
example “the use of a tape measure does not constitute measurement (of itself); it 
constitutes the measurement of length, where length functions as a theoretical attribute” 
(Haig and Borsboom 2008).  Many people, including the general public and many 
health scientists, do not see the subtle distinction between the attribute being measured 
and the means of its measurement (e.g. length and tape measure).  In the case of 
physical measurements such as length, the relationship seems clear and does not create 
any obvious problems.  However, in measurement of attributes labelled as ‘subjective’, 
the relationship between the measure and the construct measured can be more 
problematic and difficult to demonstrate. 
 
Variables commonly referred to as ‘objective’ are often also called ‘manifest’ and those 
referred to as ‘subjective’ are often also called ‘latent traits’, ‘constructs’ or 
‘dimensions’.  Measurement of latent variables (e.g. anxiety or quality of life) is more 
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difficult because it is not possible to measure them directly.  They also do not have clear 
units of measurement in the way most manifest variables do.  Although even for 
manifest variables, the agreement on standardised units of measurement is 
comparatively recent (e.g. standardization of length and weight measurement was only 
achieved in the 18
th
 century).  In the modern world for example, the manifest variable of 
height has clear units of measurement that can be used such as centimetres (cm) or 
inches.  The distance between 1 cm and 2 cm and the distance between any subsequent 
point on the scale and the next is always the same and forms an interval scale.  However 
for latent variables there are usually no accepted universal units of measurement and the 
units are dependent on which scale is used.  The distance between points on the scale 
will differ (e.g. pain evaluated on Likert or numeric scales).  Latent variables are 
therefore not ‘palpable’ and are inferred from responses on ‘pencil and paper’ (or 
electronic) Likert scales.  Measurement of such variables is therefore ‘representational’ 
rather than direct. 
 
In the representational theory, the role of numbers in measurement is to represent the 
real empirical entity (Krantz et al. 1971).  Numbers are therefore used to represent 
empirical relations in the real world.  Stevens definition of measurement has therefore 
been further criticised because it does not address this relationship, but embraces a fully 
operational approach to measurement (Michell 1990).  However, Stevens’ approach has 
strengths in enabling description of simple categories all the way through to ratio scales, 
but does not demonstrate measurement in terms of magnitude, but rather makes 
assumptions about it based on the presentation of the data.  In practice these 
assumptions may be reasonable and are certainly practical, which has led to this model 
being widely applied and accepted (Lord and Novack 1968).  However, a problem 
arises in using numbers related to categories, in anything other than interval or ratio 
scales.  The problem is that if these categories are seen as anything more than labels, in 
for example nominal scales, then the concept of measurement; using Stevens’ own 
definition no longer makes sense (e.g. categorical or ordinal scales can not be added 
together).  However, Stevens approach to measurement in the form of CTT may provide 
a starting point for development, but measurement will need to be evaluated by more 
robustly demonstrating the link between the numbers and the latent variable. 
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The ‘latent variable model’ (LVM) has been proposed as an alternative to (and 
considered by some as an expansion of) classical test theory (Borsboom 2005).  The 
latent variable model attempts to conceptualise theoretical attributes as latent variables.  
Latent variables are considered the unobserved cause of observed scores (e.g. 
intelligence and the intelligence questionnaire applied to measure it).  The LVM 
therefore also requires that a statistical model be developed of the relationship between 
the latent variable and the observed data based on a clear theory.  It is only when this 
relationship is tested and demonstrated, to explain the data seen, that the observation of 
the latent variable can be interpreted as measurement (Borsboom 2005).  The focus of 
the latent variable model is however targeted on the identification of the construct or 
latent variable to be measured, but is less concerned with the mechanism of 
measurement or scaling. 
 
Therefore, within the representational theory of measurement, concepts have been 
developed to define the relationship between the construct being measured and the 
scaling of measurements.  This approach is also known as ‘fundamental measurement’ 
and is concerned with the mathematical relationship of the scale between the variable 
being measured and the people being measured (Borsboom 2005).  The distinction is 
emphasised between the empirical entities and the numbers assigned to represent them.  
A system is therefore required to make this relationship clear so that measurement 
produced can be relied upon to represent the latent variable.  Measurement can then be 
defined as a procedure for identifying values of quantitative variables through their 
numerical relationships to other values (Michell 1990).   
 
The concept of ‘conjoint measurement’ was developed to address the requirements of 
fundamental measurement (Luce and Turkey 1964).  Conjoint measurement provides a 
concept for the identification of quantitative structure other than ‘concatenation’ (other 
wise known as physical addition).  In fact, it allows a quantitative structure to be 
identified from ordinal relations to a variable.  Therefore, ordinal scales, in some cases 
developed using a CTT approach, may have methods of conjoint measurement applied 
(such as Rasch analysis) resulting in interval level measurement scales, which conform 
to fundamental measurement and additivity as applied in classical measurement.  The 
result of conjoint measurement is that a person’s raw score (number of items scored 
correctly) is a minimal sufficient statistic for their ability (Lord and Novack 1968).  
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Methods for practically approaching conjoint measurement will be further explored 
under item response theory in Section 3.2.4 (page 76). 
 
In this thesis a representational perspective to measurement will be applied, defining 
measurement as “a procedure for identifying values of quantitative variables through 
their numerical relationships to other values” (Michell 1990).  The classical test theory 
model will initially be applied in ordinal scale development.  The latent variable model 
will then be applied, with consideration of modelling the variables under investigation 
and initially exploring the ordinal scaling properties of the scale developed.  
Fundamental measurement in the form of conjoint measurement will not be possible to 
explore within the scope of this thesis, but will be considered and recommendations 
made for future work. 
3.2 Psychometric methods 
Psychometrics is concerned with the theory and techniques for measurement and 
originated during the 19
th
 century in psychological measure development (Sokal 1971).  
The primary concern of psychometrics is the measurement of personal attributes and 
traits (e.g. intelligence), many of which are not possible to measure directly and are 
therefore considered latent variables.  It has two main foci for research; firstly, the 
development and refinement of theoretical approaches to measurement and secondly, 
the construction of measures and procedures for measurement (Streiner and Norman 
2003; Streiner 2003b).   
 
Psychometrics has a long history in the identification of methods for the development of 
questionnaires and measures in psychology and education (e.g. intelligence).  Its 
techniques have subsequently been used in the development of many clinical 
instruments both in rehabilitation and other fields (Hudak et al. 1996; Beaton et al. 
2001; Barreca et al. 2005).   
 
Psychometric methods based on CTT are widely used and have been developed and 
applied in many measures of latent variables (Lord and Novack 1968).  Other methods 
have been developed, which are argued to more directly represent measurement of 
latent variables without the assumptions inherent in CTT.  Item response theory (IRT) is 
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the general term used to describe these methods, which include approaches such as 
Rasch analysis and Mokken analysis. 
 
3.2.1 Classical test theory 
Classical test theory consists of methods for the development and evaluation of 
measures and is the underlying basis for the most commonly applied methods in 
psychometrics (Nunnally 1970; DeVellis 2006).  Measures in psychology, education 
and health care have been developed using CTT and it remains a mainstay of measure 
development (Hays et al. 2000; Hays et al. 2006).   
 
The origins of CTT began with both the work of Stevens (1946) in defining 
measurement and also earlier with the work of Edgeworth in proposing that the score 
for a measure is determined by the real or actual state of the unobserved variable plus 
error (true score plus error) (Edgeworth 1888).  This results in the following equation: 
 
Observed = True + Error 
 
This model for understanding latent variable scores is inherent in the representative 
CTT model of measurement and has been used widely in psychology and beyond 
(Nunnally and Bernstein 1994; DeVellis 2006; Hays et al. 2006).  The methodological 
approach of CTT has been most frequently applied to develop and test measures in 
psychology (Nunnally and Bernstein 1994).  In psychology and fields like rehabilitation 
there is often a need to seek proxy indicators that provide accurate information about 
latent variables that are not directly observable (see Sections 3.2.3 and 3.2.4; pages 75-
81) (DeVellis 2006).   
 
Within CTT it is accepted that error will occur in measurement between the real value 
of the variable under investigation and the observed score obtained on the test (DeVellis 
2006).  These errors are considered random and errors for different items are therefore 
considered independent of each other, unless testing can demonstrate that this is not the 
case.  Error needs to be minimised in measurement items, to accurately reflect the real 
value of the unobserved variable.  In CTT, considerable effort is expended in selection 
of items and ensuring that they are valid measures of the unobserved variable.  
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However, it is still accepted that error will occur and therefore, in general (though not in 
every case), measures require relatively large numbers of items to account for random 
error and still produce a reliable proxy of the unobserved variable by reducing the 
standard error of measurement (DeVellis 2006).   
 
A consequence of managing error by having a large number of items, is that the 
measurement scale can become very long and can be time consuming to complete, 
making it less feasible in clinical practice (DeVellis 2006).  Another problem in 
measures with many items is that some items within the scale may be unnecessary to 
produce a valid overall score, which is often referred to as item redundancy.   
 
There are seven main assumptions that are used to support the use of CTT (Hobart and 
Cano 2009).  Each assumption is very briefly explained as follows: 
1. That there is an observed score, a true score and an error score being the 
difference between the two as discussed above.  The true score of the latent 
variable is by definition unobservable.  For a person measured on a particular 
scale, the true score is assumed constant if measured at different times (in the 
absence of change).  However the error and thus the observed score will vary 
and result in a range of scores. 
2. When a scale is administered to an individual on multiple occasions (in the 
absence of change), the mean of their observed scores is equal to their true score.  
This principle assumes that repeated measurements are independent of each 
other, which will be unlikely when items are repeated for many measures. 
3. Errors of measurement are not related to the observed score. 
4. Error scores taken from two different scales (of the same construct) are 
uncorrelated and therefore unrelated. 
5. The error score on one scale is uncorrelated with the true score on another scale. 
6. Two scales are parallel if, for each person completing the scale, the true score 
and the error variance are the same. 
7. Two scales are equivalent when the true scores for each participating individual 
are the same except for an additive constant.  
 
In summary, CTT is based on a theoretical assumption that a true score exists, but that 
the observed score is complicated by the occurrence of error, which is assumed 
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unrelated to the construct under investigation.  Scales are assumed to embody interval 
level measurement if they fulfil broad criteria such as normal distribution of the study 
population.  Within CTT there is however an acknowledgement that many ordinal 
scales cannot be assumed to fulfil criteria for interval level measurement because they 
are clearly ordinal.   
 
3.2.2 Limitations of classical test theory methods 
A main criticism levelled at CTT is that the values of the true score and the error score 
cannot be determined, because they are unobservable theoretical variables (Borsboom 
2006; Reeve 2006; Hobart and Cano 2009).  This then means that the theory of 
measurement cannot be tested.  CTT therefore does not define mathematically the 
functional form of the observed score, true score or error score distributions (Borsboom 
2006).  Hobart and Cano (2009) therefore state that, because the measurement 
assumptions cannot be tested, they are considered met by most test data sets, which 
leads to the model being widely applied.  However, this may not be justified and 
Borsboom (2006) argues that modelling of the relationship between the true score 
(construct under investigation) and the observed score (measure results) should be 
undertaken as an important component of measure or scale development. 
 
In addition to concerns about the theoretical basis of CTT, issues have been raised about 
the way in which traditional psychometric methods are used in the evaluation and 
construction of scales (Borsboom 2006; Reeve 2006; Hobart and Cano 2009). 
 
An important limitation of ordinal data is that, assumptions are needed if the data from 
multiple items are to be summed into a single statistic.  The first assumption, technically 
made when assigning a ‘number’ to a point on an ordinal scale, is that in fact the 
distance between response categories is the same.  This is assumed by the fact of 
assigning a numerical value, but is usually not true.  The second assumption, is that total 
summed scores from such scales are consistent across the range of the continuum 
represented by the scale, not just as a numerical value but as a true representation of the 
construct (Hobart and Cano 2009).  These assumptions are not evaluated within a CTT 
approach, and would need to be addressed if fundamental measurement is desired. 
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A further limitation of using psychometric methods based on CTT to evaluate and 
develop a scale, is that the performance is dependent on the sample in which it was 
tested (Reeve 2006).  The implication therefore is that scale properties are re-evaluated 
if the measure is to be applied in a different patient group.  Therefore, a problem with 
CTT based psychometric method is that a person’s level of ability cannot be measured 
independently of the scale used. 
 
3.2.3 The latent variable model 
The latent variable model (LVM) can be viewed as an extension of CTT and is therefore 
discussed briefly here under this umbrella.  As discussed earlier, the concept in the 
LVM is to conceptualise theoretical attributes as latent variables.  The latent variables 
are unobserved (true score), but are measured using the observed variables (observed 
score i.e. measurement items) (Borsboom 2005).  The strength of the LVM over CTT is 
that it goes beyond an entirely operationalist concept and attempts to relate test scores to 
an underlying attribute.  In the LVM, a formal structure is set up, which relates test 
scores to the hypothesized attribute.  The empirical implications of the model are then 
deduced and the adequacy of the model is then evaluated by examining the ‘goodness-
of-fit’ with respect to empirical data (Borsboom 2005). 
 
The conceptual framework for LVM originates from the work of Spearman, who 
developed factor analytic models for continuous data in the context of testing 
intelligence (Spearman 1904).  The work of Spearman in factor analysis was developed 
further by other authors (Thurstone 1947; Lawley and Maxwell 1963) and led to the 
conceptual framework of confirmatory factor analysis (Joreskog 1971; Wiley et al. 
1973).  Factor analysis includes both exploratory and confirmatory factor analyses, 
which are discussed further in section 3.3.3.3 (page 99). 
 
Factor analysis is one method used to examine the pattern of relationship between 
different dependent variables (Kline 2000b; Darlington 2010).  Kline suggests that 
although measurement is not ensured by factor structures, these do give useful models 
about the underlying construct or latent trait (Kline 2000b).  While fundamental 
measurement is of prime importance, it is also important to ensure that the construct or 
trait of interest is being addressed.  Factor analysis may be useful in providing a model 
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of what construct or dimension scale items are detecting.  The limitation of factor 
analysis is that while it provides valuable information about the construct or dimension 
is does not address the issue of scaling in the manner of conjoint measurement. 
 
3.2.4 Item Response Theory 
In parallel to the factor analytic developments, the concept of latent variable analysis 
with continuous latent variables was applied to dichotomous data (Guttman 1950; Lord 
1952; Rasch 1960; Birnbaum 1968; Mokken 1970).  Dichotomous items are those, 
which only have an either/or response e.g. yes/no or good/bad (i.e. a nominal category), 
usually with multiple items used in the measurement tool.  These measurement 
approaches, initially used in educational testing, became known as IRT. 
 
The approach of IRT was extended to enable application with ‘polytomous’ items 
(Samejima 1969; Bock 1972; Thissen and Steinberg 1984; Molenaar et al. 2000), which 
corresponds with many scales in psychology and rehabilitation using this type of 
response option.  Polytomous items are those, which have multiple response options for 
each item. 
 
Borsboom (2006) proposes that one of the main breakthroughs of the past century in 
psychometric thinking is the realisation that measurement does not consist of finding 
the right observed score to substitute for a theoretical attribute as in CTT, but of 
devising a model structure to relate an observed variable to a theoretical attribute as 
with IRT.  Item response theory uses model-based measurement in which latent variable 
estimates of a state (e.g. level of arm function) depend on both the person’s responses 
and on the properties of the questions that were administered (Embretson and Reise 
2000; Hobart et al. 2007).  The methods used within IRT are suggested to be superior to 
CTT by some authors (Reeve 2006; Hobart and Cano 2009), because IRT item 
parameters are theoretically not dependent on the population sample used in 
development.  They are therefore assumed to be invariant (within a linear 
transformation) across divergent groups within a population and across different 
populations (Reeve 2006).  However not all authors agree and in practical evaluation, 
differences have been seen between different patient groups from the same population 
(Nunnally and Bernstein 1994; Kline 2000b).   




The theory of conjoint measurement has been considered in IRT approaches such as 
Rasch analysis.  However, the theory as proposed by Luce and Turkey (1964) has also 
been applied by other researchers in this area.  Michell (1990) has discussed the 
application of conjoint measurement in Thurstone’s theory of comparative judgment in 
measurement of attitudes (Thurstone 1927).  Another example of conjoint measurement 
is demonstrated in the application of Coombs’ theory of unfolding, which explored 
judgment behaviour among individuals (Coombs 1950).  However, although the theory 
and application of conjoint measurement is not new, it has not been extensively applied 
in the manner of CTT.  This may be due to difficulty in applying and understanding 
these techniques or limitations of IRT (see the following section), but the need to 
attempt fundamental measurement is compelling. 
 
In the following section, two methods will be discussed; Rasch analysis and Mokken 
analysis to further explore the IRT perspective.   
 
3.2.4.1 Rasch Analysis 
In this thesis, Rasch analysis will be discussed under the umbrella of IRT.  In 
rehabilitation research the most frequently applied IRT approach has been Rasch 
analysis (Dickson and Kohler 1996; Penta et al. 1998; Penta et al. 2001; Van de 
Winckel et al. 2006; Martin et al. 2007; Forkmann et al. 2009).  For example, 
ABILHAND is a measure of upper limb active function, developed by Penta and 
colleagues (Penta et al. 1998).  The measure was developed from a pool of items, which 
underwent Rasch analysis, to produce the final measure, which using the model has 
interval level measurement.   All items in the scale form a hierarchy, with each 
measurement item being more difficult than the item before.  This produces a measure, 
which provides consistent and comparable interval data and results in a person’s raw 
score (number of items scored correctly) being a minimal sufficient statistic for their 
ability (Lord and Novack 1968; Andersen 1977; Perline et al. 1979). 
  
The Rasch model has two main components (Rasch 1960).  The first component is that 
a person’s response to an item is governed by two factors: the ability of the person and 
the difficulty of the item on the construct (Pallant and Tennant 2006).  The second 
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component is the Rasch criteria of invariance – which requires that the relative location 
of any two persons on the continuum should be independent of the items used to make 
that comparison (Andersen 1977; Pallant and Tennant 2006).  When a set of items is 
used as a measurement instrument, the aim is to place the items on a continuum onto 
which people can be measured (Andersen 1977; Tennant and Conaghan 2007b; Hobart 
and Cano 2009).    
 
Rasch analysis is considered by some authors to be a one parameter model within IRT 
(de Koning et al. 2002; Raykov and Marcoulides 2011).  Two and three parameter 
models are also available; Rasch analysis is therefore the simplest example of 
parametric IRT.  However advocates of Rasch view it as distinct from other IRT 
methods because it does not seek to explain the data, but ensures that the data, using the 
model, are appropriate for interval measurement (Massof 2005; Hobart and Cano 2009).   
Rasch and other item response models use mathematical constructions to consider the 
way items and people function related to the latent variable.  However, Rasch requires 
that data fit the model.  If they do not fit, then the analysis seeks to identify why, and if 
required, removes data, re-collects data or re-conceptualises the construct.  In contrast, 
other IRT methods aim to find the item response model that best fits and therefore 
explains the data. 
 
A key feature of IRT is that a generalised linear relationship is expected between the 
items and the latent variable, with Rasch analysis being an exception, where a log-linear 
model is instead expected (Tennant and Conaghan 2007b).  The emphasis in the Rasch 
model is therefore the fit of the data to the model, which produces a form of conjoint 
measurement corresponding to the concept of magnitude in the classical measurement 
model. 
 
Hattie showed in a simulation study, that the Rasch model may be inappropriate to 
assess unidimensionality, because it failed to differentiate between unidimensional and 
multidimensional items (Hattie 1985).  However, the Rasch model assumes a 
unidimensional model and does not set out to identify unidimensionality as its main 
aim.  Software packages performing Rasch analysis provide an evaluation of principal 
components for the residuals (after the first principal component has been removed).  
Thus providing a confirmation of unidimensionality but not as the primary function of 
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Rasch analysis (Tennant and Conaghan 2007b).  Gillespie and colleagues proposed 
Mokken analysis as one method that can be used to assess unidimensionality in the 
preliminary stages of scale construction (Gillespie et al. 1987).   
 
3.2.4.2 Mokken analysis 
Mokken analysis is often referred to as non-parametric IRT because it evaluates the 
ordinality of the scale but does not attempt to produce an interval scale.  Mokken 
analysis, as with Rasch, is a probabilistic version of Guttman scaling (Van der Lee et al. 
2002; Zwinkels et al. 2004).  Guttman scaling requires that responses to an item exactly 
fit a predetermined model drawn as an item characteristic curve (ICC), items therefore 
have a fixed hierarchy.  In item response theory, an ICC describes the relationship 
between a latent trait and performance on an individual item.  In Rasch and Mokken 
analysis, the probabilistic version of the Guttman curve allows for small variations from 
the model, but requires that data largely conform to the model with a predicted fit to the 
ICC. 
 
Gillespie and colleagues identify one difficulty with Guttman scaling being, that the 
method assumes a deterministic model with measurement error excluded (Gillespie et 
al. 1987).  Deterministic in this context means that the ICC, which represents the 
probability of a correct response on the item to the latent trait, must match the 
functional form dictated by the Guttman model.  In practice, Gillespie and colleagues 
(1987) consider that this poses a difficulty in having no clear criteria for deciding if 
deviation from the scale represents measurement error in a set of items that are 
otherwise unidimensional or whether the deviations indicate that, the items lack 
unidimensionality. 
 
Mokken analysis avoids this problem by proposing a stochastic relationship between the 
item and the latent trait.  The stochastic relationship means that the model allows for 
variation in the shape of the ICC’s functional form.  Using the proposed stochastic 
relationship as a reference starting point, Mokken analysis then provides criteria for 
deciding if a set of items form a unidimensional scale, and whether a particular item 
should be included or not.  It also allows the addition of items to an existing scale and 
re-evaluation of the unidimensionality (Gillespie et al. 1987).   




The Mokken model treats the latent trait as a single construct along which a person’s 
location can be identified and also an items location or difficulty (van Abswoude et al. 
2004).  So, provided a unidimensional set of items is identified, the person parameter 
can be estimated by the number of items to which a person responds positively (referred 
to as the person score).  The item parameter can also be estimated by the proportion of 
people who respond positively (referred to as the item score). 
 
Mokken analysis therefore evaluates four assumptions.   
 
1) That items form a unidimensional scale.   
2) That item scores are locally independent, which means that item scores are 
independent within a group of persons with the same degree of the construct or 
trait being measured (Van der Lee et al. 2002).   
3) That the ‘item response function’ for each item is a non-decreasing function of the 
trait, which means each item would be expected to change in the same direction 
and to a related degree of change in performance measured against the construct or 
trait (Van der Lee et al. 2002).   
4) That ‘item response functions’ do not intersect, meaning that the items in the scale 
have an invariant hierarchical ordering across the latent trait in many different 
individuals when tested (Van der Lee et al. 2002; Zwinkels et al. 2004).  
Assumptions (1) to (3) need to be satisfied to accept differentiation between 
respondents (Monotone Homogeneity), and in addition, assumption four is 
required to accept differentiation between items (Double Monotonicity).  See 
Section 3.3.3 for further discussion and application of Mokken analysis. 
 
Hobart and Cano (2009) consider the strength of IRT methods, particularly Rasch 
analysis, to be the articulation of a theory as a mathematical model.  Unlike CTT, IRT 
focuses on the relationship between a person’s unobservable score (on the underlying 
trait) and the probability of responding to one of the response categories on a scale item.  
They see the application of a mathematical model in this way having three main 
advantages.   
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1. Because the model predicts the relationships between variables, it enables 
evaluation of the consistency of the data to determine how observed data ‘fit’ the 
predictions.   
2. It enables predictions to be made for the future (e.g. that data collected from 
another sample will fit the model).   
3. The strength of Rasch analysis in particular, comes from the analysis of 
deviations of the observed data from the predications of the mathematical model.  
Deviation of items can then be further examined and changes to item categories 
or removal of items can be considered to allow conformity to the model, which is 
closer to providing conjoint measurement. 
 
3.2.5 Limitations of Item Response theory methods 
Kline (2000), Nunnally and Bernstein (1994) have made criticisms of the Rasch 
method, which are presented as three main points and also apply to Mokken analysis.   
 
The first criticism is that Rasch analysis assumes that items are equally discriminating, 
when no test would be so constructed because it makes sense to vary the discriminatory 
power of items in a test of ability.  This is despite Rasch measurement being 
theoretically ‘population free’, which means that a measure developed using this 
method, operates in the same manner irrespective of the population group to which it is 
applied.  However, this criticism does not seem entirely justified, given that items are 
designed to form a hierarchical scale and therefore if a person is operating low down on 
the scale they will not be expected to complete the harder items at the top of the scale.  
A further criticism of Rasch measures being population free is that while in theory this 
should be true, in practice in rehabilitation this may not be the case.  If measures are 
developed on smaller samples, as is often the case in rehabilitation measures, variation 
may be seen in the operation of measures.  This may be because the different groups are 
actually different populations as seen in the development of ABILHAND in rheumatoid 
arthritis and then in stroke (Penta et al. 1998; Penta et al. 2001). 
 
Kline also comments that Rasch analysis also assumes that subjects do not attempt 
guessing or give socially desirable responses to questions.  This is a reasonable 
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criticism, which has particular relevance for aptitude or educational tests but may not be 
as significant in measures of health outcome. 
 
Second, large samples need to be tested if reliable population free scaling is to be 
established (Lord 1974).  In addition, in construction of item banks by some authors, it 
has been identified that virtually no items fit the model if enough calibration is carried 
out (Kline 2000; Kline 2000b).  However for development of measures using both CTT 
or IRT methods, large samples are often needed and Rasch analysis is probabilistic and 
designed to accommodate a small degree variation from the model.  It is therefore likely 
that if an exact match to the Guttman scale is being expected, then items will not fit the 
model. 
 
Third, Kline identified that a problem may occur with the dimensionality of Rasch 
scales.  In a study by Barrett and Kline applying Rasch analysis to the four sub-scales of 
the Eysenk Personality Questionnaire, a meaningless Rasch based scale was produced 
with the exclusion of a number of items (Barrett and Kline 1981).  However, this does 
not of itself demonstrate that Rasch is not working to produce a hierarchical scale, 
because all approaches are dependent on the selection of items, which at least have 
some relevance to a single construct, rather than reflecting four constructs.  Items may 
seem to fit the model, but this is likely to be coincidental if they have no theoretical 
relationship to the construct. 
3.2.6 Comparison of CTT and IRT methods 
Embretson (1996) compared CTT and IRT methods with reference to six measurement 
rules.  Kline (2000) has also made comments comparing CTT and IRT.  The 
comparisons made by Embretson and the comments made on these by Kline have been 
combined into the following six points. 
 
1. Standard error of measurement.  In CTT, the standard error of measurement 
allows confidence limits to be set, for individual scores, which apply to the 
whole population.  In Rasch measurement however, estimates can be calculated 
for each level of the latent trait, which are population free.  The implication of 
this is therefore, that although the Rasch method has an advantage in precision, 
it becomes most relevant in practice at the extremes of the scale. 
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2. Reliability and test length.  In CTT, longer tests with more items have been 
identified as more reliable in general.  In IRT, shorter tests can be more reliable.  
However, this is only true for IRT measures which have items, selected to fit the 
level of trait of the subjects.  In other instances, Kline (2000) argues that it is 
still the longer, full version of the test, which is more reliable than the reduced 
number of items. 
3. Parallel tests.  In CTT if scores from different groups of items from the same test 
are compared it is necessary that they are parallel or equated (i.e. the relationship 
between the items must be established before they can be compared).  In IRT, 
different sets of items measuring the same trait can be highly correlated 
indicating they are measuring the same underlying construct or dimension and 
allow comparison between them.  However according to Kline (2000), this can 
be misleading because in real-life data using the Rasch model, the latent trait 
does not account for all the variance in the items, as it is predicted to do.  Kline 
may be justified in the assumption that the latent trait may not account for all 
variance and error may be a factor, although this is not really allowed for in a 
model such as Rasch.   
4. Unbiased assessments of item properties.  In a simulation by Embretson, as 
expected, the Rasch equivalent of item difficulties when calculated from two 
different groups was highly correlated (Embretson 1996).  Kline (2000) 
comments that it is insufficient to demonstrate this in a model alone.  However, 
despite Kline’s comment, this strength of the Rasch method in particular and 
IRT in general is given some support by Embretson’s work. 
5. Standardisation.  In scales developed by CTT the meaning of scores relies on 
adequate standardisation.  However, in theory, meaningful scale scores can be 
obtained directly from Rasch measures.  However, despite the fact that items 
and individuals can be matched in the Rasch method, population norms are 
required to give meaning to the scores. 
6. Types of scale.  In CTT, it is assumed that an interval scale has been produced 
by selecting items that are normally distributed in a given population.  However 
as already discussed, these measures are then population specific.  This is not 
considered to be the case, by some authors, for a Rasch developed measure, 
which is assumed to be population free.  However, this apparent strength of 
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Rasch developed measures may not always occur in practice as already 
discussed. 
 
IRT is based on item characteristic curves, which are probabilistic in the case of Rasch 
and Mokken, while CTT is a linear model of correlations and factor analysis producing 
theoretical relationships between variables.  Kline also argues that while there are clear 
differences there are also similarities between IRT and CTT findings (Kline 2000b).  He 
has identified the following evidence for this: 
 
 Roskam demonstrated that factor loadings of the items in a test were good 
estimates of the slopes in item characteristic curves, with the proviso that the 
latent trait was normally distributed (Roskam 1985). 
 In addition, Nunnally and Bernstein (1994) have argued that there is a very high 
correlation between Rasch scales and measures produced using CTT methods.  
Beaton and colleagues (2005) demonstrated this in the development of the Quick 
DASH, an upper limb function outcome measure.  Development resulted in a 
similar measure using CTT and IRT approaches.  However clinical prioritisation 
of items by clinicians was felt by the authors to lead to a more clinically 
applicable measure with better face validity, which was the version finalised for 
use in their work.  Clinical prioritisation also resulted in a scale, which retained 
the psychometric properties of the CTT and IRT developed versions. 
 
Similar findings have been demonstrated in item analysis for other measures using IRT 
and CTT methods.  Pollard and colleagues showed similar results with core items in a 
measure of impairment, activity and participation in patients following lower limb joint 
replacement, however some different items were removed with the IRT method 
(Samejima’s Graded Response Model) and the CTT methods (Pollard et al. 2009).  
Cano and colleagues evaluated the Cervical Dystonia Impact Profile (CDIP-58) using 
CTT methods to demonstrate that this Rasch developed measure also conformed to CTT 
psychometric requirements (Cano et al. 2008).  The purpose of the analysis was 
primarily to provide evidence of psychometric properties to meet current United States 
Food and Drug Administration guidelines for patient reported measures (PROMs) to be 
used in trials.  The CDIP-58 was shown to be robust using CTT and had already been 
shown to be robust using Rasch analysis.  Therefore, CTT and IRT methods may not be 
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mutually exclusive as demonstrated by these studies.  However, it should be conceded 
that IRT offers stronger evidence of true measurement and can also support evaluation 
of the unidimensionality of a scale.   
 
The work of Cano and colleagues also highlights a practical issue that outcome 
evaluation criteria currently focus on CTT psychometric methods in the evaluation of 
scales for potential use in studies and trials.  In addition, current quality criteria such as 
the COnsensus-based Standards for the selection of health status Measurement 
INstruments (COSMIN) (Mokkink et al. 2010) and Quality criteria for measurement 
properties of health status questionnaires (Terwee et al. 2007), use primarily CTT 
psychometric method criteria to evaluate the measurement properties of scales.  The use 
of IRT methods alone to develop and validate measures may lead to those measures not 
being considered for use in clinical practice and trials.  This may change as IRT 
methods become more widely used and understood, but currently some demonstration 
of CTT psychometrics is useful to gain clinical and research acceptance of measures.   
 
The studies of Pollard and colleagues and Cano and colleagues also highlight possible 
strengths in using CTT and IRT in combination.  This approach has been seen in some 
measures such as the Impact of Psoriasis Questionnaire, which was developed using 
CTT methods and then refined using confirmatory factor analysis to more clearly define 
its sub-scales (Nijsten et al. 2006).  Each sub-scale then underwent Rasch analysis to 
produce a robust measure.  Forkmann and colleagues have used a similar approach in 
developing a depression screening measure (Forkmann et al. 2009b). 
 
Although IRT approaches and Rasch scales in particular are examples of “additive 
conjoint measurement” (in other words interval scaling), the absence of a unit of 
measurement that corresponds to something tangible in the real world, raises some of 
the same concerns as for CTT developed measures (Kline 2000c).  This is a 
fundamental concern, over and above, any practical criticisms to be levelled at 
application of approaches such as Rasch analysis.  However, Kline (2000) concludes 
that while the approach of CTT has been valuable, its assumptions do not replace the 
need to strive for ‘true’ measurement.  He also concedes that in the absence of such 
‘true’ measures, representative approaches may still be valuable.   
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Limitations to CTT and IRT approaches have been identified.  Application of CTT 
approaches are still relevant in the initial development of measurement tools and in 
particular can assist in the modelling of constructs or dimensions essential for 
measurement.  However, IRT approaches, particularly Mokken and Rasch methods, 
represent advances in scaling latent variables.  As discussed, IRT approaches also have 
limitations, which should be acknowledged and cannot resolve completely the 
difficulties of latent variable measurement, but currently represent the best options for 
scaling of latent variables.  Clinical utility is also important in the development of 
measures and will be discussed in the following section related to clinimetrics and 
psychometrics. 
 
3.2.7 Psychometric and clinimetric challenges 
The following section will briefly discuss the theoretical difference in perspective 
between psychometrics and clinimetrics and the relation of these concepts to measure 
utility.  Clinimetrics, in common with psychometrics, is also concerned with evaluating 
measurement properties, borrowing many of its methods from the psychometric 
literature.  However, the approach in clinimetrics is to emphasise strongly the clinical 
application of the resulting measure (i.e. utility) as a factor in measure development in 
addition to ensuring robust measurement properties.  These theoretical concepts are of 
relevance to this thesis because clinical utility of the measure is of prime importance in 
conjunction with robust measurement properties.   
 
A current perceived controversy in clinical measure development exists between the 
concepts of psychometrics and clinimetrics.  The controversy emphasises on one hand 
the need to ensure robust measurement properties; while on the other ensuring that 
items of clinical importance are included in measures.   
 
Clinimetrics 
Feinstein introduced the term clinimetrics in 1983 and defines it as referring to 
“arbitrary ratings, scales, indexes, instruments or other expressions that have been 
created as measurements for clinical phenomena that cannot be measured in the 
customary dimensions of laboratory data” (Feinstein 1983; Feinstein 1987).  Wright and 
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Feinstein (Wright and Feinstein 1992) state that measurement depends on four 
components:  
1. The phenomenon chosen as the focus of attention 
2. A strategy for constructing the measure 
3. The single or multiple items that describe the selected attributes of the 
phenomenon  
4. An index that expresses the final rating of the aggregated items  
 
Feinstein suggests the importance of evaluating measurement instruments for validity 
and reliability has been lacking in the development of some measures in clinical 
practice.  Feinstein also emphasises however, the importance of what he terms 
sensibility, referring to whether the measure appears to measure the intended construct 
or has face validity.  
 
3.2.7.1 Psychometrics and clinimetrics 
The difference between the two concepts has been characterised as psychometrics 
attempting to measure a single dimension or construct with multiple items using 
validation methods to demonstrate that all items measure a single attribute.  While 
clinimetrics, measures multiple attributes with a single index and strategies for measure 
development focus on selecting from a clinical perspective the most important items to 
be included (Fayers and Machin 2007). 
 
The purpose of both psychometrics and clinimetrics in theory is the production of valid 
and reliable measures.  However clinimetrics is thought to be different from 
psychometrics in being more concerned with sensibility or face validity of a measure 
while psychometrics gives more importance to the way in which the measurement items 
(a) correlate with each other and (b) measure the same construct (Wright and Feinstein 
1992).  Clinimetrics as proposed by Feinstein (1987) appears to advocate the acceptance 
of clinical measures that combine scores from items from different traits or dimensions, 
which leads to significant criticism from measurement theorists.  A number of 
clinimetric type scales have been developed, such as the Glasgow Coma Scale 
(Teasdale and Jennett 1974) for assessment of consciousness and the APGAR scale 
(Apgar 1953) for assessment of responsiveness of infants.  Both of these scales are 
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multidimensional and are often given single scores, yet provide useful clinical 
information for decision making.  However, they do not conform to the concept of 
conjoint measurement and it is not meaningful from a measurement perspective to 
produce total scores for these scales.   
 
Feinstein suggests that a conflict occurs between sensibility and standardisation of items 
to form single constructs.  That while clinimetrics may be lacking in standardisation of 
measurement items and scales, psychometrics may lack sensibility in application of 
items and measures to clinical outcome (Feinstein 1987).  It has been suggested that the 
two fields can learn from each other and that in particular applying psychometric 
techniques can progress clinimetrics and the development of measurement scales in 
clinical practice (Wright and Feinstein 1992). 
 
Clinimetrics has been criticised for being an unnecessary term, which creates confusion 
in the literature (Streiner 2003b).  Streiner states that Feinstein proposed that 
clinimetrics is a “sub-set of clinical epidemiology”, while he states it is a subset of 
psychometrics.  Streiner has also been critical of the suggestion by Feinstein that “all 
questionnaires in psychology are unidimensional and all those in medicine are 
heterogeneous” (Streiner 2003b).  He suggests that this overlooks the diversity of 
instruments in both fields and that at the extremes in both areas this may be true but is 
not for the majority of measures in either field.   
 
In summary, the debate regarding clinimetrics and psychometrics has at times become 
unnecessarily polarised, which seems counterproductive in meeting the objective of 
providing clinically useful measures.  While the introduction of clinimetrics is useful in 
highlighting the clinical utility and feasibility of measures, it risks detracting from the 
requirements for fundamental measurement.  Both clinical utility and robust 
measurement properties are required in useful clinical measurement tools.  The 
following section presents the principles of measure development and psychometric 
testing used in this thesis.   
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3.3 Principles of outcome measure development  
Donabedian defined health outcome as “a change as a result of antecedent healthcare”  
(Donabedian 1980).  This definition is directly applicable to active function outcomes, 
but is too narrow when considering passive function outcomes.  Passive function 
outcomes may include the prevention of deterioration rather than just improvement, 
which is harder to assess.  Therefore, health outcome could be more usefully defined as 
‘achievement of an intended health goal as a result of antecedent healthcare’ which is 
the definition used in this thesis.   
 
Measures may be developed from different perspectives, that of the population or that of 
the individual.  Measures, which are useful in describing a population, are described as 
‘nomothetic’.  A nomothetic measure is designed to quantify the observation made with 
population norms (Merriam-Webster Online Dictionary 2009).  An example of a 
nomothetic measure would be the Jebsen Test of Hand Function (Jones 1990), which 
compares the performance of the individual patient against population norms for 
patients with stroke and therefore needs to conform to the standards for measurement 
discussed at the beginning of the chapter.   
 
Measures that are developed from the perspective of the individual are described as 
‘idiographic’.  An idiographic measure compares an observation with a standard set by 
the patient and therefore can only be compared with that patient directly (Merriam-
Webster Online Dictionary 2009).  An idiographic example would be Goal Attainment 
Scaling (Kiresuk et al. 1994), which allows the patient to set a goal and then compare 
the outcome of intervention against the goal they have set.  This type of approach 
presents theoretical difficulties however if arithmetic evaluation and comparison against 
other individuals is undertaken who have goals set in differing goal areas. 
 
Both idiographic and nomothetic measures have strengths and weaknesses.  Idiographic 
measures have the advantage of being responsive and specific to the aims of the 
intervention, but are more limited in terms of comparisons between individuals and 
across populations.  Nomothetic measures may allow comparison easily between 
individuals but may not be sensitive to the specific needs of the individual and therefore 
may not be responsive to change in that individual.  
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3.3.1 Criteria for a good measure 
The development of any measure must include evaluation of its measurement properties 
(McDowell and Newell 1987).   
 A measure must be valid in recording what it purports to measure and relevant 
to the effects of the intervention being examined.   
 It must be reliable in distinguishing between different patients and must be able 
to distinguish important change rather than measurement error (Terwee et al. 
2007).   
 It must be responsive to change that occurs as the result of intervention (Wade 
1992a).   
 For a measure to be used in normal practice it must also be feasible, that is 
simple and practical enough to apply in routine clinical practice (Slade et al. 
1999).   
(Also, see Glossary) 
 
 
The Scientific Advisory Committee (SAC) of the Medical Outcomes Trust have 
proposed criteria for the evaluation of measures regarding their psychometric properties 
(Medical Outcomes Trust 2002).  The SAC criteria contain eight areas to be used for 
evaluation of measures.   
1) Content validity 
2) Internal consistency 
3) Criterion validity 





7) Floor and ceiling effects 
8) Interpretability 
 
Terwee and colleagues (Terwee et al. 2007) have more recently refined and updated 
these criteria by developing quality requirements for the identified properties of a 
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measure using CTT.  These criteria or criteria of a similar nature based on CTT, are 
widely used in evaluating the psychometric properties of health related outcome 
measures (Fitzpatrick et al. 1998; Moe-Nilssen et al. 2008; Scarpelli et al. 2008; Tamber 
et al. 2009).  The majority of psychometric evaluation criteria identified in a recent 
search by the author are based on CTT as indicated in those above.  One exception was 
from the patient reported outcome measures group, which in addition to CTT 
approaches to psychometrics also includes reference to the use of IRT under the heading 
of precision (Fitzpatrick et al. 1998).  The inclusion of IRT approaches in this way is 
welcome, but may be viewed by some proponents of IRT, as not giving sufficient 
importance to these methods.  However including both CTT and IRT methods has 
strengths in both a) ensuring maximum understanding and acceptance of the 
psychometric properties of a resulting measure and b) ensuring robust measurement 
properties. 
3.3.2 Item Generation 
The first step in development of a measure is usually to identify items for inclusion 
(Streiner and Norman 2003).  Items may be taken from a number of different sources: 
A) Critical analysis of the published literature (Hobart et al. 2001).  At this stage a 
number of possible items may be identified from pre existing scales (Hobart et 
al. 2001).   
B) Analysis and synthesis of the views of patients, carers and clinicians (Streiner 
2003b), which may also be used to confirm items identified from literature 
sources or initially generate new items (Hicks 1999; Hobart et al. 2001).   
C) Analysis of clinical practice also provides possible items to address areas that 
have not been included in previous measures (Streiner 2003b). 
 
A) Systematic reviews may be of value in identifying relevant measures already 
developed as well as additional items.  This approach has been used in measure 
development in neurological rehabilitation as well as other areas of rehabilitation 
management (Bot et al. 2004; Terwee et al. 2006; Rowland and Gustafsson 2008; van 
de Ven-Stevens et al. 2009).  This method can produce a large pool of items, but risks 
reflecting the accepted wisdom on a subject and in particular may be prone to reflect the 
views of clinicians rather than patients and carers.   
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B) Views of patients and carers may be more relevant to the real-life context, which 
may be of prime interest in evaluating functional outcome.  Items identified by patients 
can also be “more specific and concrete” than those generated by clinicians and are 
important to consider for this reason (Lomas et al. 1987).  In addition, they are likely to 
add to face and construct validity in the final measure.   
 
Obtaining the views of patients and carers may take a number of different forms.  
Consultation with potential users (patients and carers in this instance) may be achieved 
by applying methods such as focus groups or semi-structured one-to-one interviews.  
Both focus groups and semi-structured interviews allow participants to share their views 
and enable incorporation of participant’s experiences of healthcare and difficulty in 
functional performance into measure development.  However, group discussions may 
have advantages over semi-structured interviews for identification of measurement 
items.  While semi-structured interviews tend to be directed by the researcher (Reed and 
Roskell-Payton 1997; Smith et al. 1997), group discussions lend themselves to direction 
by the participants with researchers taking a more passive role (Bender and McKenna 
1994).  In addition Sim and colleagues have suggested that group interaction maybe 
more spontaneous and Kitzinger has suggested that focus groups allow participants to 
vocalise previously unarticulated thoughts and reveal common views with others in the 
group (Kitzinger 1994; Sim and Snell 1996).   
 
While there are advantages to focus groups, there are also potential problems that may 
occur with group interaction.  The involvement of group members may be limited by 
personal inhibitions, competition to speak or get their particular point across by group 
members and the social convention of turn-taking in conversation.   
 
C) Goal setting in rehabilitation practice provides a unique opportunity for interrogation 
of clinical records.  However, analysis of clinical practice may take a number of forms; 
including reviewing clinical records, clinical team decision-making and evaluation of 
clinical results.  The specific review of rehabilitation goals provides an innovative 
method of obtaining patient and carer views.  In rehabilitation the use of goals set for a 
specific intervention, may provide a potential ‘pool’ of items to include in the 
development of measurement tools.   
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The advantage of this method is that it focuses on the particular area under 
investigation, avoids the problems associated with group interactions and elicits the 
patients (and sometime carers) perspectives on what is important to them.  However 
disadvantages may include the researcher or clinician influencing the patient in the goal 
setting process (Reed and Roskell-Payton 1997), lack of reflection on the whole patient 
group (goals may be specific to that individual) and artificial restriction of goals to a 
very specific area.  Nevertheless using rehabilitation goals as a source of possible items, 
is both efficient at identifying the issues important to patients and carers and also 
ensures face validity of the items.   
 
In a measure of arm function, items may include many diverse activities.  It is not 
possible to include all possible items in a measure, because this would make the 
resulting scale long and time consuming to complete (Messick 1980; Streiner 2003b).  
The items initially generated will therefore, in due course, need to be reduced to make 
the scale feasible for clinical application. 
 
3.3.2.1 Item reduction 
Once the possible items have been identified, it is necessary to select the ‘best’ items to 
be used in the measure.  Item reduction may take different forms, which broadly divide 
into two categories; statistical methods to differentiate the items from a measurement 
perspective once data has been collected, and more intuitive approaches using the 
opinions of experts to identify the most important items to reflect the construct, for 
example Delphi Consultation (Reid 1988).  Delphi consultation, while still enabling 
interaction with multiple individuals, avoids some of the problems identified with focus 
groups such as personal inhibitions, competition to speak and turn-taking in 
conversation (Burns et al. 2003; Finger et al. 2006).   
 
Experts used in approaches such as Delphi consultation may be patients, carers or 
clinicians.  The priority for removal of items will firstly be those that are least relevant 
to the construct being measured and secondly those that are redundant or unreliable.  
The process ensures that items, which are clinically important, relevant to the construct 
and enhance utility and feasibility are included.  However, the Delphi approach does not 
ensure the measurement properties of the resulting items and methods to evaluate this 
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will therefore be needed.  Once items for possible inclusion in a measure have been 
identified, it is necessary to consider how responses to these items will be recorded, 
measurement properties and the possibilities for analysis that this presents (McDowell 
and Newell 1987).   
 
3.3.2.2 Relationship of measurement to the construct or trait 
Methods to evaluate the relationship of items to the latent trait or construct, such as 
exploratory factor analysis in CTT and methods such as Mokken in IRT, may result in a 
reduced number of items.  In the case of exploratory factor analysis, the focus is to 
determine the constructs covered by the items, but this may result in the exclusion of 
items which do not fit any construct or form a construct which is not the object of 
investigation (Kline 2000b).   
 
In IRT methods, such as Mokken analysis and Rasch analysis, items may be removed 
because they do not fit the scale, but again the primary aim is not the removal of items.  
In the case of Mokken analysis, the aim will be to produce a unidimensional ordinal 
scale.   
3.3.3 Psychometric properties of measures 
The following section explores the psychometric properties that apply to measures of 
function in the upper limb and discusses the benefits and challenges of considering 
these issues during measure development.  The approach taken is primarily one of 
initial evaluation using CTT methods with addition of preliminary evaluation using IRT 
methods in the form of Mokken analysis.  The criteria used to evaluate psychometric 
properties are primarily based on those by Terwee and colleagues (Terwee et al. 2007) 
incorporating the work of the Scientific Advisory Committee (SAC) of the Medical 
Outcomes Trust  (Medical Outcomes Trust 2002).  In addition, IRT methods of scale 
evaluation for measurement have also been considered as advocated by Hobart and 
Cano (2009), but using Mokken analysis to assess for ordinality of the scale as an initial 
step in IRT evaluation (See Table 3.1).   
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Table 3.1 Quality criteria used in this thesis adapted from Terwee and colleagues (2007). 
Attribute Criteria Evaluation 
Validity  





Confirmation that the measure is appropriate to its intended use 




The concept to be measured, and the intended target population (who should be involved in scale development) 
Give a clear description of the structure of the scale and intended level of measurement 
Describe empirical basis for selection of item content and combination 




Evidence that the scores of the measure are related to an accepted gold standard 
(Give rationale for choice of criterion measure) 




Evidence that the scores relate to other measures consistent with theoretically-driven hypotheses 
The extent to which the scores correlate with other measures of similar concepts (convergent validity) and do not correlate with 
unrelated measures (divergent validity) 





Information on unidimensionality and rationale for deriving scale scores (measurement) 
Describe any intended subscales built into the conceptual design 
Exploratory and Confirmatory Factor Analyses within target population – how many factors – what does each represent? 
(Positive rating if factor analysis performed on adequate sample size (n= (7 x no of items) and at least 100) 
Mokken Analysis using a monotone homogeneity model to confirm dimensionality and preliminary measurement properties in the 
scale (minimum values of H indicating a strong scale is 0.5, a medium scale 0.4 and a weak scale 0.3). 
Scaling   
Confirmation that items form a hierarchical scale conforming to either ordinal or interval scaling.  
Mokken Analysis applying a monotone homogeneity model, double monotonicity model or conformity to Rasch measurement. 









The precision of the scale based on interrelatedness of the scale’s items 
Item-total correlations (correlation of each item with the total score excluding that item) 
Cronbach’s alpha calculated for each subscale – Positive rating: alpha should be between 0.70 and 0.95 (higher than this suggests 
item redundancy) 
Reproducibility  




Extent to which scores on repeated measures are close to each other 
Minimal Important Change (MIC) < Smallest Detectable Change (SDC) outside the limits of agreement OR arguments that 




Stability of the test over time (repeatability, intra-rater reliability) and between different observers (inter-rater reliability) 
(Time period should be long enough to prevent recall, but short enough that no clinical change has occurred) 
Total scores – intra-class correlations (ICC) or Bland and Altman Limits of agreement for continuous (interval) data 
Item-by item analysis of agreement using weighted kappa statistics for ordinal data 
 (Positive rating: ICC and kappa coefficients should be at least 0.70 in a sample of at least 50 patients) 
Responsiveness  




Evidence of change in longitudinal analysis – significant differences (Wilcoxon z or paired T tests), Effect size estimation 
Ability to distinguish clinically important change from measurement error 
Positive rating, the (SDC)* or the Limits of Agreement should be smaller than MIC*; or Gyatt’s Responsiveness Ratio: MIC/SDC 
= at least 1.96 
(NB Excluding Wilcoxon, these are parametric tests suitable really only for continuous normally distributed data) 
Alternatively, the area under the Receiver Operating Characteristics (ROC) curve should be at least 0.70 









Describe how the tool should be reported and interpreted e.g. sub-scores, total scores etc 
Provide information about what change in score would be clinically meaningful – define MIC – “the smallest difference which 
patients would perceive as beneficial and would mandate a change in the patient’s management (in the absence of troublesome side 
effects and excessive cost)”. 
Comparison of change in groups expected to change with those not (e.g. responders vs. non-responders, active treatment vs. 
placebo) 




Floor or ceiling effects are present when >15% of subjects achieve the highest or lowest possible score. 
(Positive rating:  no floor or ceiling effects in a sample size of at least 50 subjects in the target population) 
Burden  
The time, effort or other demands of administering the instrument 
 
Time to administer 
 
Information on average and range of time taken to complete the instrument 
 Any special requirements or restrictions – e.g. training, level of professional expertise to apply it 
 Under what circumstances is it not suitable? 
(Positive rating: if burden is described and acceptable to target users and clinicians) 
Alternative modes of administration  
Describe if these are available 
Evidence of reliability, validity, responsiveness, interpretability and burden for each administration 
Information on comparability of the alternative modes 
Cultural and language adaptations  
Describe if these are available 
Methods to achieve conceptual and linguistic equivalence.  
Any significant differences between the original and translated versions – how any differences were reconciled 
*Smallest Detectable Change (SDC), Standard Error of Measurement (SEM), Minimal Important Change (MIC) 
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3.3.3.1 Criteria for psychometric assessment 
The criteria of Terwee and colleagues were used in a systematic review of upper limb 
function measures for rehabilitation in patients after musculoskeletal problems (Bot et 
al. 2004).  In addition to the original criteria, feasibility has been added and is discussed 
below.  Construct validity has been expanded, with the inclusion of unidimensionality 
and evaluation of ordinal scaling using Mokken analysis (see Table 3.1). 
 
Psychometric terms used in this thesis are referred to in Table 3.1 and are included for 
reference in the glossary. 
 
3.3.3.2 Validity 
Face and content validity should be established before a scale is used to evaluate the 
outcome of clinical intervention and are often considered in the development of a 
measure (Streiner and Norman 2003).  Face validity is important because: 
1. It increases cooperation and motivation among respondents 
2. It attracts respondents  
3. It reduces dissatisfaction among respondents 
4. Makes it more likely that policy-makers and funders will accept findings  
(Nevo 1985) 
 
Face validity is usually established by asking a panel of users to review the measure, but 
can also be addressed by involving users in the process of development.     
 
A closely related concept to face validity is content validity, which is similar, but 
evaluates that the instrument covers all the relevant concepts or domains (Streiner and 
Norman 2003).  A tension often exists between ensuring that a measure contains all the 
relevant items related to the construct being measured and yet is still short enough to be 
feasible to apply in clinical practice (Tansella and Thornicroft 2001).   
 
Criterion validity is usually the comparison of the new measure with an existing gold-
standard measure both applied at the same time (concurrent validity) or comparing the 
predicted result with the actual outcome (predictive validity) (Streiner and Norman 
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2003; Barreca et al. 2005).  In many cases, the reason for developing a new measure is 
that a comparable scale does not exist and therefore comparison with a gold standard is 
not possible.   
 
Evaluation of ‘construct validity’ may be undertaken by linking the detection of 
change identified by the new measure to a prediction or hypothesis of how change 
should occur (Cronbach and Meehl 1955; Streiner and Norman 2003).  The term 
‘construct validity’ therefore originates from the idea that the new measure evaluates the 
construct it has been designed to measure (Cronbach and Meehl 1955), however the 
term is often applied even more broadly in current practice.  It may be possible in some 
cases to link change in an existing measure, related to the construct, with change in the 
new measure and thus demonstrate ‘construct validity’ (Turner-Stokes et al. 1999).   
 
3.3.3.3 Unidimensionality of sub-scales 
Measures may be developed to evaluate a single construct or they may contain a number 
of sub-scales addressing different constructs, which have a relationship to overall 
function.  Multi-dimensional measures are common in evaluation of function and may 
contain sub-scales evaluating different, functional areas or constructs (McPherson et al. 
1997).  However, for conjoint measurement, evaluation needs to be focused on a single 
dimension and therefore sub-scales will often be used for multidimensional measures.  
Attempts have been made to apply conjoint measurement to multidimensional measures 
using the theory of multidimensional scaling (Michell 1990).  However, such methods 
have come under considerable criticism (Wiener-Ehrlich 1978; Tversky and Gati 1982), 
because the dimensions of such scales are unclear and therefore measurement is 
questionable.  Therefore, for measurement to be possible using current methods, a 
unidimensional scale is essential.  To establish unidimensionality (or constructs) of 
scales or sub-scales CTT approaches such as factor analysis may be used or IRT 
approaches such as Mokken analysis.   
 
Factor Analysis 
Factor analysis is used to examine the pattern of relationship between different variables 
(Kline 2000b; Darlington 2010).  Kline suggests that factor structures, give useful 
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models about the underlying construct or latent traits, which relate to a single dimension 
(Kline 1994; Kline 2000b).  
 
The term factor analysis (FA) includes a number of different methods used to examine 
how underlying constructs influence responses on measurement items (or other 
variables dependent on what is being investigated) (Kline 1994; Raykov and 
Marcoulides 2011).  Two broad types of FA are possible: exploratory factor analysis 
and confirmatory factor analysis.  Exploratory factor analysis (EFA) attempts to 
discover the constructs influencing a set of responses (DeCoster 1998).  Confirmatory 
factor analysis (CFA) evaluates if a specified set of constructs (usually identified 
through EFA) is influencing responses in a predicted way (DeCoster 1998).   
 
The model underlying FA proposes that each item response is influenced by underlying 
factors, which are common to all items or groups of items.  In addition, each item also 
has a unique underlying factor.  Factor analysis is then undertaken by examining the 
pattern of correlations (or covariance’s) between the observed items (DeCoster 1998).  
Items which are highly correlated (positively or negatively) will usually be influenced 
by the same factors.  In contrast, those that are relatively uncorrelated are likely to be 
affected by different factors.   
 
Principal Components Analysis 
The aim of principal components analysis (PCA) is conceptually slightly different to 
FA.  Exploratory factor analysis and PCA are often considered to be synonymous, 
however some differences exist.  The concept underlying PCA is to reduce the 
dimensionality of a data set consisting of a large number of interrelated items (Jolliffe 
2002).  The PCA method operates by transforming the interrelated items to a new set of 
variables (the principal components), which are ordered so that the first few components 
retain most of the variation present in all the original variables (Jolliffe 2002).   
 
The differences between EFA and PCA originate from the different models on which 
they are based.  With EFA the responses to items are assumed to be based on underlying 
factors, while in PCA the principal components are based on the measure’s responses 
(DeCoster 1998).  The PCA method has been frequently applied in rehabilitation 
research to identify the number of dimensions underlying a set of interrelated items 
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(Bedard et al. 2001; O'Rourke and Tuokko 2003).  PCA has been used for evaluation of 
measurement instruments, to identify the principal components contained within the 
item responses, before evaluation of scaling properties.  In addition, a combination of 
PCA and IRT approaches has been used to evaluate and develop measures. 
 
An example of this is provided by Siegert and colleagues who undertook a 5-step 
analysis of the factor structure and dimensionality of the Zarit Burden Interview in a 
sample of 222 carers (Siegert et al. 2010).   
 Steps 1 and 2 involved a CFA (using AMOS 16), followed by Rasch analysis of 
the full scale.   
 Step 3 used a PCA with rotation of the resulting factors (Siegert et al. 2010).   
 Steps 4 and 5 included further Rasch analysis of the two sub-scales identified by 
PCA and was followed by further CFA.   
This demonstrates a mixture of methods used in a structured manner to clarify the 
measurement properties of the scale.  Other authors have also used the combination of 
both CTT (including PCA) and IRT methods in the development and evaluation of 
clinical measures (Smith et al. 2007; Cano et al. 2008), representing a robust approach 
to development. 
 
Results from principal component analysis can be evaluated by initially considering 
Eigenvalues above 1 according to the criteria by Kaiser (Kaiser 1960).  Kaiser considers 
Eigenvalues above 1 to indicate the principal components of value and provides an 
objective criterion for retention of components (Teo and Chong 2006).  Following 
evaluation of Eigenvalues, Scree plots can then be examined to confirm the findings.  
Consideration of Eigenvalues and Scree plots in identification of principle components 
is considered to be more robust by some authors than using Eigenvalues alone (Butler et 
al. 2006).  To confirm these findings and to provide more objective criteria for the 
acceptance of the components identified, a Monte Carlo analysis may be carried out 
according to the method by Horn (Horn 1965).  The Monte Carlo analysis involves 
parallel analysis of findings against predicted objective criteria to determine acceptance 
of the principal component findings. 
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Sample size for PCA 
Sample size is important for statistical procedures such as PCA or EFA, because smaller 
samples may lead to erroneous conclusions (Osborne and Costello 2004).  These 
procedures optimise the fit of the model to the data, but no sample is able to perfectly 
reflect the population.  Over-fitting can also occur and result in key errors such as 
extraction of erroneous factors or mis-assignment of items to factors (Tabachnick and 
Fidell 2001).   
 
Sample size for PCA therefore remains the subject of confusion and considerable 
debate.  Approaches to sample size also differ with some advocating estimates based on 
total sample and others on ratios of numbers of subjects to scale items.  In general, 
samples of a larger size are preferable to smaller samples, because they tend to 
minimise the probability of errors, maximise the accuracy of population estimates, and 
increase the generalised application of results (Guadagnoli and Velicer 1988).  
Unfortunately, many of the sample size recommendations for PCA and EFA are limited 
and often have minimal empirical evidence (Guadagnoli and Velicer 1988).  Further 
discussion of sample size for PCA is undertaken in Chapter 7 in relation to 
psychometric evaluation (see Section 7.3; page 191). 
 
Different authors have suggested a range of sample sizes for PCA.  Nunnally and 
Bernstein recommend a ratio of 10:1 subjects to items (Nunnally and Bernstein 1994) 
and Terwee and colleagues (2007) a ratio of 7:1 with a total sample of 100 or greater.  
Norman and Streiner have discussed sample sizes between 50 and 1000 (Norman and 
Streiner 2000).  A number of studies have used multiples of 100, but all below 1000 for 
PCA in rehabilitation research (Smith et al. 2007; Cano et al. 2008; Siegert et al. 2010). 
 
3.3.3.4 Scaling 
Measurement principles are discussed at the beginning of this chapter (Section 3.1; page 
65); the following section will focus on how Mokken analysis can be applied for 
evaluation of ordinal scaling properties.  Mokken analysis is considered in more detail, 
due to the preliminary nature of the evaluation in this thesis, the relatively small number 
of participants (n=92) and the desire to establish ordinality in the scale as appose to 
Rasch analysis, which operates on transformed scores.  Confirming the ordinality of the 
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measure has particular relevance for a clinical tool where raw scores may be used to 
interpret patient outcome. 
 
In Mokken analysis, the ‘item response function’ for each item is a non-decreasing 
function of the trait.  Meaning that each item would be expected to change in the same 
direction and to a related extent, to change in the construct or trait (Van der Lee et al. 
2002).  The Mokken model treats the latent trait as a single construct along which a 
person’s location can be identified and also an items location or difficulty (van 
Abswoude et al. 2004).  The final assumption evaluated in Mokken analysis for Double 
Monotonicity, is that items in the scale have invariant hierarchical ordering across the 
latent trait in different individuals when tested (Van der Lee et al. 2002; Zwinkels et al. 
2004).   
 
Monotone Homogeneity 
As discussed (Section 3.2.4; page 76), the Mokken model specifies the relationship 
between the item and the latent trait using an item characteristic curve.  An important 
feature of the Mokken approach, which is different to other IRT models, is that it makes 
no assumptions about the functional form of the item characteristic curve.  This is the 
reason for Mokken analysis being referred to as non-parametric.   
 
Double Monotonicity 
Double Monotonicity, in addition to the assumptions of Monotone Homogeneity, 
assumes that the item response curves do not intersect.  So that, the probability of a 
positive response decreases with the difficulty of the item, which will still allow for 
variation in the shape of the ICC, but will reflect the greater difficulty from the previous 
item through the entire range of that item on the latent trait (Gillespie et al. 1987).   
 
The Double Monotonicity model is a ‘special case’ of the Monotone Homogeneity 
model, the fit of the Monotone Homogeneity model should be explored before non-
intersection of item response functions are investigated (Molenaar et al. 2000).  
Monotone Homogeneity was therefore considered in this thesis before further 
evaluation of the scale developed. 
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Application of Mokken Analysis 
Mokken analysis produces the H coefficient of scalability (Loevinger 1948), which is a 
measure of the accuracy of ordering participants.  The minimum values of H indicating 
a strong scale is 0.5, a medium scale 0.4 and a weak scale 0.3 (Roorda et al. 1996; Van 
der Lee et al. 2002; van Schuur 2003).  van Schuur also identifies that no item in a 
unidimensional scale should have an item H below 0.3 (van Schuur 2003).   
 
A Crit value is also produced using the Mokken scale analysis program for polytomous 
items (MSP) (Molenaar et al. 2000), which calculates a combined single value from all 
H coefficients for items included with evidence about the items frequency, size of 
model violations and significance of violations.  Crit values of 0 are considered to 
indicate perfectly non-intersecting items in a scale.  While Crit values of <40 (i.e. not 0) 
are thought to be the result of sampling error and values of >80 are considered to 
indicate violations of monotone homogeneity and double monotonicity.  It is therefore 
acceptable to include Crit values between 0 and 40 (Molenaar et al. 2000; Deary et al. 
2010).   
 
A further statistic is produced by the Mokken scale analysis for polytomous items 
software package (Molenaar et al. 2000), the Pmatrix.  The Pmatrix, shows the 
probability of obtaining items that are non-intersecting (Deary et al. 2010).  However a 
value is also produced which replaces visual inspection by a ‘count’ of violations.  
When serious violations occur, it is recommended to a) consider if non-intersection 
(double monotonicity) is essential for the measure application under investigation or b) 
remove one item at a time beginning with the worst fitting and re-evaluate the scale 
(Molenaar et al. 2000).   
 
Mokken analysis also produces a rho statistic which can be considered an equivalent of 
Cronbach’s alpha for evaluation of internal consistency (Van der Lee et al. 2002; van 
Schuur 2003).  Mokken analysis therefore also allows for the evaluation of internal 
consistency. 
 
Sample size for Mokken analysis 
Sample size, as in CTT methods, is important for IRT approaches.  For the Rasch 
model, to be 95 per cent confident that no item calibration score is more than +1 logit 
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from its stable value, 30 participants are required for dichotomous response options.  To 
improve on this calibration to + ½ logit 100 participants are needed (Linacre 1994; 
Wright and Tennant 1996).  However, evaluations of measurement items using the 
Rasch IRT method have generally used much larger numbers of subjects, particularly 
for polytomous items (Barrett and Kline 1981; Cano et al. 2008; Hobart and Cano 
2009).   
 
In Mokken analysis participant numbers of 100 to 200 and above have been 
recommended (Molenaar et al. 2000; Koh et al. 2006).  Some authors have used 
participant numbers within this range (Biemans et al. 2001).  However, as in Rasch 
analysis, studies evaluating scales using Mokken analysis have often used much larger 
numbers (Gillespie et al. 1987; Wismeijer et al. 2008; Deary et al. 2010).  Some authors 
have also applied Mokken analysis in a preliminary manner with smaller numbers.  Van 
der Putten and colleagues used it in evaluation of the Top Down Motor Milestone Test 
in 66 children with profound multiple disabilities and Van der Lee and colleagues 
applied it to evaluate the Action Research Arm Test in 63 participants  (Van der Lee et 
al. 2002; van der Putten et al. 2005).  In the van der Putten study, it was not possible to 
confirm double monotonicity but monotone homogeneity was identified.  The number 
of participants was a possible limiting factor in not being able to further evaluate this 
measure. 
 
3.3.3.5 Internal consistency 
Internal consistency refers to the interrelatedness of a set of items (Schmitt 1996).  In 
CTT psychometric methods, this is often attributed to homogeneity of the items.  
Homogeneity refers to the degree to which scale items are measuring aspects of the 
underlying construct or trait (Henson 2001).  Measures of internal consistency should be 
applied to scales or sub-scales only if they are related to a single underlying construct.  
Internal consistency applied across multiple sub-scales would be meaningless as they 
are theoretically (or actually if dimensionality has already been demonstrated) not 
addressing a single trait.  A number of methods for calculating internal consistency are 
widely used, such as item-total correlation (Nunnally 1978), split-half internal 
consistency (Nunnally and Bernstein 1994), Kuder-Richardson 20 (Kuder and 
Richardson 1937) and Cronbach’s alpha (Cronbach 1951).   




Cronbach’s alpha gives the average of all split-half reliabilities of the scale.  In split-half 
calculation, items are randomly divided into two sub-scales (for example odd and even 
numbered items) and the correlation between the two is then evaluated.  If internal 
consistency is demonstrated, the two halves should be highly correlated.  Limitations of 
this method are that there are many ways to divide a test and it does not indicate which 
items may not be as highly correlated.  Cronbach’s alpha therefore gives the average of 
all split halves, which is a more robust measure of internal consistency. 
 
The utilisation of Cronbach’s alpha to index the internal consistency of measures has 
been common practice in developing questionnaire based clinical scales (Schmitt 1996; 
Streiner 2003a; Barreca et al. 2005).  All items addressing the same concept should at 
least moderately correlate with each other and have a moderate correlation with the total 
score (Streiner 2003a).  Schmitt has discussed when coefficient alpha might be useful as 
well as its limitations (Schmitt 1996).  He has identified four considerations or 
limitations for the use of Cronbach’s alpha. 
 
The first issue raised is the use of homogeneity and internal consistency, which have 
been used by some authors as approximately the same thing (Schmitt 1996).  However, 
internal consistency measured by Cronbach’s alpha refers to the interrelatedness of a set 
of items, while homogeneity refers to the unidimensionality of a set of items (already 
discussed in this section).  Schmitt therefore indicates that in his view internal 
consistency is insufficient to demonstrate unidimensionality.  Secondly, the appropriate 
level of alpha is raised as a possible area of confusion among researchers.  A level of 
alpha above 0.70 does not necessarily indicate that a scale items are interrelated; for 
example, a scale of more than 20 items is likely to have a high alpha regardless of the 
degree of relationship between the items.  Thirdly, related to the previous example and 
the possibility that more than one construct may be represented in the scale (Van de 
Winckel et al. 2006), the resulting alpha may be the product of more than one construct 
and still be relatively high. Fourthly, in light of the previous limitations, presenting only 
alpha when discussing the relationships between multiple measures is not sufficient.  
This view has also been echoed by authors in the rehabilitation literature (Hobart et al. 
1996; Tennant and Young 1997; Davis et al. 1999; Hobart et al. 2001; Tennant 2007).   
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Nunnally and Bernstein proposed a criterion for Cronbach’s Alpha, with an alpha of 
0.70-0.90 indicating “good” internal consistency (Nunnally and Bernstein 1994).  
However Terwee and colleagues propose a figure between 0.70 and 0.95 and argue that 
higher Cronbach’s alpha is often recorded in scales in which all items are clinically 
important and may not always indicate redundancy (Terwee et al. 2007).  Another way 
of considering this is that items are important in this context because of the contribution 
they make to scale totals.   
 
If outcome measures or sub-scales are to truly act as measures and therefore form 
unidimensional, interval scales, items cannot be included which do not fit the scale or 
dimension (Hobart et al. 2001; Hobart and Cano 2009).  The measurement properties 
from a scaling perspective must therefore take precedence.  However there is a dilemma 
from a clinical perspective, where specific items give useful clinical information.  If 
these items also ‘fit’ the construct and scaling is demonstrated (e.g. by IRT approaches) 
then their retention is reasonable.  However, if they do not fit the construct or fail to 
demonstrate fundamental measurement properties, in the context of the whole scale or 
sub-scale, they cannot form part of the measure (also see Section 3.2.4; page 76).  An 
alternative may be for such items to be recorded separately as individual items, which 
inform the clinical picture but do not contribute to the measurement scale.  
 
3.3.3.6 Reliability (Reproducibility)  
Reliability from a CTT perspective is concerned with detecting the amount of error 
occurring during application of a measurement instrument (Streiner and Norman 2003).  
If the measurement error is relatively small (i.e. reliability is high), the results obtained 
can be relied upon (Streiner 2003a).  Some authors (Stratford 1989; Terwee et al. 2007) 
have proposed that reliability should be distinguished from agreement (absolute error) 
and that both concepts fit under a heading of ‘reproducibility’.   
 
Terwee and colleagues (Terwee et al. 2007) propose that agreement concerns absolute 
error, which is how close the scores on repeated measures are, expressed in the unit of 
the measurement scale being evaluated.  Reliability however is concerned with the 
degree to which different conditions can be distinguished from each other, despite 
measurement error (relative measurement error).  Agreement is important because a 
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small degree of error is required for evaluative purposes in which one wants to 
distinguish clinically important changes from measurement error.  A high degree of 
reliability is important for discriminative purposes to distinguish between different 
conditions (e.g. more or less severe disease).   
  
Test re-test reliability is the standard CTT method of reliability evaluation and can be 
divided into two sub-categories of inter-rater and intra-rater reliability, when an external 
rater or observer applies a measure (Hicks 1999; Streiner and Norman 2003).   
However, if a measure is self-report then inter and intra-rater reliability do not apply 
and simple evaluation of test re-test reliability will be needed with completion of the 
measure on two occasions separated by time. 
 
Test re-test reliability is often expressed in the form of coefficients, such as intra class 
correlation coefficients or Cohen’s Kappa coefficient (Terwee et al. 2007).  According 
to Terwee and colleagues for the calculation of reliability for ordinal measures, the 
weighted Cohen’s Kappa coefficient should be used as opposed to intra class correlation 
coefficients (Terwee et al. 2007).   
 
Test re-test reliability, as evaluated by Cohen’s Kappa coefficient, is considered to be a 
more robust measure than simple percent agreement calculation, which could also be 
used, since it takes into account the agreement occurring by chance (Fleiss 1981).   The 
Kappa coefficient can also be weighted to take into account agreement, which is not 
exact.  A weighted Kappa coefficient places greater emphasis on widely different scores 
and less emphasis on only slight differences (Streiner and Norman 2003).  Of the two 
possible methods used for weighting Kappa coefficients quadratic weights are 
recommended by Terwee and colleagues because they again give greater emphasis to 
large differences between scores and less emphasis to small differences (Altman 1991; 
Terwee et al. 2007).   
 
There are no absolute levels for agreement as calculated by Kappa coefficient.  A 
number of authors have provided guidelines for the interpretation of kappa coefficients; 
two are discussed in the context of this thesis.  Landis and Koch have published 
guidelines for interpretation of kappa coefficient: below 0.00 = poor; 0.00-0.20 = slight; 
0.21-0.40 = fair; 0.41-0.60 = moderate; 0.61-0.80 = substantial and 0.81-1.00 = almost 
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perfect (Landis and Koch 1977).  According to Terwee and colleagues when evaluating 
the psychometric quality of measures, a positive rating for test re-test reliability is given 
when the intra class correlation coefficient or weighted Kappa is 0.70 or above in a 
sample size of at least 50 patients (Terwee et al. 2007). 
3.3.3.7 Responsiveness and sensitivity to change 
Sensitivity to change can be defined as ‘the ability of an instrument to measure change 
in a state regardless of whether it is relevant and meaningful to the decision maker’ 
(Liang 2000).  Responsiveness is defined as ‘the ability of an instrument to measure a 
meaningful or clinically important change’ (Liang 2000) when change occurs and 
record ‘no-change’ when the condition is stable.  Sensitivity to change and 
responsiveness are more recent terms used in the evaluation of measures and are 
considered by some authors as an extension of validity.   
 
The term “sensitivity” can also be confusing due to its use in the area of predictive 
validity.  It is therefore generally useful to use the term “responsiveness” for the 
following reasons a) the change is meaningful and b) confusion with predictive validity 
is avoided.  If a measure is to be used to evaluate outcome following a given 
intervention, it must be responsive to the degree of change expected (Beaton et al. 
2001).  When evaluating measures for clinical application it is important and 
appropriate to establish that change can be recorded in a meaningful manner by the 
measure.  The term responsiveness will be used in this thesis. 
 
Evaluation of responsiveness will usually involve examining, either prospectively or 
retrospectively, the amount of change between two points in time as measured by the 
scale.  If a prior measure is not available, retrospective scoring is possible, but is 
vulnerable to potential bias.  Two main sources of bias of this method have been 
identified (Fayers and Machin 2007): 
1. It is very difficult for participants to remember their past status and accurately 
recall it when asked to do so.  The correlation in this situation between the 
current state and the measure is high, but is low between the measures recording 
of the previous state and the actual previous state (Guyatt 1987).  The 
implication is that asking participants to do a post outcome rating of baseline is 
unreliable. 
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2. A further complication is that of response shift.  Response shift means that even 
if accurately recalling the previous state, the participants perception of that state 
changes with time (Schwartz and Sprangers 1999).  For example in rating pain, 
the participant may have rated initial pain as 8 out of 10, but having had much 
worse pain, now rate it as 4 out of 10. 
 
For both of these reasons it is more reliable to score the measure at baseline and 
following intervention (i.e. prospectively), rather than do a retrospective score.  Having 
acquired pre and post scores, it is then necessary to compare the scores. 
 
There are different methods for assessing change between two measurement points on a 
scale.  The most commonly applied methods are based on parametric assumptions 
within the realm of CTT and are therefore not really applicable to ordinal scales.  Three 
methods will be discussed here due to their relevance to clinical studies (Hobart et al. 
2001).  Most methods are based on effect size (ES).  Cohen’s ES is mean change 
divided by the standard deviation of the baseline scores (Cohen 1988).  This test is 
simple to apply between pre-intervention to post-intervention.  A similar method is 
Guyatt’s responsiveness, which was specifically developed for a pre-intervention, post-
intervention cohort (Guyatt 1987).  Another method is the standardised response mean 
(SRM).  SRM is the ratio of the mean change (of the group) to the standard deviation of 
the change scores (McHorney and Tarlov 1995).  An alternative non-parametric 
approach to descriptive presentation is the proportion of positive and negative ranks for 
the measure in question.   
 
ES and SRM (and Guyatt’s responsiveness) are measures of variability in results, from 
baseline.  However, these methods have been used in evaluating many, if not most, 
measures developed using CTT approaches, in keeping with the assumptions of this 
approach.  Hobart and colleagues compared effect sizes derived from total scores, with 
scores from the same measures derived from person locations having undergone Rasch 
analysis (Hobart et al. 2010).  They found the responsiveness of the two measures 
(Barthel Index - BI and Functional Independence Measure motor scale - FIMm) was 
similar using total scores.  But also found that FIMm had better responsiveness using a 
Rasch transformed scale.  Nevertheless, both measures were shown to be responsive 
using total scores despite the limitations of using a method appropriate for interval data 
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on ordinal scores.  Therefore, measures developed using CTT may still provide a valid 
record of clinical change despite their limitations. 
 
3.3.3.8 Interpretability 
The term interpretability, used by Terwee and colleagues, refers to the degree to which 
qualitative meaning can be assigned to quantitative scores from a measure (Terwee et al. 
2007).  The principal of interpretability is providing information about what change in 
score or point on the scale would be clinically meaningful.  According to Terwee and 
colleagues, this requires the interpretation of scores from reference populations and thus 
providing normative values.  In addition, a Minimal Important Change (MIC) value is 
also desirable, this is:  
“the smallest difference in score in the domain of interest which patients 
perceive as beneficial and would mandate, in the absence of troublesome side 
effects and excessive cost, a change in the patient’s management” (Jaeschke et 
al. 1989). 
 
 The MIC can be calculated using two methods; a criterion based method and a 
distribution-based method.  The criterion-based method is produced by calculating the 
average change in the responder group.  The distribution-based method, as 
recommended by (Norman et al. 2003), is calculated by using half the baseline standard 
deviation as an estimate of MIC.  However, calculation of MIC using these methods 
requires interval scaling.   
 
The criterion-based method is an indication of mean change in the responder group and 
therefore may not be a clear indication of what true MIC should be.  The distribution-
based method is a prediction of what meaningful change should be, and is therefore a 
more robust indication, although does not test this.  A preliminary approach to testing 
may include calculation of sensitivity (proportion of actual positives correctly 
identified), specificity (proportion of actual negatives correctly identified), positive 
predictive value (proportion of those identified by the test who actually have responded 
to intervention) and negative predictive value (proportion of those not identified who 
have actually not responded to intervention) at the predicted levels of MIC, if a method 
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to identify individuals who respond from those who do not is possible (Lynch and 
Lanspa 2010; MedStats.Org 2011). 
3.3.3.9 Feasibility 
Outcome measures should be both practical to use in routine practice and retain 
psychometric properties, thus ensuring the utility of the data produced (Slade et al. 
1999; Slade 2002b).  Data may then be put to research purposes, but more importantly 
in this context, may be used to inform and direct treatment (Slade 2002).   
 
To be feasible the measure needs to be suitable, sustained, meaningful in typical clinical 
settings and be applied in a specified manner for a specified purpose (Slade et al. 1999).  
‘Meaningful in typical clinical settings’ is defined as psychometric properties being 
retained when the measure is used in routine practice.  ‘Typical clinical settings’ are 
those where the staff are not routinely involved in research, and have no association 
with the measure.  ‘Use in a specified manner’ entails identifying what is being 
assessed, where, when, by whom and on whom the assessment is being made.  The 
‘specified purpose’ is the identification of the use to which the information identified 
will be put.  Feasibility is therefore important when developing a new clinical measure 
for application in ‘normal’ clinical settings, ensuring that such measures are practical 
and timely to apply. 
3.4 Summary 
A range of considerations for developing and evaluating measures have been discussed.  
The key issues for this thesis are:  
 
 Theoretical models such as classical test theory, latent variable modelling and 
item response theory underpin our understanding of development and use of 
measures of latent traits.  Classical test theory, latent variable modelling and 
item response theory have resulted in the development of specific 
methodologies, which enable the testing, and development of measurement 
scales in rehabilitation. 
 Clinical imperatives can be used as a starting point for measure development.  
However, the use of psychometric principles in the process is desirable to ensure 
the resulting measure is based on sound measurement principles. 
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 It is essential that if a series of observations are to form a measurement scale 
they need to refer to the same dimension or construct.  In addition, to enable 
fundamental measurement, observations need to conform to hierarchical interval 
scaling such that the summed score is a sufficient statistic.   
 Rasch analysis has been developed and applies a mathematical model to scales, 
which if they conform to the model, confers interval level measurement. 
 Initial stages of measure development may include exploration of the ordinality 
of measure data and evaluation of dimensionality using non-parametric item 
response methods such as Mokken analysis.   
 For a measure to be useful in clinical practice it should be feasible, that is 
suitable, sustained, meaningful in typical clinical settings and be applied in a 
specified manner for a specified purpose.  According to Slade (1999), feasibility 
relies on the retention of the psychometric properties of the measure when used 
in the clinical context. 
3.5 Measure development strategy taken in this thesis 
The development of the Arm Activity measure (ArmA) originates from clinical practice 
in that the constructs of active and passive function as concepts have been identified in 
focal spasticity management using BTX and PT interventions.  Evaluation of the 
properties of ArmA needs to identify that active and passive function are separate 
dimensions, because without the confirmation of the sub-scales as distinct entities, 
measurement (rather than just describing a group of items) is not possible.  The 
evaluation should therefore also begin to determine if items in these sub-scales can be 
used to effectively measure the underlying constructs or dimensions. 
 
Possible items for inclusion in the ArmA will be identified from the literature and 
clinical practice sources.  Initial reduction of the items will use a modified Delphi 
consultation followed by a wider confirmatory process.  Psychometric evaluation of the 
ArmA will use CTT approaches and a preliminary application of Mokken analysis.  
Mokken analysis has been applied because of the desire to confirm unidimensionality 
using an IRT method in addition to a CTT method (principal components analysis).  
Mokken analysis allows the evaluation of raw scores for ordinality as oppose to Rasch 
analysis, which examines interval scaling on transformed scores.  Ordinality is 
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particularly important in measures used in clinical practice where interpretation of raw 
scores may be used to evaluate patient outcome. 
3.5.1 Item generation and reduction 
As part of this work, identification of clinically useful and applicable items is of high 
importance (see Item generation; page 91).  Using the literature solely as a source of 
items is a well-tested approach, but risks missing potentially important items.  The 
combination, of using both the literature and analysis of agreed goals as sources, 
ensures that the list of possible items more fully reflects the constructs under 
investigation.  A particular emphasis of the goal analysis was identification of passive 
function items, which have more limited representation in the literature, but were a 
particular focus of the goals analysis. 
 
A modified Delphi consultation is then used in this thesis to select the items.  Modified 
Delphi consultation has the advantages of anonymity to participants and reduction of 
the influence of socially dominant individuals (Burns et al. 2003; Finger et al. 2006).  
These characteristics make this consultation method well suited to obtaining individual 
views on measurement items from different professionals.  A wider consultation with 
different clinicians, patients and carers is included to ensure the wide acceptance and 
face validity of the items selected. 
3.5.2 Unidimensionality and scaling 
In this thesis, CTT methods will initially be applied to development and evaluation.  
The broadly clinimetric approach to identification of items that are feasible combined 
with the wide acceptance of CTT in the literature provide strong arguments for this 
approach.  However, the limitations of CTT approaches in terms of measurement 
scaling are acknowledged.  
 
Therefore, the measurement approach used in this thesis is broadly CTT in orientation 
but with preliminary application of an IRT method (see Unidimensionality page 99 and 
Scaling page 102).  Initially principal components analysis is applied to confirm the 
dimensionality of the two clinically conceived sub-scales.  However, to ensure robust 
measurement principles, IRT in the form of Mokken analysis (monotone homogeneity) 
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was used, as a preliminary step, to identify the capacity of the sub-scales to differentiate 
people with ordinal scaling and to confirm dimensionality.   
 
Monotone homogeneity only allows differentiation between people and not items; 
therefore reference is made to implications for double monotonicity, and ordering of 
items, in the future evaluation of the scale.  
3.5.3 Validity 
Given the importance of feasibility of the resulting measure, content validity will be 
addressed during measure development.  Face validity will be also initially addressed 
but could be more formally evaluated with a specific group of patients and carers for 
this purpose.  However, evaluation with patients and carers is integrated within pilot 
testing in this work and tests both content and face validity.  Ecological validity will 
also be tested by consulting patients and carers who have undergone spasticity 
management intervention in the upper limb. 
 
Construct validity will be important to ensure that items reflect the constructs of the two 
sub-scales and therefore also support unidimensionality.  Construct validity will be 
evaluated by comparison with other measures, evaluating hypothesised change for 
convergence and divergence (see Validity page 98).   
3.5.4 Internal consistency 
Internal consistency in this thesis will be evaluated using Cronbach’s Alpha (see 
Internal consistency page 105).  Internal consistency is a CTT method, which could be 
seen as unnecessary when the application of Mokken analysis is planned.  However, the 
application of Cronbach’s Alpha supports evaluation of the resulting measures 
psychometric properties using CTT requirements, allows comparison with those of 
other measures, and for these reasons will be included.   
3.5.5 Reliability (Reproducibility)  
Evaluation of reliability uses a CTT perspective and is concerned with keeping 
measurement error to a minimum.  Test re-test evaluation will be undertaken because 
the scale is self-rated and therefore inter-rater evaluation is not appropriate (see 
Reliability page 107).  In ordinal scales such as the ArmA, non-parametric methods will 
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be required.  Weighted Cohen’s Kappa coefficient is the statistical test used in this 
thesis and takes into account agreement occurring by chance.   
3.5.6 Responsiveness to change 
Responsiveness will be evaluated between two time points, before and after intervention 
in addition to ES and SRM (see Responsiveness page 109).  The primary method of 
determining responsiveness is by comparing the ArmA detection of functional 
improvement with a clinician categorisation of outcome.  Amount of change is then 
compared between responder and non-responder groups identified by clinicians.  This 
approach will be applied as the primary approach because ES and SRM require 
parametric assumptions, which are not met.  The use of ES and SRM will be applied 
(given that these techniques require interval scaling), to allow comparison with other 
measures and to inform discussion of findings.  Due to the acknowledged limitations of 
these parametric approaches, positive and negative ranks are also presented for each 
measure from baseline to review.   
3.5.7 Interpretability 
In this preliminary exploration of the ArmA, evaluation of interpretability will only be 
tentative, because only one reference population will be used.  In addition, calculation 
of MIC again requires interval scaling, the evaluation of which will not be undertaken.  
However, initial calculation will be used to give an indication of MIC (see 
Interpretability page 111).  This will need to be confirmed once Rasch analysis has been 
applied evaluating interval measurement in future work. 
 
The MIC will be calculated using two methods; a criterion based method and a 
distribution-based method.  Both these methods will be used to calculate MIC in the 
responder group for ArmA passive and active function sub-scales.  These calculations 
of MIC will then be tested by determining sensitivity and specificity of the ArmA using 
those rated by clinicians to have responded to intervention or not. 
3.5.8 Feasibility 
Feasibility will be assessed by obtaining the views of patients and carers (see 
Feasibility page 112).  Patients and carers will complete a questionnaire with the 
purpose of providing comment on the ArmA’s ease of use, relevance, acceptability 
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and value in the clinical situation.  These concepts include the time taken to complete 
the measure and ease with which the individual is able to undertake the completion, 
both of which are particularly relevant in a self-report measure.   
 
Feasibility is difficult to evaluate in a psychometric evaluation study, where by 
definition practice is not normal because research is being undertaken.  However, in 
this study, the actual impact on normal practice is considered small and the evaluation 
of feasibility, while having limitations, is justifiable although again preliminary. 
3.5.9 Summary 
The criteria used to evaluate psychometric properties will be adapted from those by 
Terwee and colleagues (Terwee et al. 2007) incorporating the work of the Scientific 
Advisory Committee (SAC) of the Medical Outcomes Trust  (Medical Outcomes Trust 
2002).  These adapted criteria will be applied in a systematic review of upper limb 
function measures in this thesis (Chapter 4).  The further adapted criteria presented in 
Table 3.1 (page 95) will be subsequently used to evaluate the ArmA measure following 
its development (Chapter 7).  In addition, IRT methods of scale evaluation for 
measurement will be considered in a preliminary manner, using Mokken analysis to 
assess for ordinality of the scale as an initial step (See Table 3.1).   
 




Chapter 4 Systematic review of activity measures in the upper limb 
 
4.1 Introduction 
Outcome measurement is applied in rehabilitation to determine the effectiveness of 
interventions.  Whether in clinical practice or for research, measures need to be valid, 
reliable and responsive to clinically relevant change.  Global measures of function in 
daily activities, such as the Barthel Index (Wade and Collin 1988), provide a general 
assessment of independence but are often unresponsive to focal interventions in the 
upper limb.  Small changes, which may be extremely important to the patient and/or 
their carers are easily lost amongst the larger number of unchanging items (see Chapter 
1; Section 1.3; page 40) (Ashford and Turner-Stokes 2006).  Measures of active and 
passive function are required which capture outcome following focal interventions in 
the upper limb.  Both active and passive function have potential for improvement 
following spasticity intervention with passive function improvements often more 
common (Bhakta et al. 2000a).  Any comprehensive outcome measure for spasticity 
intervention needs to assess both active and passive function to fully reflect the changes 
seen post intervention, despite active function changes being comparatively rare. 
 
4.2 Objectives 
This Chapter will address objectives 1 and 2 of the thesis.  
 
Objective 1. To identify standardised outcome measures of active and passive function 
used to assess outcome following focal intervention, in the hemiparetic 
upper limb, which reflect ‘real-life’ function. 
 
Objective 2. To identify candidate items for inclusion in a measure of upper limb 
function for use following focal spasticity interventions, in the hemiparetic 
upper limb. 
 
4.2.1 Search criteria:  
Criteria for selection and review are summarised in Box 4.1.  



























Stage 1 – Selection to identify standardised outcome measures 
1. Clinical relevance - applicable in the hemiparetic upper limb 
2. Include items measuring: 
b. Active function 
AND/OR  
b.  Passive function 
Stage 2 – Real-life relevance (as opposed to under test conditions) 
3. Assessed in a manner reflective of ‘real-life’ function 
Stage 3 – Literature based evaluation of evidence for psychometric properties 
of measures 
4. Practical to apply in everyday clinical practice 
5. Valid and reliable for upper limb function evaluation 
6. Responsive to change occurring as a result of intervention 





The review was undertaken in three stages.  
 In stage 1, a ‘pool’ of possible measures was identified from a broad-based 
systematic search.  
 In stage 2, these were reduced to those reflective of ‘real-life’ performance.  
 In stage, 3 measures were evaluated based on the published evidence for 
psychometric properties.   
The Quality of Reporting of Meta-analyses (QUOROM) provides guidance on the most 
appropriate methods of presenting systematic review data and these principles were 
used in the presentation of data and results (Moher et al. 1999). 
 
The review was confined to neurological rehabilitation for three reasons: 
1) Measures identified outside of the neurological rehabilitation literature have 
limited applicability to this population due to the impairment pattern 
presented with hemiplegia (Wade et al. 1983).   
2) Many of the items included in measures designed for general rehabilitation 
populations, are often too difficult for the minority of patients with 
hemiplegia who re-gain active function with the upper limb.  The result of 
item difficulty is that improvements are not demonstrated even when clinical 
change is taking place (floor effect). 
3) A joint initiative of the American Academy of Orthopaedic Surgeons, the 
Council of Musculoskeletal Specialty Societies and the Institute for Work 
and Health (Toronto, Canada) conducted a literature review of currently 
available measures of function and disability in the upper limb.  The review 
identified no current measures which were “self administered, able to assess 
functional status for upper extremity musculoskeletal conditions and were 
feasible for use in research or routine clinical settings” (Hudak et al. 1996; 
Davis et al. 1999) p1.  As a result the Disability of the Arm, Shoulder and 
Hand measure (DASH) was developed.  The literature review conducted; 
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though not a systematic review was detailed and wide-ranging in identifying 
musculoskeletal self-report measures for upper limb function available.  
Other reviews have been undertaken since, such as that by Bot and 
colleagues (Bot et al. 2004), which focused on the impact of shoulder 
impairment on function, however this identified the DASH as the most 
useful measure of function in the upper limb for musculoskeletal 
presentations.  The DASH remains the most relevant ‘real-life’ measure of 
active function in a non-neurological, rehabilitation population, but was not 
designed for individuals with neurological impairment.  
 
4.3.1 Stage 1 Measure selection 
Criteria for selection and review are summarised in Box 4.1. In Stage 1, standardised 
outcome measures were identified for further consideration if they were:  
a) Applicable in the hemiparetic upper limb. 
b)   Included items measuring active and/or passive function.  
 
Data sources 
The Cochrane Database of Systematic Reviews was investigated to identify databases 
and other data sources to be searched for this review.  The following data sources were 
then searched:  
1. Medline search based on the strategy outlined by Dickersin 
(Dickersin et al. 1994).  (1996 to 7
th
 May 2008). 
2. CINAHL (1982 to 7th May 2008). 
3. BIDS Science Citation Index (1991 to 7th May 2008).  
4. Embase (1974 to 7th May 2008). 
5. Relevant trials were identified in the Specialised register of Stroke 
trials.  (1993 to 7
th
 May 2008). 
6. National Health Service National Research Register, MRC Clinical 
Trials directory, Database of Abstracts of Reviews of Effects (DARE), 
Google, ProFusion and SIGLE (medical/rehabilitation grey literature), 
(until 7
th
 May 2008). 
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7. The Cochrane Database of Systematic Reviews (1993 to 7th May 
2008). 
8. Reference lists from papers identified.  
9. Conference proceedings, books and book chapters. 
10. Communication with lead authors of published studies and other 
researchers. 
Search strategy 
The search strategy for the clinical group (stroke or brain injury) was;  
 
1. (hemiplegia or hemiplegic or hemiparesis or hemiparetic)  
2. AND (arm or upper limb or hand or shoulder)  
3. AND (stroke or post stroke or CVA)  
4. OR (brain haemorrhage or haemorrhage or haematoma or hematoma)  
5. OR (brain injury)  
6. OR (brain tumour or tumor)  
7. OR (brain infection or encephalitis or abscess)  
 
The further search strategy for the outcome measurement sub-group was; 
  
8. AND (Outcome measurement [MESH] OR Outcome assessment) 
9. AND (function* OR activity). 
 
Recommended by the Cochrane Collaboration (Dickersin et al. 1994). 
 
The search strategy for data sources 3, 4, 5 and 6 (see Data Sources) was modified to 
that given above due to the more limited search capacity available in those search tools.  
Single search term searches were undertaken and then combined to allow full searching 
in those data sources.  Search terms were altered when required to comply with ‘key’ 
terms used in other databases as appropriate.   
 
The search strategy for data source 7 (see Data Sources), also involved a modified and 
simplified search strategy from that used in 1 and 2. 




Reference lists and textbooks were searched by hand (Data Sources 8 and 9). Textbooks 
were either identified in the wider search (as indicated above) or through searching the 
catalogues of a number of medical libraries or through discussion with expert clinicians 
in rehabilitation medicine or physiotherapy.  Conference proceedings were identified 
from the search strategies applied in 1 and 2 searching medical libraries and discussion 
with expert clinicians or researchers as well as searching key textbooks. 
 
Where appropriate, as indicated by the literature or through discussion with other 
clinicians or researchers, published authors and researchers (n=6) were contacted about 
the scales that they had used or developed (see Appendix 1) (Data Source 10).  Contact 
was usually by e-mail or telephone and was followed up a maximum of twice if an 
initial response was not obtained.  
 
The title was reviewed to identify potentially relevant studies, and then the abstract was 
reviewed where available.  When the abstract indicated relevance or no abstract was 
available, the full text paper was retrieved and a final decision made about inclusion.  
Initial selection was undertaken by the author and was then evaluated by a second 
reviewer; any areas of disagreement were discussed.  Publications selected were 
restricted to those in the English language. 
4.3.2  Stage 2: Real-life relevance 
Measures were excluded if they did not use a method of assessment reflective of ‘real-
life’ function to measure day-to-day performance.  In Stage 2, selected measures were 
considered to have ‘real-life’ relevance if they assessed day-to-day performance in the 
person’s normal environment, as opposed to performance when observed under test 
conditions (such as a standardised test in a clinic setting). 
4.3.3 Stage 3: Evaluation 
The names of measures identified in stage 2 were used as terms for a further search of 
the electronic databases to obtain original and any subsequent publications concerning 
their development and psychometric evaluation.  Medline, CINAHL and the reference 
lists of identified publications containing relevant outcome measures were then searched 
to identify further literature on the development of these outcome measures and their 
Chapter 4 Systematic review of activity measures in the upper limb 
 
 124 
psychometric properties.  Authors of outcome measures were contacted for further 
details when required.   
 
Based on this published literature, the psychometric properties of each measure were 
evaluated against the following review criteria: 
 Practicality for use in everyday practice: time to complete, burden, readability  
 Validity and reliability: content validity, internal consistency, construct 
validity, floor and ceiling effect, test-retest reliability, agreement 
 Responsiveness to change: demonstration of change following focal upper limb 
intervention, interpretability and minimal important change (MIC) 
 
Descriptive information was tabulated for each of the selected measures including; the 
items in the measure, the methods of administration and the method of scoring applied. 
The quality criteria developed by Terwee et al (Terwee et al. 2007) and used by Bot et 
al (Bot et al. 2004) for a “clinimetric evaluation of shoulder disability questionnaires” 
from those produced by the Scientific Advisory Committee (SAC) of the Medical 
Outcomes Trust (Medical Outcomes Trust 2002) were used to evaluate the quality of 
the instrument properties.  The full criteria used with minor alterations to those 
produced by Bot and colleagues are given in Appendix 2 and the application in this 
instance is described in assessment methods below. Two reviewers independently 
evaluated each measure using these criteria. Findings were then compared and any 
discrepancies resolved through discussion.  The option was available for a third 
reviewer to resolve any areas of disagreement following comparison, but was not used. 
 
Data sources 
The following data sources were then searched:  
1. Reference lists from papers identified above 
2. Medline (1996 to 7th May 2008). 
3. CINAHL (1982 to 7th May 2008).  
4. Communication with lead authors of published studies and other researchers. 




The search strategy  
 
1. Measure name AND 
2. Psychometric evaluation  
3. OR testing  
4. OR validity  
5. OR reliability  
6. OR application 
7. OR clinical application 
 
Procedure used to evaluate each measure  
Psychometric properties were rated for each measure, using a scale of Adequate (+), 
Doubtful (+), Poor (-), or Unknown (?).   
 
Administrative burden 
Administrative burden was assessed using the same scoring method, modified as 
follows: Easy (+), when dichotomous items were simply summed; Moderate ( ), when 
an ordinal or visual analogue scale was used to quantify individual items then summed, 
and Difficult (-) when a summary score was applied in combination with a formula.  
Timing for completion of the measure was also rated as positive for measures 
completed within 10 minutes. 
 
Validity 
The instruments were evaluated for content and construct validity on the scale used for 
all psychometric properties.  A positive rating for content validity was given when there 
was evidence that either patients, carers or other experts had been consulted regarding 
the initial selection of items (e.g. through focus groups or surveys) or had provided 
evaluation or feedback as part of the development. A positive rating for construct 
validity was given if there was evidence that the measure was based on hypothetical 
constructs, which had been tested and supported during its evaluation. 
 
Internal consistency 
A positive rating for internal consistency was given if the factor structure of the measure 
had been tested through factor analysis, or where ratings for Cronbach’s alpha were 
between 0.70 and 0.95 for each dimension or subscale. 
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Floor and ceiling effects 
Floor and ceiling effects were considered present if more than 15% of respondents 
achieved the highest or lowest possible score respectively.  Floor effects were also 
considered present if the measure only assessed bilateral or complex tasks (e.g. thread a 
needle or sharpen a pencil). 
 
Reliability 
Test-retest reliability was rated as positive if repeat testing of the same condition had 
yielded comparable results e.g. an intraclass correlation coefficient (ICC) of greater than 
0.70 for total scores.  In item-by-item analyses, agreement was also rated as positive if it 
had been evaluated and shown to be satisfactory, using accepted statistical methods 
such as the Kappa coefficient or standard error of measurement. 
 
Responsiveness 
Responsiveness was rated as positive if the measure had demonstrated significant 
change in response to intervention, in the context of an appropriate study design (see 
full criteria Appendix 2). 
  
Interpretability 
Interpretability (see Glossary) is the degree to which qualitative meaning can be 
assigned to quantitative scores (Nunnally and Bernstein 1994).  Positive ratings were 
given if at least two types of information were given to aid in understanding of the 
scores.  Information considered included, means and standard deviations of the score 
totals before and after treatment, information in relation to other clinical variables, 
which might be expected to change, or information on the minimum change in score 
that might be clinically meaningful using the MIC. 





4.4.1 Stage 1: Measure selection 
The search yielded 1,144 studies, including primary reports, abstracts and conference 
proceedings.   
 Eighty-four papers were identified following initial review of the abstracts as 
including measures of functional outcome following focal upper limb 
intervention, yielding a total of 20 outcome measures after stage 1.  A summary 
of the stages of review, according to QUOROM, is given in Figure 4.1.   
 
The initial evaluation of these 20 measures is shown in Table 4.1.  This includes 
identification of psychometric evaluation in the published literature, but does not 
indicate the quality of the evaluation carried out.   









Studies identified as relevant from title 
(n=1,144). 
Abstracts reviewed (n=468). 
Excluded: 




1. Not used or no potential for use 
in focal intervention. 
(n=273) 
2. No passive or active functional 
outcome measure used.  
(n=111). 
Outcome measures identified (n=20) 
Outcome measures reflecting ‘real life’ (n=6) 
LASIS 
MAL (4 versions 12, 14, 26, 28 items) 
ABILHAND 
Outcome measures evaluated (n=6) 
LASIS- passive and lower level function-limited 
evaluation 
MAL (4 versions 12, 14, 26, 28 items) - middle 
range of function –variable evaluation 
ABILHAND – higher-level bimanual and complex 
tasks with robust psychometric properties 
Stage 1 criteria 
Stage 2 criteria 
Stage 3 criteria 
Further database search: 
Psychometric evaluation 
publications 
Full text retrieved (n=84) 





Table 4.1 Identified outcome measures 



















1 Leeds Adult Spasticity Impact 
Scale (LASIS) (Bhakta et al. 
1996; Bhakta et al. 2000a) 
     
2 Disability Assessment Scale 
(DAS) (Brashear et al. 2002a; 
Brashear et al. 2002b) 
     
3 Motor Activity Log (MAL-14) 
(van Kuijk et al. 2002; Page et 
al. 2003; van der Lee et al. 
2004; Yelnik 2004; Dettmers 
et al. 2005; Ring and 
Rosenthal 2005) 
     
4 Motor Activity Log (MAL-12) 
(Popovic et al. 2003) 
     
5 Motor Activity Log (MAL-26) 
item (van der Lee et al. 2004) 
     
6 Motor Activity Log (MAL-28) 
(Uswatte et al. 2006) 
     
7 ABILHAND (Penta et al. 
1998; Penta et al. 2001) 
     
8 Wolf Motor Function Test 
(Wolf et al. 2001; Page et al. 
2003; Cusick et al. 2005; 
Dettmers et al. 2005) 
     
9 Box and Block Test 
(Desrosiers et al. 1994; Alon 
et al. 2003; Lannin and 
Herbert 2003; Higgins et al. 
2005) 
     
10 Action Research Arm Test 
(Wade 1992a; Boiteau et al. 
1997; Broeks et al. 1999; 
Parry et al. 1999; Page and 
Levine 2003) 
     
11 Frenchay Arm Test (Wade 
1992b; Alon et al. 1998; 
Lagalla et al. 2000) 
     























12 Rivermead Motor Assessment 
Arm Scale (Wade 1992b; 
Parry et al. 1999) 
     
13 Nine Hole Peg Test (Wade 
1992b; Lindberg et al. 2004; 
Ring and Rosenthal 2005; 
Rodgers 2008) 
     
14 Upper Extremity Function 
Test (Popovic et al. 2003) 
     
15 Motor Club Assessment 
(Wade 1992b) 
     
16 Jebson Hand Function Test 
(Wade 1992b; Jones et al. 
1996; Richardson et al. 1997; 
Lannin and Herbert 2003) 
     
17 Fugl-Meyer Upper Limb Test 
(Berglund and Fugl-Meyer 
1986; Wade 1992b) 
     
18 Purdue Peg Board Test (Wade 
1992b; Desrosiers et al. 1995; 
Hurvitz et al. 2003) 
     
19 Arm Motor Ability Test 
(Kopp et al. 1997) 
     
20 Chedoke Arm and Hand 
Activity Inventory (Barreca et 
al. 2005) 
     
Key:  Indicates that the attribute is present, without any assessment of quality.  
 
4.4.2 Stage 2: Real-life relevance 
Six measures were identified, which met both Stage 1 and Stage 2 criteria (i.e. were 
relevant to real life functional performance). These were the LASIS, the ABILHAND 
and the MAL, which had four different versions MAL-14, MAL-26, MAL-28 and 
MAL-12 (see Table 4.1).  All four versions of the MAL had undergone separate 
psychometric evaluation so were included.  The scaling methods, number of items and 
methods of administration for these measures are shown in Table 4.2. 
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Table 4.2 Selected measures of function 
Outcome measure Method and procedure of scoring Context for development 
Leeds Adult Spasticity Impact Scale 
(LASIS) (Bhakta et al. 1996; Bhakta et al. 
2000a) 
Items: 12  
Scoring: Patients and carers, over the past 7 days. Items rated 
between 0-4. Scores summed and divided by the number of 
questions answered. 
Administration: Semi-structured interview. 
Spasticity (BTX) 
intervention 
Motor Activity Log (MAL-14) (van Kuijk et 
al. 2002; Page and Levine 2003; van der Lee 
et al. 2004; Yelnik 2004; Dettmers et al. 
2005; Ring and Rosenthal 2005; Uswatte et 
al. 2005) 
Items: 14. 
Scoring: by patients, over the past 7 days.  Scores range from 0 
(never use the affected limb for this activity) to 5 (always use the 
affected arm for this activity).  Subjects are rated on the amount they 
use their paretic arm (“amount scale”) and on the quality of their 
movement during the functional activities (“how well scale”). 
Administration: Semi-structured interview. 
Constraint Induced 
Movement Therapy (CIMT) 
26 Item MAL (MAL-26) (van der Lee et al. 
2004) 
Items: 14 original items, 11 additional items and 1 optional item 
chosen by the patient. 
Scoring: by patients, over the past 7 days as per the MAL. 
Administration: Semi-structured interview. 
CIMT 
28 Item MAL (MAL-28) (Uswatte et al. 
2006) 
Items: 28  
Scoring: by patients, over the past 7 days or past 3 days.  
Administration: Semi-structured interview. 
CIMT 
12 Item MAL (MAL-12) (Popovic et al. 
2003) 
Items: 12  
Scoring: by patients, over the past 7 days as per the MAL. 
Administration: Semi-structured interview. 
CIMT 




Scoring: Patients asked to estimate their ease or difficulty of 
performing each task (without help) only on tasks they have 
performed.  
Administration: Semi-structured interview. 
Chronic Stroke rehabilitation 
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4.4.3 Stage 3: Evaluation  
The detailed evaluation of the properties of the selected measures is presented in Table 
4.3, using the upper limb specific quality criteria developed by Bot and colleagues (Bot 
et al. 2004). 
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Table 4.3 Quality assessment of selected measures based on analysis of the published studies 



































- + + + + - + + + + 
Method or result was rated as: + Adequate; + Doubtful; - Poor; ? No data available. 
 
 
Quality assessment based on the criteria by Bot et al (2004).
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Table 4.4 provides a summary of the methodological quality of the specific 
psychometric evaluation studies for each of the selected measures. 
 




Table 4.4 Summary of the methodological quality of the psychometric studies of selected measures using the COSMIN checklist 
Outcome measure Methods Applied Measurement properties 
addressed in the paper 
Comments on methodological quality 
Leeds Adult Spasticity Impact 
Scale (LASIS) (Bhakta et al. 
1996; Bhakta et al. 2000a) 
No published formal 
evaluation 
Content Validation Using an open interview with patients and carers to create 
and item bank.   
 Details of the methods for this not published. 
Second study used the measure in an intervention study. 
Motor Activity Log (MAL-14) 
(Uswatte et al. 2005) 
 




Examination in 41 stroke participants. 
 Internal consistency using Cronbach’s alpha was 
demonstrated for both sub-scales 
 Construct validity evaluation was inconclusive. 
 Limited methods to correlate change for responsiveness 
(Pearson Correlation) 
Limited evaluation of psychometric properties. 
26 Item MAL (MAL-26) (van 
der Lee et al. 2004) 
CTT Internal consistency  
Test-retest reliability (Bland 





Clinimetric evaluation in 56 chronic stroke patients. 
 Internal consistency demonstrated in both sub-scales 
 Test-retest reliability measurements 2 weeks apart but 
used Bland and Altman in MAL data which is ordinal. 
 Correlation of the two sub-scales with each other and 
with the total score but not with another measure. 
 Longitudinal construct validity evaluated by 
responsiveness ratio (mean change after intervention) 
non significant responsiveness demonstrated. 




Outcome measure Methods Applied Measurement properties 
addressed in the paper 
Comments on methodological quality 
28 Item MAL (MAL-28) 







Comparison of MAL-28 scores with accelerometer 
findings in 222 stroke patients.   
 Item analysis using item total correlations resulted in 
removal of two items. 
 Internal consistency demonstrated. 
 Construct validity involved comparison with 
accelerometer recordings and a subjective hand 
Function Scale but had limitations with accelerometer 
comparison and application. 
12 Item MAL (MAL-12) 
(Popovic et al. 2003) 
CTT (clinimetric) Content Validation Clinimetric reduction of items from 14 to 12, no further 
evaluation of psychometric properties. 
ABILHAND (Penta et al. 1998; 
Penta et al. 2001) 
 








Reliability (error measure 
variance) 
Initial evaluation in 18 rheumatoid arthritis patients (Penta, 
1998). Preliminary evaluation using Rasch analysis. 
 
Subsequent evaluation on 103 chronic stroke patients 
(Penta, 2001). More expansive robust evaluation using 
Rasch analysis. 
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In table 4.4 reference has been made to the COSMIN checklist for assessing the 
methodological quality of studies of the measurement properties of health status 
questionnaires (Mokkink et al. 2010).  However, these criteria were not available at the 
time of the original review and therefore the Bot (2004) upper limb specific criteria 
were used in Table 4.3. 
 
Table 4.5 shows the item content of each of the six identified measures can be broadly 
placed in a hierarchy of increasing difficulty.   
Table 4.5 Items included in each measure 










Passive Function Items 
Cleaning the palm affected hand 1      
Cutting fingernails affected hand 2  25*   4* 
Cleaning the affected elbow  3      
Cleaning the affected armpit  4      
Cleaning the unaffected elbow 5      
Putting arm through coat sleeve  6 1* 1*    
Difficulty putting on a glove  7      
Difficulty rolling over in bed 8      
Doing physiotherapy exercises to arm 9      
Active Function Items 
Difficulty balancing standing  10      
Difficulty balancing walking 11      
Hold object steady, use other hand (jar
a
) 12     10
a 
Steady myself while standing  2 2    
Carry an object from place to place  3 3 23 12  
Pick up fork or spoon, use for eating  4 4 24 10  
Comb hair  5 5 25   
Pick up cup by handle  6 6 26 11  
Hand craft/card playing  7 7    
Hold a book for reading  8 8    
Use towel to dry face or other body part  9 9    
Pick up a glass  10 10 20 5  
Pick up toothbrush and brush teeth  11 11 21 6  
Shaving / make-up  12 12    
Use a key to open a door  13 13 22 7  
Letter writing/typing  14 14  8  
Pour coffee / tea   15    
Peel fruit or potatoes   16   3 
Dial number on the phone   17    
Open / close a window   18    
Open an envelope   19    
Take money out of a wallet or purse   20    
Undo buttons on clothing   21    










Undo a zip   23    






















Other optional activity   26    
Turn on a light with a light switch    1   
Open a drawer    2   
Remove item of clothing from drawer    3   
Pick up phone    4 1  
Wipe kitchen counter    5   
Get out of car    6   
Open refrigerator    7   
Open a door by turning a door knob    8 2  
Use a TV remote control    9   
Wash your hands    10   
Turn water on/off with faucet (tap)    11 4  
Dry your hands    12   
Put on your socks    13   
Take off your socks    14   
Put on your shoes    15   
Take off your shoes    16   
Get up from chair with arm rests    17   
Pull chair away from table before sitting    18   
Pull chair toward table after sitting    19   
Eat half a sandwich or finger food    28 3  
Use removable computer storage     9  
Hammer a nail      1 
Thread a needle      2 
Wrap gifts      5 
File nails      6 
Cut meat      7 
Peel onions      8 
Shell hazel nuts      9 
Open pack of chips (crisps)      12 
Sharpen pencil      14 
Spread butter      15 
Fasten ‘snap’ (press stud)      16 
Cap of a bottle      18 
Open mail (post)      19 
Squeeze toothpaste      20 
Unwrap chocolate      22 
Wash hands      23 
Key:  
Items in the table are given the number at which they appear in order in the measure. 
Items in LASIS included under passive function all asked respondents ‘how difficult’ a task was to 
undertake related to care of the limb by the patient him or herself or a carer. 
* Items in the passive function section included in MAL-14, MAL-26 or ABILHAND could be done 
either passively or with more active involvement by the individual, with the focus being on active 
involvement in these measures. 
a and b refer to specific objects used for the functional items in a measure. 
 
At the lowest level of the hierarchy in Table 4.5, the LASIS, includes mainly passive 
function items.  In the middle of the hierarchy, the MAL contains items of active 
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function, increasing in the following order: MAL-14, MAL-26, MAL-28, and MAL-12.  
At the upper level of the hierarchy, the ABILHAND contains complex items often 
requiring bilateral hand use, and for ABILHAND, the order of difficulty has been 
confirmed by Rasch analysis (Penta et al. 1998; Penta et al. 2001). 
 
Administrative burden and time for completion 
The administrative burden was adequate for all measures apart from the LASIS.  The 
LASIS requires the calculation of the measure total, however this calculation in practice 
is not complex.  The calculation of the LASIS involved totalling the item scores and 
calculating the mean.  There is no lower limit to the number of items, which need to be 
answered for a valid global score, so the score across different individuals may not be 
comparable. 
  
All measures are completed by the clinician using a structured interview with the patient 
and carer and require allocation of clinician time.  The LASIS, three versions of the 
MAL (excluding MAL-12), and the ABILHAND were thought to involve a time for 
completion of greater than 10 minutes, although specific data on this were not available. 
 
Validity 
Construct validity was adequately addressed in three versions of the MAL (14, 26 and 
28) and ABILHAND.  Information on floor and ceiling effects was difficult to identify 
or not formally addressed in the majority of measures.  However, given that the 
measures have a hierarchical relationship in their item content, it may be expected that 
the LASIS would have ceiling effects in a higher function group, and similarly the MAL 
and ABILHAND would have floor effects for detecting changes in lower level and 
passive function tasks. 
 
Reliability 
Internal consistency was demonstrated in four measures; three versions of the MAL (14, 
26 and 28) and ABILHAND.  Test-retest reliability evaluation was documented in four 
measures the ABILHAND, the MAL-14, MAL-26 and the MAL-28 (van der Lee et al. 
2004; Uswatte et al. 2006).  Adequate methods have been used in the ABILHAND, but 
were less convincingly applied in the MAL-14, MAL-26 and MAL-28.   





Responsiveness was demonstrated in the ABILHAND and was also assessed in the 
MAL-14 and 26.  However, the change in the MAL-14 and 26 did not correspond to 
change identified by other measures, and responsiveness was therefore rated as 
inadequate in this evaluation (van der Lee et al. 2004; Uswatte et al. 2005).  
Responsiveness in both measures was evaluated in post stroke hemiplegic patients who 
had good return of arm movement and related function. 
 
Interpretability 
Interpretation of specific scores with respect to qualitative meaning had only been 
evaluated in the MAL-14 and ABILHAND.  The ABILHAND had been evaluated using 
Rasch analysis and demonstrated a clear gradation of increasing ability of different 
items within the scale (Penta et al. 1998; Penta et al. 2001). It was therefore given a 
positive rating. The MAL, however, did not show an adequate relationship between 
overall scores or achievement of individual items and qualitative meaning.  The MIC 
was not clear and it was therefore given a doubtful rating overall.  
 
4.5 Discussion 
This systematic review identified six measures (including four versions of MAL), which 
had been used in the published literature to evaluate function reflective of real-life or 
actual performance.  The six measures appeared to fall broadly into a hierarchy of 
increasing difficulty.  The LASIS evaluates passive function and low-level active 
function, such as using the affected hand to hold and stabilise objects. The MAL and 
ABILHAND were more comprehensive (and consequently complex) measures for 
active function, evaluating a wide range of activities, including unilateral and bimanual 
function. 
 
In terms of their psychometric properties the LASIS and MAL-12 have received limited 
evaluation and met only one of the Stage 3 review criteria each. The MAL-14, 26 and 
MAL-28 have been more extensively validated, but although they each met two criteria, 
their performance was doubtful on the remainder. Only the ABILHAND has been 
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thoroughly evaluated and was shown to meet 9 of the 11 criteria, although it failed on 
time for completion and floor effects in a more dependent group.   
 
The implication of these findings for clinicians is that there are several measures 
available and the choice of measure will depend on the patient’s current level of 
function and the anticipated goals for treatment.   
 The LASIS is likely to be useful for individuals who have little or no active 
movement or function, but nevertheless have care and maintenance issues 
related to the hand and upper limb.   
 The MAL-14 contains more unilateral and simple items, which may be useful 
for detecting change in individuals who have some (but limited) arm function. 
 The MAL-26 also includes the 14 items but adds a further 12 -including some 
tasks (such as peeling potatoes or taking money out of a purse) which require 
two hands.  
 The MAL-28 includes seven items from the MAL-14/26, but adds a further 21 
functional tasks, some of which challenge reach and strength (such as putting on 
shoes and socks or pulling a chair towards a table after sitting), while the MAL-
12 represents a short version that spans the entire range of MAL items 
 The ABILHAND has six items in common with these scales, but adds a further 
sixteen, all of which are more complex bilateral tasks. It is therefore likely to be 
useful for patients functioning at a higher level (see Table 4.2 for details of the 
measures and Table 4.5 for the included items). 
4.5.1 Limitations: 
The systematic review has limitations in three main areas: identification of items, 
missing studies and evaluation of psychometric properties. 
 
Identification of measures  
The starting point for the review was the scientific literature, and it is possible that 
measures have been missed that are used in clinical practice, but have not been applied 
in research.  However, as the objective was to identify measures for which there is some 
evidence of psychometric evaluation, it is considered appropriate to base the review in 
the research literature.  
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The possibility of missing studies 
The secondary search for literature regarding psychometric evaluation included 
identification of references from the original publications and a search of the cited 
literature based on the name(s) of the measures.  The LASIS has not been referred to by 
this name in the literature, but as disability and carer burden scales in BTX intervention 
studies by the Bhakta and colleagues (Bhakta et al. 1996; Bhakta et al. 2000a).  The 
current version of the LASIS was obtained by directly contacting the author after the 
initial search.  As highlighted in the case of the LASIS, it is possible that the narrower 
secondary search may have missed some of the grey literature. However, it was 
anticipated that these other publications would generally be of lower quality, and would 
not add significantly to the body of evidence that was found. 
 
Evaluation of psychometric properties 
The use of formal evaluation criteria supported a detailed assessment of the published 
psychometric properties for the respective measures.  The criteria published by Terwee 
et al (Terwee et al. 2007) were based on an earlier review by the same group (Bot et al. 
2004).  The criteria were not developed for the context of hemiplegia, although the 
earlier review was a systematic review of shoulder disability questionnaires for 
application following musculoskeletal injury.  The current review did not identify any 
of the same measures evaluated by Bot, due to the different patient populations 
considered.  For example, Bot identified the DASH (Hudak et al. 1996) questionnaire 
which best met their search criteria and had undergone the most extensive psychometric 
evaluation.  The DASH is a self-report measure of everyday active function.  Self-
reporting may have advantages in reducing the clinical time required to administer the 
measure.  However, it is designed to assess higher-level function and, like the 
ABILHAND, is likely to show floor effects in a neurologically impaired population.  At 
the other end of the scale, none of Bot’s measures contained any passive function items.  
Passive function applies particularly in the context of neurological damage, but could 
also have relevance in very severe musculoskeletal conditions, such as deforming 
arthritis.  This emphasises the wide range of functional activities of the upper limb.  
 
The results of the review can also be compared to those of an Occupational Therapy 
(OT) orientated review by Rowland and Gustafsson (Rowland and Gustafsson 2008).  
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Their review, published after the systematic review in this thesis, considered upper limb 
measures of activity as defined by the ICF for specific application in occupational 
therapy practice.  The OT orientated review involved searches of Medline, the 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane 
library.  This was a less extensive search than that conducted for this thesis, which 
included searches of other databases based on the strategy outlined by Dickersin and 
colleagues (Dickersin et al. 1994).  Rowland and Gustafsson’s review was not 
systematic in nature, which in part explains the smaller number of sources searched.  
The review criteria were similar in focussing on measures of activity, though differed in 
not specifying measures that reflect everyday performance.  They used quality criteria 
proposed by Law and Baum (Law and Baum 2001) rather than those by Terwee and 
colleagues (Terwee et al. 2007) used in this review. 
  
The criteria by Law and Baum address the focus of the measure, clinical utility, scale 
construction, standardization, reliability and validity.  Explicit definitions for each 
criterion were not given with the degree of detail provided by Terwee, although the 
evidence for each measure relating to individual criteria was included.  Some of the 
measures identified were the same as those identified in this systematic review; Wolf 
Motor Function Test; Arm Motor Ability Test; Action Research Arm Test; Motor 
Activity Log (14 and 28), Upper Limb – Motor Assessment Scale; ABILHAND and 
Chedoke Arm and Hand Inventory.  The LASIS was not identified because it is referred 
to by different titles in the literature, it was specifically developed for evaluation of 
spasticity and does not have published psychometric evaluation. 
 
4.6 Implications and conclusions 
This systematic review of measures identified a selection of validated tools available for 
the evaluation of ‘real-life’ active function in the hemiparetic upper limb.  None provide 
a comprehensive assessment of both active and passive function. Depending on 
difficulty of the goals for treatment, clinicians could select from the six measures 
presented in this review but would need to be aware of the limitations in psychometric 
evaluation for some of these measures as discussed. 
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The ABILHAND appears to be a robust measure for higher levels of function, and the 
range of different versions of the MAL allow for assessment of abilities in the middle 
range.  However, there is a specific gap in relation to measures that assess passive and 
lower level function.  Moreover, all of the measures identified in this review are 
administered by structured interview, which has implications for clinician time if used 
in routine clinical practice.  The development of self-completed questionnaires has the 
potential to improve the practicality of application, although some patients with 
neurological disability may find this difficult, especially if they have significant 
cognitive or communicative problems.  Further exploration and development of 
measures to address these issues is required. 
 
An alternative to the development of a single new measure, addressing these 
deficiencies is the development of an item bank of the type referred to by authors such 
as Tennant (2007) using Rasch analysis techniques for development.  Such an approach 
would use the six measures identified in this review and the preliminary hierarchy 
presented in Table 4.5 as a basis for development.  There are potential strengths in 
having a range of items which fully capture the extent of active function.  In addition 
the measure would also have potential application in both spasticity intervention and in 
other focal upper limb interventions, in which, active function improvement is much 
more likely.   
 
However a weakness of item banking for this work is evident with limited exploration 
of passive function items having been undertaken in the development of the current 
measures.  The majority of change following spasticity intervention is expected in 
passive function rather than active function and therefore this issue is particularly 
important.  This will be addressed further in Chapter 5.  In addition, for active function 
items, development of an item bank would make the assumption, that all relevant items 
are included in the existing measures without evaluating this.  This will also be 
evaluated further in Chapter 5. 
 
In a minority of cases (possibly those with more recent injury) improvement in active 
function may still also occur following focal spasticity intervention.  It may therefore be 
important to capture improvements in both active and passive function.  This presents a 
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difficulty in selecting items from the item bank for clinical application, where active 
function items may not be applied because change is expected only in passive function.  
If active function change does occur no baseline measure of this sub-scale will have 
been recorded. 
 
One way of ensuring that passive function is appropriately measured and that changes in 
active function are detected if they occur, is initially to develop a measure which has 
two sub-scales addressing both active and passive function.  Such a measure could, in 
due course, form the lower end of an item bank (or two item banks for active and 
passive function) but would also ensure initial clinical utility in spasticity management 
practice. 
 
In summary, there is a need for a self-report measure of passive and active function in 
the upper limb.  Chapter 5 identifies further items for inclusion in such a measure. 




Chapter 5 Identification of patient selected items  
5.1 Introduction  
The systematic review yielded a range of possible measurement items, which primarily 
addressed active function rather than passive function.  This chapter complements the 
systematic review by involving patients and carers at an early stage of measure 
development, focusing on identifying passive function items as well as confirming the 
importance of items already identified from the literature.  The analysis in this chapter 
involves the evaluation of actual clinical goals set by patients and carers in conjunction 
with the clinical team.  The purpose of this work is to ensure that items of particular 
relevance to patients and carers, particularly those for passive function, are reflected in 
the development of the new measure. 
 
Setting goals with patients and carers has been identified as a core activity in 
rehabilitation practice (Playford et al. 2009; Wade 2009).  The application of goal 
setting in directing intervention is established practice for most neurological 
rehabilitation professionals and within most service settings.  Although currently much 
discussion is taking place as to the exact nature and purpose of goals in rehabilitation 
practice (Hart and Evans 2006; Hurn et al. 2006; Latham and Locke 2007), the use of 
some form of goal setting is widely accepted (Wade 2009).  A rehabilitation goal is 
defined as the aim or target of a specific intervention or programme of interventions 
(Wade 1992a).  In practice, goals are often set at a number of different levels from 
completion of small tasks such as sitting in a wheelchair for 30 minutes, to whole 
rehabilitation programmes with the aim of being independent and self-caring at home.  
The emphasis in rehabilitation practice is on making goals functional and meaningful to 
the patient.   Goals are therefore usually directed at achieving change in either the 
activity or participation levels of the ICF (Wade 1992b; WHO 2002).  Intervention may 
be aimed at changing impairments to body structures, but the primary focus is likely to 
be functional improvement.  Goal attainment scaling (GAS) is one method used to set 
goals, which has the advantage of enabling the quantification of the outcome related to 
the goal in a systematic manner (Kiresuk and Sherman 1968).   
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The GAS technique is suitable for health problems, which warrant an individualised 
approach to outcome evaluation (Stolee et al. 1992; Rockwood et al. 1997; Stolee et al. 
1999; Zaza et al. 1999).  GAS has been used in a number of rehabilitation studies 
(Stolee et al. 1992; Rockwood et al. 1997; Stolee et al. 1999) and has also been used 
following spasticity intervention (Ashford and Turner-Stokes 2006; McCrory et al. 
2009; Turner-Stokes et al. 2010).  In addition, application of GAS has been 
recommended for evaluation of individual patient goals in the recent guidelines for 
management of spasticity with botulinum toxin (Royal College of Physicians et al. 
2009).  A full description of the GAS method is given in Appendix 3.   
 
When evaluating function in the arm, much of the clinical focus has been on the hand 
and distal upper limb.  The hand and distal upper limb perform the tasks essential to arm 
function, such as manipulating and using objects and tools.  Many of these tasks are 
assessed in existing outcome measures (Penta et al. 1998; van der Lee et al. 2004).  The 
proximal upper limb and shoulder also have an important role in positioning the upper 
limb to perform many manipulative tasks.  Shoulder and elbow movement is also 
important for passive function tasks such as cleaning the armpit or elbow crease and 
these functions are not as frequently addressed in existing measures.  This was felt to be 
an important omission. 
 
The work presented in this chapter was a secondary analysis of a cohort study 
previously published (Ashford and Turner-Stokes 2008) (see Appendix 20) and 
followed the systematic literature review (Ashford et al. 2008).  The review yielded a 
range of possible items to be included in a new measure, but revealed a preponderance 
of active function measurement items, with far fewer addressing passive function, and 
indicating the need for further research to determine a core set of items for inclusion in a 
new measure.  A key secondary aim was to identify proximal as well as distal upper 
limb items.   
 
This secondary analysis therefore has three aims:  
1. Identification of new passive function items by patients and carers. 
2. Confirmation of items identified in the systematic review. 
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3. Ensuring that items relevant to the proximal upper limb are considered for 
inclusion.   
  
5.2 Objective  
Objective 2 was addressed in Chapter 4 and will also be addressed in this chapter. 
 
Objective 2.  To identify candidate items for inclusion in a measure of upper limb 
function for use following focal rehabilitation interventions, in the 
hemiparetic upper limb. 
5.3 Method 
The analysis used goals for spasticity intervention involving combined BTX and focal 
PT intervention (physical interventions specific to the upper limb, such as splinting).   
5.3.1 Design 
The study used a prospective observational cohort design.  Ethical permission for the 
study was obtained from the Harrow Research Ethics Committee – EC2773 (see 
Appendix 10).  
5.3.2 Setting 
Physical therapy (PT) interventions and BTX were provided according to a previously 
described ICP (see Appendix 11) for spasticity management as standard clinical practice 
through a tertiary spasticity service (Ashford and Turner-Stokes 2006).  Injection of 
BTX used a flexible protocol according to the different muscles involved, together with 
concurrent PT interventions, consisting of splinting, serial casting, exercise 
programmes, functional electrical stimulation, arm supports and patient and carer 
education on arm positioning and stretching.   
5.3.3 Selection of participants 
Participants were identified from a tertiary service resulting in a sample with more 
severe disability than in typical stroke populations and to include proximal upper limb 
problems as a particular focus. 
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Inclusion criteria:  
 Hemiplegic upper limb impairment affecting function. 
 Impairment resulting in an increase in muscle tone and alteration to strength and 
control. 
 Undergoing treatment for spasticity management in the shoulder girdle or 
proximal upper limb requiring BTX intervention and physical therapy. 
 Age between 18 and 85 years. 
 
Exclusion criteria:  
 Patient declines to participate or family and/or treating team declines on their 
behalf. 
 Unable to complete goal setting process and no carer (professional or family) 
available to undertake completion.  Examples of situations that may lead to 
exclusion are indicated below: 
o Does not speak English  
o Unable to communicate responses (where feasible, communication using 
adapted methods was employed, including support from a speech and 
language therapist to avoid exclusion). 
o Cognitively unable to understand process. 
 
The sample comprised a consecutive cohort of patients referred for proximal upper limb 
spasticity management with BTX and physical therapy intervention.  All presented with 
spasticity following either brain injury or stroke and had been referred to the service by 
their physiotherapist, general practitioner or medical consultant.  Carers of patients were 
also consulted about goals for intervention when they were involved in providing care.   
 
5.3.4 Procedure 
Patients were provided with information before agreeing to participate in the study (see 
Appendix 4).  Consent to participate in the study was obtained and a written record kept 
(see Appendix 5).  All functional goals were determined through discussion between 
patient and/or their carers and the clinical team (state registered health professionals).  
Goals were set using GAS (Turner-Stokes 2009b) using the standard method and were 
entered into the ICP proforma to ensure appropriate recording and capture.  Goal 
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achievement was also recorded on the clinical ICP document (see Appendix 11 for the 
current version of the ICP).  A second clinician reviewed the goal setting procedure, to 
ensure that goals had been recorded for each patient and were appropriate to the clinical 
presentation.   
 
Goals were reviewed to identify categories.  Goal category identification, followed by 
assignment of goals to a category, was undertaken by the author and then reviewed by a 
colleague.  Active or passive function goals were retained and others were excluded.  
Each goal was then considered as a potential item for the ArmA.  Goals with slightly 
different wording but representing the same issue were collapsed into a single item.  
The resulting list of items was compared with those identified in the systematic review.   
Items not already identified from the literature were included in the development of the 
ArmA. 
 
5.4 Results from goal setting analysis 
A total of 78 patients were treated for upper limb spasticity, of which 16 had treatment 
for shoulder girdle or proximal involvement and were included in the secondary 
analysis. All consecutive referrals undergoing BTX intervention for proximal upper 
limb spasticity gave consent to be included as participants.  The mean age of the 16 
patients was 54.5 years (SD 15.7), 9 were male and 7 female, and diagnostic groups 
were brain injury due to trauma (n=1) and stroke (n=15).  The mean age is at the 
younger range of ages in the general stroke population.  The median baseline Barthel 
Index was 10.5 (Inter-quartile range 5 to 18), from a total possible score of 20, which 
indicated a moderate level of disability in this group.  Mean time since neurological 
injury was 15.7 (SD 20.9) months. 
 
Intervention goals were reviewed and then allocated to one of five categories; passive 
function, active function, symptoms (e.g. pain), cosmesis and impairment (see Figure 
5.1). 



























32 Individual goals identified 







Activity level of ICF 
Passive function (20) 
Active function (1) 
 
Identified in systematic review? 
Passive function (5) 
Active function (1) 
 





Candidate items identified (8) 
Passive function (7) 
Active function (1) 
Removal of duplicates 
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Thirty-two goals were set in all for the 16 patients, two goals per patient (see Table 5.1).   



















































1 Reduce shoulder pain      
 
Allow independent selective shoulder movement to enable reach for 
cup 
     
2 
Enable positioning of right upper limb with reduced pain      
 Enable washing and dressing of upper limb with reduced pain.      
3 Reduction in difficulty dressing due to reduced shoulder pain      
 Reduction in difficulty washing under arm due to reduced arm pain      
4 Improved ease of dressing arm      
 Improved ease of washing arm      
5 Reduction of shoulder pain      
 Improved ease of positioning arm      
6 Enable tolerance of wrist and hand splint      
 Enable positioning of upper limb      
7 
Improve positioning of upper limb for improved postural control in 
sitting 
     
 
Improved cosmesis of upper limb      
8 
Prevent further loss of range of movement      
 
Enable splint application      
9 
Enable palmar hygiene      
 
Improve ease of dressing upper limb      
10 
Reduction in shoulder pain      
 
Increase ease of axillary hygiene      
11 
Prevent deterioration in range of movement      
 
Prevent elbow hygiene difficulties      
12 
Ease of splint application      
 
Prevent loss of range at the elbow      
13 Reduce associated reaction from moderate to mild      
 Reduce wrist pain by two points on visual analogue scale      
14 Maintain current range of movement      
 Maintain current ease of care      
15 Prevent further loss of range of movement at the elbow      
 Maintain elbow crease skin hygiene      
16 Increase ease of washing left shoulder      
 Increase ease of dressing left shoulder      
Totals 20 1 9 1 5 




The option was available to set more than two goals (3 to 4 goals are recommended for 
spasticity intervention in recent guidelines (Royal College of Physicians et al. 2009)).  
However, in practice only two were set per patient in the 16 patients included in this 
study based on the GAS discussions between patients, carers and the clinical team.  The 
setting of no more than two goals may have occurred due to the relative novelty of the 
GAS procedure or time restriction in the clinic environment.  However, goals set for 
patients 2 and 3 corresponded to two goal categories.  When reduced to a list of 
candidate items, eight items were identified relating to the activity level of the ICF, 
comprising seven passive function and one active function.  The items were then 
compared with the systematic review.  Two passive function items had not been 
identified by the systematic review and were then included in the item reduction process 
to develop the ArmA (see Table 5.2).  The two items were splint application and 
placement of the upper limb on a support (wheelchair tray). 
 
Table 5.2 Passive function items identified by participants (n=16) 
Identified items Number of times 




1. Washing upper limb including shoulder. 4  
2. Dressing upper limb including shoulder. 4  
3. Axillary hygiene. 2  
4. Elbow crease hygiene. 2  
5. Palmar hygiene. 1  
6. *Splint application. 3  
7. *Enable placement of upper limb on a 
support (wheelchair tray). 
2  
Key: * Items included in item reduction for the ArmA 
 





Goals were allocated to categories, goals in irrelevant categories were deleted, and 
duplicate goals were conflated to produce a list of candidate items.  These items were 
included for item reduction in the development of the ArmA and support content 
validity of the subsequent measure.  The use of this methodology has enabled inclusion 
of patient and carer selected items in the measure development process.  
 
The five passive function and single active function items identified in both the 
systematic literature review and goal-setting review have been supported as relevant for 
use in measurement.  These items have face validity evidenced by their selection by 
patients and carers.  The construct validity for the subsequent development of the ArmA 
is also supported by the use of items identified in pre-existing measures and in this 
review of goal setting. 
 
Of the two additional items not identified in the literature, only one ‘Enable placement 
of upper limb on a support (wheelchair tray)’ involved the proximal upper limb and 
shoulder.  The other item of ‘upper limb splinting’, focused on the wrist and hand.  
Taking all eight items identified, five involve the proximal upper limb or shoulder and 
were passive function.  Based on this finding, most relevant items are present in 
currently available measures.  However, the process ensures that passive function items 
relevant to the proximal upper limb have been considered in development as intended. 
 
5.5.1 Strengths and limitations 
This analysis had three primary functions; 1) identification of new passive function 
items by patients and carers for inclusion in the ArmA, 2) confirmation of items 
identified in the systematic review, which enhances ecological validity and construct 
validity and 3) ensuring that items relevant to the proximal upper limb were considered 
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Passive function items 
In a sense, it may be surprising that more passive function items were not identified, in 
part demonstrating that patients have similar goals for focal spasticity intervention.  An 
alternative possible explanation maybe that using goals, as a source of items could tend 
to produce more components that are homogeneous.  In general, items measuring the 
same underlying construct are desirable in a sub-scale.  Theoretically, this could lead to 
a measure which has limited ability to discriminate between patients of different ability 
(Gillespie et al. 1987).  However, it is more likely that the key passive function items 
were identified and that others had already been identified by the systematic review.   
 
Active function items 
Active function goals are less frequently set in spasticity management intervention and 
active function improvements are only rarely seen, but do sometimes occur.  Therefore, 
specific purposive sampling would have been unlikely to identify new items in 
spasticity management.  Evaluating goals set for other interventions, such as ‘constraint 
induced movement therapy, could be undertaken, but are less likely to identify items 
particularly relevant to spasticity intervention.  In addition, the specific purpose of this 
work was to identify passive function items to redress the imbalance in the literature, 
which primarily focuses on active function items.  Alternative methods could have been 
employed (see Item generation; pages 91), such as focus groups or interviews, but again 
may not have added to items identified in the systematic review.   
 
Sample 
A further limitation is that data were available on only 16 participants, all of whom had 
very specific problems related to proximal spasticity.  While this is a strength, in 
potentially identifying items relevant to the shoulder and proximal upper limb, it may 
restrict identification of other items because the participant’s clinical problems are so 
similar.  In addition, the sample used was relatively small and all taken from one centre.  
However, the fact that only two new passive function items were identified indicates a 
degree of ‘saturation’ in the items already identified by the systematic review, despite 
being fewer than for active function. 
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Comparing this sample (a relatively young group with proximal upper limb spasticity) 
to the general stroke population, the participants were at the younger end of the age 
range of patients with stroke (mean age 54.5).  Patients with cognitive difficulties which 
prevented them participating in the goal setting process in any way were excluded, as 
well as those who were unable to communicate responses due to significant 
communication impairment.  However, considerable effort was expended in supporting 
communication and cognitive impairment to prevent exclusion.  Support for such 
patients included communication using adapted methods such as visual aids and support 
from a speech and language therapist.  The criticism could be made that the ArmA may 
not be suitable for older adults or those with communication difficulties.  However, the 
approach taken has attempted to ensure that communication and cognitive difficulties, 
while certainly a barrier, are controlled for as far as is possible.  The impairments and 
disabilities of the patients are also likely to be the more significant factors than pure 
chronological age in ensuring that the measure is appropriate and applicable. 
 
User involvement 
Patient and carer involvement in research and measure development has been 
emphasised in the rehabilitation literature and this review has facilitated this 
involvement in the ArmA development (Playford 2008; Giordano et al. 2009).  
However, a limitation of using goal analysis, is that patients and carers are setting goals 
of relevance to them, which may not allow them to reflect on the broader application of 
measurement items to other people.  As emphasised by INVOLVE (the Department of 
Health body for public and patient involvement in health and research) (INVOLVE 
2009), patients and carers have unique insights into research.  In this regard, the study 
may have been strengthened by further consultation in the form of qualitative methods 
to generate items with patients and carers, in addition to reviewing personally identified 
goals.   
 
Comparison with other work 
Turner-Stokes and colleagues reviewed the goals for treatment in a randomised 
controlled trial of spasticity management using BTX (Turner-Stokes et al. 2010).  The 
review indicated that GAS was an effective method of evaluating change following 
BTX intervention.  However, goals were often not achieved, possibly due to over-
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optimistic active function goals being set.  More importantly, when goals were 
categorised according to the ICF, 28% (46) were set within domains related to 
impairment of body function, with the remaining 72% (119) goals related to the 
domains of activity or participation (WHO 2002; Takahashi 2004).  The majority of 
goals however related to activity.  Activity goals were identified in the following 
categories: 
 Upper limb activities – such as lifting and carrying or holding objects still 
(generally not achieved) 
 Mobility – e.g. maintaining balance or improving gait 
 Self-care tasks such as hygiene, dressing or feeding 
 Domestic and community tasks such as housework or recreational activities 
 
It should be noted that the patient group used in the above study were more able than 
that used for the review of goals in this Chapter, and a difference was expected because 
of this.  However, all the passive function items identified in the current study 
correspond to self-care tasks in that by Turner-Stokes and colleagues (2010), with no 
additional items identified by them.  This supports the inclusive nature of items 
identified by the work in this chapter. 
5.6 Conclusions 
In summary, the aim, of undertaking an investigation of goal setting for spasticity 
intervention, to identify passive function items, was achieved addressing a possible gap 
in the literature.  Secondary aims of considering proximal spasticity and comparison 
with systematic review findings were also achieved.  The patient group, used in this 
goal analysis was, undergoing spasticity intervention and therefore had few active 
function goals as expected.   
 
The approach used in this chapter, has provided a complementary and innovative 
approach to that of the systematic review, thus enhancing validity as well as identifying 
additional items for inclusion in the development of the ArmA.  The analysis was 
particularly useful for identification and confirmation of passive function items.   
Chapter 6 will describe how the candidate items identified in Chapters 4 and 5 were 
used to develop the ArmA.   




Chapter 6 Development of the ArmA measure 
6.1 Introduction 
The need for a new self-report measure of active and passive function for application in 
the hemiparetic upper limb has been identified.  In this Chapter, the development of the 
measure is reported. Items are derived from measures identified in the systematic 
review (Chapter 4) and the patient identified items (Chapter 5).   
6.2 Objectives 
This Chapter describes the method for addressing objectives 3 and 4. 
 
Objective 3. To develop a self-report measure to assess both ‘active’ and ‘passive’ 
function in the hemiparetic upper limb following focal rehabilitation 
interventions. 
 
Objective 4. To confirm face and content validity by investigating item relevance for 
professionals (content), patients and carers (face and content). 
 
6.3 Methods of ArmA development  
The ArmA was developed using a modified Delphi Consultation, followed by wider 
consultation with other clinicians, patients and carers and piloting.  A sub-scale was 
developed for both active and passive function. The theoretical concepts of active and 
passive function are based on the discussion in Chapter 1. 
 
A Delphi approach uses an iterative consultation to measure opinion from identified 
experts (Burns et al. 2003).  The pre-existing items from the systematic review and the 
patient-identified items, were used as a starting point for the process, rather than initial 
generation of items using the Delphi technique. 
 
Modified Delphi consultation was selected because it provides anonymity to 
participants and reduces personality based influences such as the impact of socially 
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dominant individuals on the consensus process (Burns et al. 2003; Finger et al. 2006).    
Finger and colleagues consider the Delphi method to have four key characteristics:  
 anonymity for those participating;  
 iteration of concepts;  
 statistical group response based on frequency of selections (in this instance item 
selection); and  
 informed input from expert participants (Finger et al. 2006).   
The literature provides no definitive recommendation on panel size, which have ranged 
greatly in different studies between 10 and 1685 (Reid 1988) and in the rehabilitation 
literature from 15 (Raine 2006) to 263 (Finger et al. 2006).  Raine suggests that good 
results can be obtained with between 10 and 15 panel participants where the group is 
homogenous, and that smaller groups such as this are also more likely to retain group 
members (Raine 2006).   
6.3.1 Ethics and Research & Development (R&D) approval  
Ethical approval for all three modules of the research programme was received, from 
Central Office for Research Ethics Committees (COREC), now the National Research 
Ethics Service (NRES) by the Research Ethics Committee (Oxfordshire REC A) at John 
Radcliffe Hospital, Oxford (COREC number 05/Q1604/110) shown in Appendix 10.  
Site-specific assessment for all three modules of the study was carried out and approved 
by Northwest London Hospitals NHS Trust, (Northwick Park Hospital).  The Research 
and Development department also gave approval on behalf of Northwest London 
Hospitals NHS Trust and agreed to be sponsor for the project. 
  
The psychometric evaluation and cohort study required the inclusion of an additional 
site added to the COREC approval, the Alderbourne Rehabilitation Unit, Hillingdon 
Hospital, London.  A Principal Investigator was identified at this site and a Site-Specific 
Assessment undertaken and Research and Development approval was obtained.  See 
Appendix 10 for ethical approval documentation. 
6.3.2 Summary of development 
The process of the ArmA development is summarised in Figure 6.1. 




Figure 6.1 Summary of ArmA development 
Systematic review: 
 
 Identified possible 
items for inclusion 
 
 
Patient selected items: 
 
 Identified possible 
items for inclusion  
(1) Item Reduction – Delphi Consultation 
Three round consultation with selected expert clinicians 
 
Consultation 1 Initial item reduction 
Consultation 2 Further item reduction 
Consultation 3 Final item reduction 
 






(2) Item confirmation – 
Patients & carers 
 




Final measure  
Arm Activity Measure (ArmA) 
 Total number of possible items (n = 75) 
 Active Function n = 64 



















Stage 1 (reduction of items) involved modified Delphi consultation with a purposive 
sample of experienced clinicians.  Stage 2 (confirmation of items) involved wider 
consultation for confirmation of items selected with a different group of clinicians in 
addition to pilot testing with patients and carers. 
  
Stage 1. Reduction of items using modified Delphi consultation  
Participating clinicians (n=10) worked in two regional rehabilitation units, two district 
rehabilitation services and a community rehabilitation team within the London Region.  
The sample therefore included a spectrum of clinicians with experience of assessment in 
the upper limb from a range of clinical services.  The panel of clinicians included 
physiotherapists (n=4), occupational therapists (n=4) and rehabilitation medicine 
physicians (n=2).  All the therapists were either clinical specialist or senior level and the 
rehabilitation medicine physicians included were both consultant level.   
 
Stage 2. Confirmation of items by wider clinician involvement and pilot testing 
with patients and carers 
 
Clinicians  
The group consisted of specialist physiotherapists, occupational therapists and 
rehabilitation nurses none of whom had been involved in earlier stages of development 
or evaluation.  The invited physiotherapists were all identified from the UK 
Physiotherapy Adult Spasticity Forum, with the consultation document sent to the 
whole membership (n=58).  All physiotherapists in the forum were involved in 
spasticity management services managing the upper limb following BTX intervention.  
Occupational therapists were identified through initial contact with the physiotherapists 
and worked with them in specialist neurological rehabilitation services, with 
involvement in spasticity management.  Rehabilitation nurses were identified from 
rehabilitation services in North West London NHS Trust and worked with patients with 
upper limb activity limitation following stroke and brain injury.   
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Pilot testing: Patients and Carers  
Patients (n=13) and carers (n=13) were identified from those receiving inpatient, 
outpatient or outreach spasticity management input from North West London, 
Hertfordshire and Bedfordshire through the Regional Rehabilitation Service.   
6.3.4 Procedure 
The following section describes the procedure for each stage of development 
comprising; initial item reduction using modified Delphi consultation, wider 
consultation with clinicians and pilot testing with patients and carers.  The process 
utilized consultation documents electronically or paper based dependent on the 
participant’s preference.   
 
Stage 1. Item reduction using Modified Delphi Consultation 
In Delphi Consultation, consensus is deemed to have been identified when the votes 
from respondents fall within a pre-defined range.  For example, Raine (2006) used an 
80% response level for acceptance of an item, where 80% of respondents agree with the 
item or change to the item.  A range of acceptance levels can be found in the literature 
between 55 and 100 percent (Deane et al. 2003; Powell 2003).  The COSMIN study 
group (see page 85) used 67% agreement between experts in the group as a cut-off point 
for agreement (Mokkink et al. 2010).  This cut-off point was arbitrarily chosen based on 
evaluation of the levels of agreement seen between members of the group. 
 
In this study, the level was set at 60% consensus for exclusion or inclusion of items.  
The level of agreement was set before data collection and analysis at a level thought to 
allow agreement between group members and to enable the reduction of items.  Item 
reduction was a key focus of this work as well as the confirmation of the content 
(patients, carers and professionals) and face (patients and carers) validity of items.  
Reduction of items from the original 75 was needed to ensure that the measure 
developed was feasible in normal clinical practice.  Reduction of items (or responses to 
Delphi questions) is an appropriate use of the technique and often involves the re-
presentation of findings from earlier rounds of the consultation process (Strauss and 
Ziegler 1975; Burns et al. 2003; Deane et al. 2003; Powell 2003).  This principal was 
used in the Delphi consultation in this work and the 60% cut off point for inclusion of 
items was used based on levels recommended by Deane et al (2003). 




Three rounds of Delphi consultation were planned to enable the feedback of comments 
to the group.  Item prioritisation by group participants, in light of the feedback, was then 
possible to enable decisions on inclusion or exclusion of remaining items.  The 
approach to initial item reduction in this thesis was to use a clinical prioritisation 
approach within the Delphi framework to prioritise items based on clinical opinion.  
This approach was shown to be effective in the development of the Quick DASH, 
resulting in a shorter, clinically feasible measure with items prioritised by clinicians 
thought to have greater face validity (Beaton et al. 2005). 
 
Delphi Consultation Round 1  
The list of possible items, from the systematic review and patient identified items (see 
Tables 4.5; page 137 and 5.2; page 153) was presented to the purposively selected 
sample of expert clinicians.  See Appendix 6 for the ‘Item selection grid’ including the 
list of items.  The list was distributed by post or electronic mail.  Respondents were 
asked to identify: (a) items which were important to include in a measure of active and 
passive arm function from the list; (b) items from the list, which should be excluded 
along with the reason for exclusion; (c) any items that were not on the list which were 
of particular importance and explain why they should be considered for inclusion.  Once 
the comments had been returned, participants were, where necessary, contacted to 
clarify any points and ensure no issues had been missed.  The initial list of items was 
revised in light of these findings to produce a short list for round 2. 
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Delphi Consultation Round 2  
The revised list was then returned for further comment and verification, consisting of 
the original list and the revised short list.  Respondents were asked to comment again on 
the items repeating the previous process.  They were also asked to consider which of the 
remaining items were unlikely to apply in a majority of cases and would therefore not 
be as relevant to include.  Once the comments had been returned, participants were, 
where necessary, contacted to clarify any points and ensure no issues had been missed.  
A further revision to the short list was produced in light of round 2 findings. 
 
Delphi Consultation Round 3  
The results from round two of consultation were sent out again to the same group, 
consisting of the original list (round 1) and the further revised short list from round 2.  
The respondents were asked to confirm the selection of items, with the full list of 
possible items available for reference.  Once the comments had been returned, 
participants were, where necessary, contacted to clarify any points and ensure no issues 
had been missed. 
 
Following third round consultation, a draft measure was constructed using the items 
identified by the group.  Based on the findings of the systematic review the method of 
scoring items was adopted from the six measures selected for psychometric evaluation 
(see Table 4.5; page 137).  The method comprised completion based on activity over the 
preceding 7 days and was scaled on a five point ordinal scale.  This method of scaling 
responses was adopted as the method for the draft ArmA. 
  
Stage 2. Item confirmation - wider review by clinicians  
Consultation was then undertaken through e-mail or post with physiotherapists, 
occupational therapists and nurses who formed the clinicians for the item confirmation 
group.  Item confirmation was undertaken because a main focus of the Delphi 
consultation had been reduction of items and further confirmation of content validity in 
a larger group of clinicians would strengthen and reconfirm the findings.  In addition the 
wider consultation allowed for the inclusion of nurses who were a professional group 
not included in the Delphi consultation and enabled this possible limitation to be 
addressed. 
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The multistage approach to development of the ArmA was in part modelled on that used 
in development of the DASH.  The initial consultation for DASH was undertaken with 
clinical experts and methodologists by reviewing items from relevant measures in use 
(Hudak et al. 1996).  This was then followed by item reduction using the same group to 
remove items which were not relevant for various reasons defined by the group.  Further 
item reduction was then undertaken by field testing the items with a small number of 
patients.  The development of the Quick-DASH then involved further item reduction 
using three methods: the concept-retention method, the equidiscriminative item-total 
correlation and IRT – Rasch analysis (Beaton et al. 2005).  Multiple stages of item 
reduction and confirmation were shown to be of value in the DASH work and 
contributed to the resulting face, content validity and utility of the measure developed.  
A similar multi-stage approach was therefore used in the development of the ArmA, 
with an aim to strengthen face, content validity and utility. 
 
The consultation document consisted of the draft ArmA and the original list of items 
from the systematic review (see Table 4.5, page 137) and patient-identified items (see 
Table 5.2; page 153).  The patient and carer version of the item confirmation 
questionnaire is shown in Appendix 7.  Respondents were asked to identify: (a) items 
not included in the draft ArmA from the original list which should be included; (b) 
items included in the draft ArmA, which should be excluded along with the reason for 
exclusion; (c) any items that were not included in the draft ArmA or the original list 
which should be included and explain why.  Respondents were also asked to comment 
on the way in which items were scaled.   
 
Clinicians who had not returned the consultation document within two weeks were 
contacted again and a new consultation document sent where required.  If they had not 
returned the consultation document following a further two weeks, they were contacted 
a third time, after which time follow-up was discontinued.   
 
Patients and Carers - item confirmation 
Patients were provided with information before agreeing to participate in the study (see 
Appendix 8).  Consent to participate in the study was obtained and a written record kept 
(see Appendix 9).   




Patients and carers were also asked to comment on draft ArmA items by responding to 
the same consultation document as the item confirmation group of clinicians.  The 
patient and carer version of the item confirmation questionnaire is shown in Appendix 
7.  As the measure is designed for self-report or structured interview, patients and carers 
were also asked to complete the ArmA, and give their views on; (a) its relevance to 
them; (b) ease of completion (c) presentation style.  Consultation documents were 
distributed to patients and carers, either face-to-face, returned by post or over the 
telephone.  If patients or carers had not returned the document after two weeks they 
were then contacted and an additional document sent if needed.  If they had not returned 
the document after a further two weeks, they were contacted a third time, after which 
time follow-up was discontinued.   
 
The responses were then compared with the modified Delphi consultation results.  If 
new items were presented these were considered provided they were identified by more 
than one respondent, either clinician, patient or carer.  The researcher reviewed all 
comments and made decisions on changes to ArmA based on (1) issues raised by 
multiple respondents, or (2) issues corresponding to findings from the systematic 
review.  Decisions about items were then discussed with a colleague for concordance 
before changes were made.  This process resulted in version two of the ArmA for 
psychometric evaluation. 
 
ArmA item mapping onto the ICF 
To further demonstrate the content validity of the ArmA (version-2) it was mapped onto 
the ICF.  The aim was to confirm the domains addressed in the ArmA by comparison 
with sub-categories of the ICF.  The mapping was undertaken using the online ICF 
illustrated library available from the International University of Health and Welfare 
(Takahashi 2004).   
  
Cieza and colleagues identified that with the development of the ICF its concurrent use 
and comparison with health outcome measures would be necessary and particularly 
relevant in rehabilitation to enable identification of relevant measures for practice 
(Cieza et al. 2002).  To enable the classification of health status questionnaires such as 
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the ArmA using the ICF, Cieza and colleagues produced rules or criteria for the 
classification process (Cieza et al. 2002).  These linking rules were used in the 
classification of the ArmA.  The author and a colleague undertook the classification 
separately and blind to each other’s initial classification.  The results were then 
compared and any differences discussed.  Agreement was achieved for classification of 
all ArmA items, but the option was available to ask a third researcher to adjudicate 
should it have proved impossible to reach agreement. 
 
6.4 Results 
The results for reduction of items using modified Delphi technique at stage one, the 
confirmation and pilot testing of ArmA at Stage two and the ICF classification are 
presented below. 
 
6.4.1 Stage 1 - Reduction of items 
Delphi Consultation Round 1  
All 10 clinicians initially approached returned the round one consultation document.  
Following round one 48 active function items were excluded and 4 passive function 
items.  Consensus for exclusion was between 60 and 100% (6-10 clinicians). Table 6.1 
shows the initial short list of items following round one.  The table also shows the 
measures from which the items originate or identifies that they were patient selected 
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Table 6.1 Initial short list of passive and active function items (round 1), mapped back onto the other measures. 
Functional Items  Patient 
Identified 
LASIS    MAL-14 MAL-26 MAL-28 MAL-12 ABIL-
HAND 
Proximal, Distal,  
Whole arm 
Splint application *       Whole arm 
Positioning the arm comfortably *       Whole arm 
Putting on a glove   *      Distal 
Cutting fingernails   *      Distal 
Cleaning the armpit   *      Proximal 
Cleaning the palm   *  *    Distal 
Putting arm through coat sleeve 
or dressing the arm  
 * * *    Whole arm 
Eat with a knife and fork   * * * *  Whole arm 
Pick up a glass, bottle, or can   * * * * * Whole arm 
Brush teeth   * * * * * Whole arm 
Use a key to unlock the door+   * *   * Whole arm 
Comb hair   * * * * * Whole arm 
Pick up a cup by the handle   * *  *  Distal 
Write on paper     * *  Distal 
Carry an object in the hand   * *    Whole arm 
Dial a number on the phone    * *  * Distal 
Open a jar      * * Distal 
Pick up phone     *   Whole arm 
Put on T-shirt       * Whole arm 
Do or undo buttons on clothing    *   * Distal 
Do or undo a zip    *   * Distal 
Drink from cup/mug       * Whole arm 
Wash your back       * Whole arm 
 Items in bold indicate those retained at the end of round three of item reduction – modified Delphi consensus; Item marked with a + was initially excluded. 




During round one, a passive function item, ‘Cleaning around the elbow’ was removed.  
This item was removed on the recommendation of eight members of the consultation 
group (80%), because it was identified as not being relevant for many patients.  
However a misconception about the meaning of this item may have occurred, which 
was not immediately evident.  Clinicians may not have understood this item to be 
referring to the elbow crease as well as the extensor surface of the elbow.  Clinically 
this item seems important for patients with flexor spasticity at the elbow.  However, its 
wording may have confused clinicians in the consensus process and would also be 
likely to confuse patients.   
 
Delphi Consultation Round 2  
All 10 clinicians again returned the round two consultation document.  A further six 
active function items were removed following round two.  Consensus was between 60% 




Delphi Consultation Round 3  
All 10 clinicians returned the final round three-consultation document.  No further items 
were excluded and there was between 80 and 100% (8-10 clinicians) consensus for the 
inclusion of the items chosen.  One item which had initially been removed; ‘use a key to 
unlock the door’ was re-inserted with the agreement of 80% (8/10 of clinicians (see 
Table 6.1, item marked with ‘+’).  Figure 6.2 shows a summary of the Delphi 
consultation process. 



















Candidate items: 75 Items 
 
(64 Active function)   (11 Passive function) 
   
 
Delphi Consultation 1 
n = 10 
(7 Passive function) 
(16 Active function) 
 
Items excluded   
Not prioritised by 
clinicians 
(48 Active function) 
(4 Passive function) 
Delphi Consultation 3 
n = 10 
(7 Passive function) 
(11 Active function) 
Items excluded 
(6 Active function) 
 
Delphi Consultation 2 
n = 10 
(7 Passive function) 












6.4.2 Stage 2 - Item confirmation 
A total of 58 questionnaires were sent to clinicians and 36 (62%) were returned.  The 
characteristics of these 36 clinicians are shown in Table 6.2. 
 
Table 6.2 Demographic information for wider clinician consultation (n=36) 
Professional Group Numbers (%) 
 
Physiotherapist 25 (69%) 
Occupational Therapist 6 (17%) 
Nurse  5 (14%) 
 
Thirty-two questionnaires were posted or directly presented to 16 patients and 16 carers.  
Thirteen questionnaires were completed in each group (81%).  Table 6.3 displays the 
characteristics of the patients and carers returning questionnaires. 




Table 6.3 Demographic information of patients (n=13) and carers (n=13) 
 Characteristics Patients Carers 
Age of patients (years)  
 
Median (range) 48.5 (30-64) - 
Gender Male 8 (62%) - 
Female 5 (38%) - 
Ethnicity White 10(77%) - 
Black 1 (8%) - 
Asian 2 (15%) - 
Primary Pathology Haemorrhagic Stroke 5 (38%) - 
Ischemic Stroke 8 (62%)  - 
Questionnaire 
completion method 
Face to face 8 (62%) 3 (23%) 
Postal Return 4 (31%) 7 (54%) 
Telephone 1 (8%) 3 (23%) 
 
The median and range of ages presented in Table 6.3 is at the younger range of ages in 
the general stroke population.  Recommendations by clinicians, patients and carers 
(respondents) for the exclusion and inclusion of items following item confirmation are 
presented in Table 6.4. 











PASSIVE FUNCTION   
1. Splint application 1 - 
2. Positioning the arm comfortably 1 - 
3. Putting on a glove  2 - 
4. Cutting fingernails  - - 
5. Cleaning the armpit  - - 
6. Cleaning the palm  - - 
7. Putting arm through coat sleeve or 
dressing the arm  
- - 
ACTIVE FUNCTION   
8. Eat with a knife and fork - - 
9. Pick up a glass, bottle, or can 1 - 
10. Brush teeth 1 - 
11. Use a key to unlock the door 2 - 
12. Comb hair 1 - 
13. Write on paper 1 - 
14. Dial a number on the phone 1 - 
15. Open jar - - 
16. Do or undo buttons on clothing - - 
17. Drink from cup/mug 1 - 
18. Wash your back 5 - 
19. Tuck in a shirt - 4 
20. Effect of the arm on balance when 
walking 
- 6 
21. Hold an object still while using the 
unaffected hand 
- 7 
22. Rolling over in bed because of arm 
tightness 
- 2 
23. Shaving / make-up application - 1 
- No preference for removal or insertion 
 
The majority of items were not considered by respondents for removal (n=12), of the 
other items only one had more than two votes.  Five items from the additional list 
provided, were recommended for inclusion.  The specific modifications and the items 
changed are detailed below. 





Several modifications resulted from the wider consultation with clinicians, patients and 
carers.  The active function item ‘Wash your back’ was removed and replaced by 
‘Tucking in a shirt’, since five of the respondents identified that washing your back is 
done by many able bodied people using an aid, which concurred with views expressed 
by clinicians during item reduction.  Two additional items were added.  The ‘Effect of 
the affected arm on balance when walking’ was added following comment by six 
respondents.  Two clinicians considered this item to potentially fit in either passive or 
active function, since although walking is active, the effect of the arm is passive.  
However, the other four respondents felt it should be in the active function sub-scale.  
The task ‘Hold an object still while using the unaffected hand’ was also added following 
support from seven respondents.   
 
The term ‘Within the last week’ was replaced with ‘In the last seven days’.  The 
instructions for completion of the two main sections were further refined.  The final 
measure consists of two domains, active and passive function.  Passive function 
contains 7 items.  Active function contains 13 items.  Figure 6.3 displays a summary of 
the changes to items through the different stages of development.  Version 2 of the 
ArmA for psychometric evaluation is presented in Appendix 12.  The ArmA is designed 
to be completed in a self-report manner by patients and carers.  However as an 
alternative when supported completion is needed for patient or carer, it may be 
administered as a structured interview by a clinician. 
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Systematic review:  73 Items 
(9 Passive function) 
(64 Active function) 
 
Goal Analysis:  2 Items  
(2 Passive function) 
 
 
Candidate items: 75 Items 
 
(64 Active function)   (11 Passive function) 
   
 
Delphi Consultation 1 
Consultation with clinicians  
n = 10 
(7 Passive function) 
(16 Active function) 
 
Items excluded   
Not prioritised by 
clinicians 
(48 Active function) 
(4 Passive function) 
Delphi Consultation 3 
Consultation with clinicians 
n = 10 
(7 Passive function) 
(11 Active function) 
Items excluded 
(6 Active function) 
 
Delphi Consultation 2 
Consultation with clinicians  
n = 10 
(7 Passive function) 
(10 Active function) 
 
Clinicians  
n = 36 
Items excluded: 








Patients & carers 





 (3 Active) 
 
ArmA (version 2) 
(7 Passive function) 
(13 Active function) 
Item confirmation 




6.4.3 ArmA item mapping onto the ICF 
The ArmA (version 2) items were mapped onto ICF chapters and sub-categories to 
assess their relationship to the ICF classification system.  Mapping onto the ICF is 
presented for passive function in Table 6.5. 
 




Chapter Sub-category 1 Sub-category 2 
1. Cleaning the palm 5 - Self care d510 Washing oneself d5100 Washing body parts 
 
2. Cutting fingernails 5 - Self care d520 Caring for body parts d5203 Caring for 
fingernails 
 
3. Putting on a glove 5 - Self care d540 Dressing d5400 Putting on clothes 
 
4. Cleaning the armpit 5 - Self care d510 Washing oneself d5100 Washing body parts 
 
5. Putting arm through a 
sleeve 
 
5 - Self care d540 Dressing d5400 Putting on clothes 
6. Putting on a splint 5 - Self care d520 Caring for body parts d5208 Caring for body 
parts specified 
 
7. Positioning the arm 
comfortably  
 
5 - Self care d520 Caring for body parts d5208 Caring for body 
parts specified 
ICF: International classification of functioning disability and health 
 
All items in the passive function subscale are found in the self-care chapter of the ICF.  
The mapping of the active function sub-scale is shown in Table 6.6.   








Chapter Sub-category 1 Sub-category 2 
1. Do up buttons on 
clothing 
4 - Mobility d440 Fine hand use d4400 Picking up 
 
2. Pick up a glass, bottle 
or can 




3. Use a key to unlock 
the door 
4 - Mobility d445 Hand and arm use d4402 Manipulating 
d4453 Turning or twisting 
hands or arms 
 
4. Write on paper 4 - Mobility d445 Hand and arm use d4402 Manipulating 
d4453 Turning or twisting 
hands or arms 
 
5. Open a previously 
opened jar 
4 – Mobility 
 
d445 Hand and arm use d4402 Manipulating 
d4453 Turning or twisting 
hands or arms 
 
6. Eat with a knife and 
fork 
4 – Mobility 
5 - Self care 
d445 Hand and arm use  
d550 Eating 
d4402 Manipulating 
d4453 Turning or twisting 
hands or arms 
 
7. Hold an object still 
while using unaffected 
hand 
4 – Mobility d445 Hand and arm use d4402 Manipulating 
d4453 Turning or twisting 
hands or arms 
 
8. Difficulty balancing 
when walking due to 
your arm 
4 - Mobility d450 Walking  
9. Dial a number on 
home phone 
3-Communication d360 Using communication 
devices and techniques 
 
 
10. Tuck in your shirt 5 - Self care d540 
Dressing 
d5400 
Putting on clothes 
 
11. Comb or brush hair 5 - Self care d520  
Caring for body parts 
d5208 Caring for body 
parts specified 
 
12. Brush teeth 5 - Self care d520 Caring for body parts 
 
d5201 Caring for teeth 
13. Drink from cup/mug 4 - Mobility d430 Lifting and carrying 
objects 
 
d4300 Lifting (glass from 
table) 
ICF: International classification of functioning disability and health 
 
Items in the active function sub-scale are spread between three chapters; self-care, 
mobility and communication shown in Table 6.6. 
 




The development of ArmA has culminated in a measure comprising seven passive 
function items and thirteen active function items.  All items in the passive function 
sub-scale are found in the self-care domain of the ICF, which confirms the care 
related nature of these items.  The items in the active function sub-scale are spread 
across three domains: self-care, mobility and communication, concurring with the 
more diverse nature of active arm function. 
 
The process has further confirmed content and face validity of the ArmA in ensuring 
items are representative of active and passive function, despite the different ICF 
categories identified for active function.  The ICF does not take into account passive 
function as a concept.  The language and structure of the ICF are based on individuals 
carrying out personal care and other tasks themselves rather than being assisted by a 
carer.  Although items will map onto the ICF, the changed nature of the task in 
passive function, often involving partnership between patient and carer, is not 
reflected. 
 
6.5.1 Strengths and limitations 
The development of the ArmA has three areas of strength relating to the process of 
development:  
1. Methods used for item selection,  
2. Method of item reduction,  
Delphi consultation 




1. Item selection (generation) 
Selection was undertaken using items from measures identified during the systematic 
review and patient selected items.  These methods provided an extensive list of items.  
All but two of these items were selected from the six existing measures identified in the 
systematic review, indicating that other researchers in the field had also found these 
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items to be relevant.  Because there were relatively few passive function items, a further 
step (goal analysis from clinical practice) was undertaken to ensure full item coverage.  
In fact this added only 2 further items.  Both these aspects of initial development 
provide support for the face validity of the items within the measure.  The use of the 
goal setting analysis for the patient identified items ensures that items are likely to be 
clinically applicable and that patient and carer perspectives have been considered at an 
early stage in development.  The structure and scoring mechanism for the ArmA were 
taken from those measures identified in the systematic review and used methods that 
had been well tested in these measures.  
 
2. Item reduction – Delphi Consultation 
Initial item reduction involved a modified Delphi consultation with 10 selected 
clinicians.  The process ensured content validity, due to the experience of the clinicians 
in this area of practice and therefore appropriate reduction of items.  The modified 
Delphi consultation was effective due to the rigorous process applied.  However, a more 
robust consensus process could have been used, possibly including further rounds of 
consultation and higher thresholds for inclusion or exclusion of items.  Many studies 
using Delphi consultation have applied an 80% level of agreement between participants 
for inclusion or exclusion of items.  However, consensus in round three of consultation 
was achieved at 80% regardless of the 60% criteria used and an 80% criteria would 
therefore have been unlikely to change the final outcome.   
 
3. Item confirmation – Wider consultation  
The wider consultation with clinicians experienced in spasticity management confirmed 
the selection of items, and also enabled some modification.  This consultation ensured 
comment was obtained on the presentation of the items and the measure as a whole by a 
larger group of clinicians, patients and carers.  The document was sent to all members 
of the UK Adult Physiotherapy Spasticity Forum, which is a relevant group of clinicians 
involved with upper limb rehabilitation and spasticity management.  The occupational 
therapists contacted were approached because they worked with the physiotherapists but 
were a smaller group and the nurses were contacted through rehabilitation services in 
one large NHS trust.   
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Selection of all clinical groups could have been enlarged to ensure a true national survey 
through approaching the respective professional bodies or special interest groups for 
physiotherapists, occupational therapists and nurses.  Breadth of experience among the 
clinicians may also have been improved by selection through a professional 
organisation.  This approach would have given more support to the content validity of 
the measure and may have led to a larger consultation with a more consistent national 
focus.  The clinicians involved in the wider review included individuals from different 
services and different regions of the United Kingdom but did not provide an even 
spread across regions of the United Kingdom. The group selected was also biased 
towards physiotherapists and although this professional group undertake much upper 
limb assessment and spasticity management, they are certainly not the only profession 
involved.  Although occupational therapists and rehabilitation nurses were involved and 
patients and carers were involved in pilot testing, involvement more widely in 
development could have provided a more representative group of professionals and 
future users.  However, given that physiotherapists are commonly working in 
management of spasticity in the UK the approach taken was adequate and produced 
comprehensive comments. 
 
During pilot testing of the ArmA, the size of the group of patients and carers used could 
also have been increased.  The group was relatively small (n=26), but it is unclear if 
increasing this would make a difference to achieving feedback that is more informative.  
A more representative sample could however have been considered, including patients 
from other services, to ensure that there were no service or practice specific factors 
affecting their views.  However, these limitations, while important considerations, do 
not invalidate the pilot testing applied for the ArmA, which was sufficient to enable 
subsequent psychometric testing (see Chapter 7).  
 
A possible limitation of prioritising the items generated using the Delphi process and 
wider consultation, is that a set of homogeneous items may be produced.  An initial 48 
active function items and 4 passive function items were excluded at round 1. This was 
likely to be because participants were asked to identify the most relevant items for 
patients undergoing focal spasticity intervention (PT and BTX).  However, this may risk 
losing the uniqueness of the broader range of items important for ensuring a wide range 
to any hierarchical scale.  Homogeneity may be a strength in supporting 
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unidimensionality (in a single or multiple dimensions), but a group of homogeneous 
items can result in an inability to differentiate between people at extremes of the scale.  
This may be more of an issue for active function items, many of which were excluded in 
the Delphi consultation.  However, while this is a theoretical concern, in practice it may 
be less significant because items selected were focused on lower level active function 
more likely to change in a group undergoing spasticity intervention, but may limit the 
application of the ArmA for other focal interventions. 
 
Other approaches to evaluation of the draft ArmA (7 passive and 13 active function 
items) by patients and carers could have been considered.  Such approaches could 
include structured interviews (Reed and Roskell-Payton 1997; Smith et al. 1997) or 
focus groups (Kitzinger 1994; Sim and Snell 1996).  Structured or semi-structured 
interviews or focus groups may obtain more detailed and expansive feedback from 
respondents than asking for written feedback as was the case in this review (Sim and 
Snell 1996). 
 
6.5.2 Comparison with development of other measures 
The Motor Activity Log was developed to measure the outcome of CIMT (Taub et al. 
1993; Uswatte et al. 2005).  The aim of the MAL as with the ArmA was to measure 
functional performance outside the clinic environment in individuals following stroke.  
A number of different versions of the MAL have been developed as described in 
Chapter 4.   Detailed description of the development of the original 14-item scale is 
limited but items were chosen by the authors on the basis of those thought to change 
following constraint therapy by the development team (Taub et al. 1993).  Item 
selection and reduction for the ArmA was more structured by incorporating items from 
other measures identified in a systematic manner from the literature, combined with 
patient or carer selected items.  However the approaches have similarities in attempting 
to identify items, which have clinical relevance to practice, as well as considering items 
from the perspective of their contribution to the overall measure. 
 
A different approach using Rasch analysis, was used to develop and validate the 
ABILHAND, a measure of manual ability in rheumatoid arthritis (Penta et al. 1998).  
Penta and colleagues initially used a relatively small group (n=18) of patients, which 
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could be challenged as too few for undertaking Rasch analysis.  The measurement items 
were generated either from existing scales or by the researchers, which resulted in 57 
initial items.  Limited information is provided about initial item identification from the 
literature or additional items added and how they were selected.  It would be desirable 
to have a clearer methodology for this as given for the ArmA.  The number of items was 
reduced from 57 to 46, the other 11 items were thought not to be measuring the same 
construct based on Rasch analysis.  Unidimensionality and reliability of the measure 
were supported.  Despite the limitation in the number of participants for item 
generation, Penta and colleagues used the Rasch method to produce a unidimensional 
single construct scale measuring arm function.  The ABILHAND was then further 
evaluated in 103 patients with chronic stroke (>6 months post onset), which addressed 
the limitations of sample size with the original study (Penta et al. 2001).  The second 
study provided an acceptable sample size for preliminary Rasch analysis, although still 
relatively small.  Further evaluation of ArmA using the Rasch method may be useful in 
due course. 
 
Hudak and colleagues undertook the development of the DASH, an upper extremity 
outcome measure for application in patients with musculoskeletal problems involving 
the upper limb (Hudak et al. 1996).  The measure was developed in three stages.  The 
first stage involved the generation of items from a literature review of measures, which 
initially produced 821 candidate items from 13 measures.  In stage two, item reduction 
was undertaken by group consensus through three rounds of consultation resulting in a 
78-item questionnaire.  In stage three of development, reliability and validity testing 
resulted in the reduction of items to 30 in total (Davis et al. 1999).   
 
Development of the ArmA took a similar approach to that used for the DASH, except 
that an additional source was added for item generation, involving patients and carers.  
The ArmA process also included consultation with a wider group of clinicians to 
confirm item selection and none of the clinicians involved with item selection were 
involved with the development of the measure.  In contrast, those involved in the DASH 
consultation group also developed the measure. 
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6.5.3 The role of the user (patient and carer) in item selection and reduction 
The involvement of users has benefits at a number of levels, from appropriate research 
design to consultation about aspects of measures for application in studies and 
dissemination of findings.  The Department of Health and the National Research Ethics 
Service have both emphasised the importance of patient involvement in research 
projects and measurement of health outcome (Department of Health 2009; INVOLVE 
2009).  However there are costs both financial and in time when involving users in 
research.  These issues will be briefly explored and related to the development of the 
ArmA.   
 
User involvement in research has been defined as users of services being active partners 
in the research process rather than just research participants (Hanley et al. 2004).  User 
involvement as a concept has undergone development over the past 10 years with 
moves from very peripheral input, such as obtaining users views during data collection, 
to user involvement at every stage of development.  Partnership may take place in 
different phases of the research process (Lacey and MacNamara 2000) or may be 
present all the way through from conception of the project to dissemination of findings 
(Jones et al. 2009).   
 
In the ArmA development process, early patient involvement was used to identify 
measurement items through goal setting, but essentially involved users as research 
participants.  Users were again involved in piloting and commenting on the draft 
version of the ArmA.  These instances of user involvement in the ArmA development 
did not involve users at all stages, which may represent a weakness in the process from 
a user involvement perspective.  However, strength in this involvement is evident in 
identifying clinically relevant items in a focused manner particularly supported by using 
clinical goals for spasticity management. 
 
User involvement in both the ArmA development and the work of Lacey and 
MacNamara was at a consultation level rather than full integration of users into research 
question generation and project design now being incorporated in some studies (Jones et 
al. 2009).  Another possibility in ArmA development was the inclusion of users at an 
earlier stage in commenting on the manner and theoretical conception of measurement.  
However, the approach taken in the ArmA development has resulted in a measure, 
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which does incorporate items important to patients and carers as evidenced in the pilot 
testing.  The ArmA development has also benefited from consultation and pilot testing 
of the measure with patients and carers.  Given these aspects of patient and carer input, 
involvement of users in development is considered adequate. 
 
Patient Reported Outcome Measures (PROMs) such as the ArmA, are receiving 
attention in the rehabilitation literature (Playford 2008).  User involvement in the 
development of such measures is emphasised in generating items (Thissen et al. 2007; 
Playford 2008).  Tennant has given qualified support to the use of approaches such as 
GAS, as used in this thesis, in identifying items (Tennant 2007).  Items identified in this 
way can then undergo Rasch analysis to determine the possible scaling properties of the 
set of items identified and fit to the Rasch model. Alternatively, non-parametric IRT 
methods such as Mokken analysis may be used to initially consider the ordinality of the 
data.   
 
6.6 Conclusion 
The use of Delphi consultation with the addition of further clinician and patient 
involvement has resulted in a measure, which should provide important clinical 
information and be feasible in practice.  The process of item selection, reduction and 
confirmation was comprehensive and while limitations to the methodology are present, 
the overall process had a high degree of rigour ensuring confidence in content and face 
validity of the list of items produced. 
 
The next phase of development for the ArmA (version 2) was psychometric testing, 
which is presented in Chapter 7.  Version 2 of the ArmA will be referred to as the 
‘ArmA’ for the remainder of the thesis. 




Chapter 7 Evaluation of ArmA properties and application 
7.1 Introduction 
The purpose of this part of the overall project was to demonstrate the psychometric 
properties of the ArmA in a patient sample of sufficient size.  This psychometric 
analysis was undertaken in the context of a prospective cohort study of BTX and PT 
intervention in the clinical setting.  In this Chapter, the two inter-linked sub-studies that 
were carried out are described.   
 
Sub-study 1 – An evaluation of the psychometric properties of the ArmA 
The global psychometric concepts explored comprised reliability, validity, 
unidimesionality, ordinal scaling and responsiveness to change.  These psychometric 
properties were discussed in theoretical terms in Chapter 3 (pages 94-112), and 
specific methods for evaluation are described in the methods section (pages 201-204 of 
this chapter).  Criteria adapted from Terwee and colleagues (Terwee et al. 2007) were 
applied to evaluate the psychometric properties of the ArmA (see Table 7.1 for an 
overview). 
   
 




Table 7.1 Quality criteria applied in the ArmA evaluation. 
Psychometric Requirement Evaluation Criteria 
Construct validity  
Relate to other measures appropriately. 
 
Correlation with other measures for 
convergent and divergent validity. 
Homogeneity of measurement items 
The unidimensionality of a set of items. 
 
Preliminary evaluation of 
unidimensionality using Principal 




Extent to which measurement items form 
an ordinal or interval scale 
Preliminary evaluation of ordinal 
scaling properties using Mokken 
analysis. 
 
Internal consistency  
Extent to which items in scale correlate. 
 
Evaluation using Cronbach’s Alpha:  
Rating between 0.70-0.95. 
Test re-test reliability (Repeatability) 
Extent to which patients can be 
distinguished despite measurement error 
(relative measurement error). 
 
Test re-test at two time points 
evaluated by weighted Kappa  0.70. 
Responsiveness  
Detects change over time relating to 
actual change occurring. 
 
Demonstrating change over time when 
change is expected.  Comparison of 
responders with non-responders, 
Effect Size (ES) and Standardised 
Response Mean (SRM) estimations. 
 
Interpretability 
The degree to which qualitative meaning 
can be assigned to quantitative scores. 
Preliminary indication of minimal 
important change (MIC). 
 
 
Floor and ceiling effects 
Number of respondents achieving the 
lowest or highest scores. 
 
Less than or equal to 15% of 
respondents at either extreme of scale 
(or sub-scale). 
Feasibility 
Suitable for routine clinical use, while 
maintaining psychometric properties. 
 
Using a questionnaire with 
participants, evaluate use of the 
measure in clinical practice with 
psychometric properties retained. 
 
Burden 
The time, effort or other demands of 
administering the measure. 
 
Using a questionnaire with 
participants to obtain information on 
time taken and effort to complete the 
measure. 
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 The sub-study also enabled the feasibility of the ArmA to be determined.  This element 
was added because the ease with which the ArmA could be used in standard clinical 
practice environments was considered to be an essential requirement. 
 
Sub-study 2 – A hypothesis-generating cohort investigation of the course of 
functional changes 
The cohort study was undertaken using the ArmA to explore changes in passive 
function and spasticity occurring after intervention with BTX and PT interventions at 8 
weeks and at 16 weeks. 
 
Reduction in spasticity has been demonstrated in a number of randomised trials 
following BTX injection (Bhakta et al. 2000a; Bakheit et al. 2001; Brashear et al. 2002; 
Bakheit et al. 2004b; Bhakta et al. 2008).  Change in function has also been 
demonstrated by some authors for passive function (Bhakta et al. 2000a; Francis et al. 
2004).  However, the clinical effect of BTX alone would be expected to reduce as BTX 
is eliminated from the neuromuscular junction from approximately six to eight weeks 
onward (Brin 1997; Bell and Williams 2003), potentially leading to a decrease in 
previous functional gains. 
 
Despite this, some studies have also indicated that passive functional improvements can 
be maintained at least to 12 weeks following administration of BTX (Bhakta et al. 
2000a; Brashear et al. 2002).  In addition, in the secondary analysis by Francis and 
colleagues (Francis et al. 2004), functional improvements were found to take longer to 
develop in a minority of patients than reduction in spasticity.  These authors suggest that 
PT interventions such as positioning or serial casting regimes may be important in 
reaching and maintaining improvements following BTX (Francis et al. 2004).   
 
In summary, intervention with BTX in the absence of PT would be expected to lead to 
reduction in spasticity and improvement in passive function by 8 weeks after injection 
followed by a reversion to near pre-intervention levels by 16 weeks as the effect of BTX 
wears off (see Figure 7.1).  In contrast, when applying PT in combination with BTX it is 
possible that the improved level of passive function will be maintained to 16 weeks post 
injection (see Figure 7.1). 




Figure 7.1 A diagrammatic representation of the potential for maintenance of -






















BTX BTX + PT
 
The aim of the cohort study was to test this model of passive function maintenance in 
the presence of increasing spasticity using the ArmA.  The study also aimed to include 
systematic documentation of which PT interventions had been applied and in what 
manner in each case.  It was anticipated that this would also lead to the generation of 
clinically important research questions for future evaluation. 
Potential maintenance 
of passive function 
improvement with the 
combination of BTX 
with PT 





This chapter describes the method for addressing the remaining three objectives. 
 
Sub-study 1 – Psychometric evaluation 
Objective 5.To evaluate the reliability, internal consistency, construct validity, 
unidimensionality and ordinal scaling of the Arm Activity measure 
(ArmA) – a measure of difficulty in active and passive function. 
 
Objective 6. To evaluate the responsiveness and feasibility of the measure when using it 
to assess outcome following spasticity intervention in the upper limb. 
 
Sub-study 2 – Cohort study 
Objective 7. To apply the ArmA in measuring change in passive and active function 
following spasticity management intervention. 
 
In this cohort study, the utility of ArmA will be tested through the following null 
hypothesis.  The hypothesis addresses passive function, but not active function because 
change in this sub-scale was expected in only a minority of participants undergoing 
spasticity management. 
 
Null hypothesis: Improvement in passive function measured by the ArmA at 8 weeks 
following BTX and PT intervention will not be maintained above baseline levels as the 




Psychometric evaluation of the ArmA was undertaken on the passive and active 
function sub-scales of the measure.  Two groups of participants were recruited for the 
evaluation.   
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 Group 1, a prospective consecutive sample undergoing spasticity intervention 
were the primary group used for evaluation of the ArmA measure psychometric 
properties.   
 
 Group 2 were purposively selected after it became apparent that the large 
majority of subjects in group 1 had no active function, resulting in the ArmA 
scores not being representative of the full range of the scale.  In addition, a 
greater sample size was required to fulfil requirements for psychometric 
evaluation.  Group 2 were a more able group selected on the basis that they were 
able to perform at least one of the active function activities within the ArmA.  
This group were not undergoing management for spasticity.   
  
Both groups were assessed at baseline (Time 1) and one day later (Time 2). In addition, 
group 1 were assessed at 8 weeks (Time 3) and 16 weeks (Time 4).  
 
Sub-study 1 – Psychometric evaluation of the ArmA 
Data collected at baseline (Time 1) and one day later (Time 2) were used to evaluate 
reliability (repeatability).  Data collected at baseline (Time 1) was also used in 
evaluation of construct validity, internal consistency and to confirm the dimensions of 
the active and passive function sub-scales using Principal Components Analysis and 
Mokken analysis.  Mokken analysis was also used to undertake a preliminary evaluation 
of ordinal scaling.  Data at 8 weeks (Time 3) were used following intervention to 
evaluate responsiveness.  
  
Sub-study 2 – Functional change evaluation: A cohort study 
Data at baseline (Time 1), 8 weeks (Time 3) and 16 weeks (Time 4) were used for 
comparison of change following intervention in spasticity and passive function.    
 
Setting  
Data were collected at two sites during the psychometric evaluation and cohort study to 
ensure recruitment of sufficient participants in groups 1 and 2.  The sites were the 
Regional Rehabilitation Unit (RRU), Northwick Park Hospital and the Alderbourne 
Rehabilitation Unit (ARU), Hillingdon Hospital. 




Both services provide inpatient rehabilitation, outpatient clinics including spasticity 
clinics and, in the case of the RRU, an outreach service providing specialist spasticity 
management intervention.  Participants at both sites were managed through the 
spasticity management ICP developed on the Regional Rehabilitation Unit, Northwick 
Park Hospital (see Appendix 11 for current version). 
 
Sample 
The sample size was based on the criteria by Terwee and colleagues for evaluation of 
construct validity and test re-test reliability in groups of at least 50 participants (Terwee 
et al. 2007).  However, given that unidimensionality is an important requirement for 
measurement, this was considered with relation to the sample size for this work.   
 
Determination of sample size can be based on two broad methods. 1. Subject to variable 
ratios have been proposed (Pedhazur 1997), 2. alternatively total sample sizes for the 
study group have also been used (Aleamoni 1976; Barrett and Kline 1981; Comfrey and 
Lee 1992).   
 
1. Authors have made a number of different recommendations using the ratio method.  
When undertaking PCA, Nunnally and Bernstein (page 102) recommended a sample 
size with a ratio of 10:1 subjects to items (Nunnally and Bernstein 1994) and Terwee 
and colleagues (2007) a ratio of 7:1 with a total sample of 100 or greater.  The ArmA 
has 20 items, so using these ratios results in a sample of 200 or 140 respectively.  
Gorsuch (1983; p. 332) and Hatcher (1994, p 73) both made recommendation for a 
minimum subject to item ratio of 5:1 in exploratory factor analysis (EFA), which would 
result in a sample of 100 for the current work. 
 
2. A range of sample sizes have also been suggested for minimal total sample size, 
ranging from: 50 giving very poor adequacy to 1000 giving excellent adequacy of 
sample size according to Comfrey and Lee (1992).  Barrett and Kline (1981) have also 
recommended sample size with a minimum of 50, while Aleamoni (1976) suggests a 
minimum of 400. 
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Briefly, considering Mokken analysis (also discussed in Chapter 3; application of 
Mokken analysis, page 104), Molenaar (2000) recommends a lower limit of 100 in 
Mokken analysis for total sample size.  The studies by Van der Lee and colleagues 
(2002) and van der Putten and colleagues (2005) had participant numbers as low as 66 
and 63 respectively.  DeJong and Molenaar also used a sample of 82 in an example of 
Mokken analysis application (DeJong and Molenaar 1987).   
 
In summary, a review of studies applying EFA or PCA concluded, that absolute 
minimum sample sizes, rather than subject to item ratios, are the most relevant 
(Guadagnoli and Velicer 1988).  In contrast, many advocates of the ratio of items to 
subjects, suggest that this is the superior method (Gorsuch 1983; Hatcher 1994; Osborne 
and Costello 2004).  There is therefore no universally agreed approach to identifying 
required sample sizes for these methods.  Absolute sample sizes however seem over 
simplistic, given as suggested by Osborne and Costello (2004), the variance in the types 
of scales to be examined and the variation in the number of items in such scales.  
Nevertheless Osborne and Costello (2004) consider both the ratio and the total 
minimum number of participants to be important in undertaking PCA.  Consideration of 
item to subject ratio has however, been considered of prime importance in this thesis.   
 
The aim in this thesis was therefore, to recruit participant numbers of 100, to ensure 
robust preliminary findings consistent with the recommendations of Gorsuch (1983), 
Hatcher (1994) and Molenaar (2000).  In addition, this conforms to the 
recommendations of Barrett and Kline (1981) for minimal total sample size of 50 
participants or more.  In common with other psychometric methods used in this thesis 
the application of PCA and Mokken analysis, represent preliminary evaluations of the 
ArmA measure.   
 
Inclusion and exclusion criteria:  
Inclusion criteria were: 
 Hemiplegic upper limb impairment affecting either active or passive function. 
 Age between 18 and 85 years. 
In addition for Group 1 
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 Undergoing treatment for spasticity management in the upper limb requiring 
BTX intervention and PT.   
 
Reasons for exclusion were:  
 Patient declines to participate or family and/or treating team declines on their 
behalf. 
 Unable to complete a questionnaire and no carer (professional or family) 
available to undertake questionnaire completion.  Examples of situations that 
may lead to exclusion are indicated below: 
o Does not speak English  
o Unable to communicate responses (where feasible communication using 
adapted methods will be employed, including support of a speech and 
language therapist to avoid exclusion). 
o Does not have the cognitive ability to understand the questions. 
 




Eight measures were used. 
 
Arm Activity Measure (ArmA) 
The ArmA (shown in Appendix 12) is a measure of difficulty in passive and active arm 
function.  The ArmA comprises a seven-item passive function subscale and thirteen-
item active function subscale.  It has a Likert scoring system between 0 (No difficulty) 
and 4 (unable to do task).  It is self-rated by the patient or carer for a period of the 
preceding 7 days.  If activities have not been performed in the past 7 days but are 
possible, then a ‘best estimate’ was made of the task.  For passive function, if a carer 
was involved, then they agree the score with the patient as both contribute to completion 
of the activity.  If only the carer was involved in completion of the activity, then the 
carer alone rates difficulty for that item.  Active function is scored by the patient.  If the 
patient has no active function ability, this is recorded as being ‘unable to do the tasks’ 
even if the carer is undertaking scoring.  A total of the individual item scores are made 
for both sub-scales, but sub-scale totals are not combined.  The passive function sub-
scale scores range from 0-28 and the active function sub-scale scores range from 0-52. 
 
Leeds Adult Spasticity Impact Scale (LASIS)  
The LASIS (Bhakta et al. 1996; Bhakta et al. 2000a) (Shown in Appendix 13) is a 
measure of the impact of spasticity on arm function, for use in evaluating spasticity 
management intervention.  The LASIS has two sub-scales: a disability sub-scale 
consisting of 12 items and a carer burden sub-scale consisting of 9 of the same items.  
The LASIS uses a scale between 0 (No difficulty) and 4 (Unable to do task).  The 
patient and carer rated the LASIS over the preceding 7 days.  The LASIS was either 
completed as a structured interview or self-completed by the patient and carer on a 
small number of occasions.  A modified approach to scoring was used.  When patients 
and carers were both involved in the activity, the two scores were combined to produce 
a mean.  Items 1 to 9 were classified as passive function and items 10 to 12 were 
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Disabilities of the Arm Shoulder and Hand (DASH)  
The DASH (Hudak et al. 1996) (Shown in Appendix 14) questionnaire comprises 30 
items, 21 of which are arm active function items, 5 are symptom related, for example 
pain and the remaining 4 items review the impact of arm impairment on well being and 
participation (there are no passive function items in the DASH).  The DASH uses a 
scale between 0- none and 5- extreme difficulty for functional tasks.  For other domains 
the six point scale is still used, but adapted with relevant descriptors.  The patient rated 
the DASH over the preceding 7 days.  If activities have not been performed in the past 
week but were possible, then a ‘best estimate’ was made on the task.  The DASH is 
designed for self-completion in musculoskeletal upper limb impairment, but was 
applied in a neurorehabilitation group for this study.  The DASH items are usually 
summed into one total, which is then divided by the number of responses to the 30 
questions (if more than three responses are missing a total is not generated), 1 is then 
subtracted and the total multiplied by 25.  In this study for comparison with the ArmA 
an overall total for the measure was not produced in this way, instead a total sum was 
produced for the active function items only (DASH Active; items 1 to 21) for 
comparison with ArmA. 
 
Goal Attainment Scaling (GAS) 
GAS (Ashford and Turner-Stokes 2006) (Shown in Appendix 3) is a method of scoring 
the extent to which patient’s individual goals are achieved in the course of intervention.  
In GAS, goals are individually identified to suit the patient, and the outcome levels set 
around their current and expected levels of performance using the standard method.  
The GAS process provides a consistent framework for recording goals.  The GAS is 
scored on a 5-point scale, with anchor points for attainment at each level set before 
intervention.  Scoring of GAS followed the approach proposed by Turner-Stokes 
(Turner-Stokes 2009b).    
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If the patient achieves the expected level, this is scored at 0. 
If they achieve a better than expected outcome this is scored at: 
+1 (Somewhat better)  
+2 (much better) 
If they achieve a worse than expected outcome this is scored at: 
-1 (Somewhat worse) or  
-2 (much worse) 
 
An important part of GAS is the establishment of the clinical outcome which is 
considered as successful before the start of intervention (see Appendix 3).  If the patient 
was unable to contribute to goal setting, goals were agreed by the carer and treating 
clinician.  For each goal, the spasticity clinic team, dependent on achievement of the 
predefined outcome, assigned an attainment level.  A full description of the GAS 
procedure is provided in Appendix 3. 
 
Clinician’s Categorisation of Response (CCR)  
The Clinician’s Categorisation of Response was the treating clinician’s rating of the 
overall outcome following intervention.  The treating physiotherapist or occupational 
therapist (not part of the spasticity clinic team) was asked to categorise the outcome of 
the intervention as either, ‘responder’ or ‘non-responder’ when reflecting on the goals 
of intervention set, but separately and without knowledge of final GAS scores (Brashear 
et al. 2002). 
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Barthel Index (BI) 
The Barthel Index (Wade and Collin 1988) (Shown in Appendix 15) is a measure of 
global disability and function.  The Barthel Index self-completion version was 
completed by patient or carer (Gompertz et al. 1994).  The measure comprises 10 items 
relating to personal ADLs, with each item scored on either a scale of 0 to 2 or 0 to 3.  
The total scale ranges from 0 (total dependence) to 20 (complete independence) in the 
version used in this study. 
 
Feasibility Questionnaire (FQ)  
The feasibility questionnaire (Shown Appendix 16) was used to evaluate ease of use, 
relevance and value in the clinical situation.  It comprises one question each for time to 
complete, relevance, usefulness of the active function section, usefulness of the passive 
function section and ease of completion.  The FQ was designed for completion by 
patients and carers for evaluation of ArmA.  Each question is rated on a 5 point Likert 
scale.   
 
Modified Ashworth Scale (MAS)  
The MAS (Wade 1992b; Brashear et al. 2002) (Shown Appendix 17) is a clinical 
measure of spasticity, which is widely used in research (see Table 1.3; page 44) and 
clinical practice.  The MAS forms a single item scale from 0 (no increase in muscle 
tone) to 4 (affected part rigid in flexion or extension), with an additional point at +1 
(slight increase in muscle tone…) producing a six-point scale (see Appendix 17).  The 
MAS therefore provides a single score to represent spasticity.  The MAS is scored by 
grading the resistance to passive stretch and was scored in this study by the spasticity 
clinic team.  A single score was given for measurement at each joint at each time point.  
If the MAS was recorded for more than one joint, the mean was used to represent total 
spasticity affecting the upper limb for comparison to functional change on other 
measures. 







Group one (G1)  
All patients referred to the spasticity services at the RRU and ARU over a 21 month 
time period were offered the opportunity to participate.  Participants and carers were 
initially approached by their treating physiotherapist or occupational therapist and asked 
to participate.   
 
Group two (G2)  
Patients were offered the opportunity to participate by their treating physiotherapist or 
occupational therapist.   
 
All patients were given an information sheet about the project (see Appendix 8).  The 
researcher answered any questions they might have before gaining consent (see 
Appendix 9).   
 
Recruitment 
In cases where the participant was unable to sign (for example in the case of impaired 
arm function), a witness signed to indicate consent had been given.  In cases where 
patients were unable to consent due to cognitive impairment assent confirmed in writing 
was sought and obtained from the next of kin and treating team. 
 
Data collection 
Baseline (Time 1) assessments comprised all 8 measures.  4 measures (ArmA, DASH, 
BI and FQ) were self-completed by the person carrying out the care activity (patient 
and/or carer).  Of the remaining 4 measures, MAS and CCR were completed by the 
spasticity clinic team and the LASIS was completed as a structured interview.  The 
GAS goals were set by the patient and/or carer in conjunction with the spasticity 
clinicians.  The clinicians formally documented the identified GAS goals.  
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All measures were completed at the clinic appointment where possible.  The order of 
presentation of the measures was counter-balanced to limit bias from order effects.   
Patients and carers unable to complete measures at the clinic appointment took the 
questionnaires away and returned them in a ‘freepost’ envelope.  This occurred in a 
minority of cases when for example they were dependent on hospital transport. 
 
One day follow-up (Time 2) the ArmA was returned by post for outpatients or outreach-
patients and collected by hand for in-patients.   
 
Eight week (Time 3) and 16 week (Time 4) assessments were undertaken in the clinic or 
at a prearranged appointment.  Table 7.2 indicates the measures completed at each time 
point. 




Table 7.2 Measures completed at each time point 
Measures Time 1  
Baseline 
Time 2  
Baseline plus 
One day 






Groups 1 and 2 Groups 1 and 2 Group 1 Group 1 
ArmA     
LASIS  -   
DASH  -   
GAS  -   
Clinicians 
Categorisation 
of Response  
- -   
Feasibility 
Questionnaire 
 - - - 
Barthel Index  -   
Modified 
Ashworth 
 -   
Data collected =  
See Section 7.4.1 and Table 7.3 (page 205) for the number of participants approached, 
recruited and reviewed at each time point. 
 
Intervention 
Participants received BTX administration following baseline (Time 1) assessment as 
part of normal clinical practice.  This was followed by PT interventions appropriate to 
clinical need over the subsequent 16 weeks.  The treating therapist(s), usually following 
recommendation by the spasticity clinic team, gave concomitant intervention (e.g. 
splinting of the wrist and hand).  The BTX and PT interventions are described in the 
results of the cohort study. 
 
Data Management and Error Checking 
A list of patients recruited and their stage of progression through the study was recorded 
electronically in a password-protected file.  Paper records for individual patients were 
stored in a locked filing cabinet and electronic records were anonymised and password 
protected. 
 
The researcher and a colleague undertook double entry of all the data apart from 
Modified Ashworth Scores to ensure accuracy of insertion into the database for 
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analysis.  Modified Ashworth Scores were entered by the researcher and checked by 
another researcher in 20 cases.  For double entered data, these were entered into two 
duplicate data entry sheets without reference to each other.  The two versions were then 
compared and errors identified.  When errors occurred these were checked and 
corrected by referring to the original paper questionnaires. 
  
7.3.2 Analysis – Psychometric methods 
Data analysis was undertaken using SPSS v15 (SPSS 2000) and STATA v10 (Stata 
2001) statistical analysis packages.  Mokken analysis was undertaken using MSPWIN 
5.0 software package (Molenaar et al. 2000).  The evaluation of psychometric properties 
is referred to in Chapter 3 (Section 3.3.3; page 94 and Section 3.5; page 113), the 
methods of evaluation for these properties are referred to again here specifically as 
applied in this chapter. 
 
Floor and ceiling effects 
Floor and ceiling effects are normally examined to determine if items are missing, in 
terms of the range of the scale, at the extremes of the measure.  However, in the case of 
the ArmA, floor effects for difficulty were anticipated in the passive function sub-scale 
in participants who had high active function ability.  It was also expected that 
participants who had high passive function difficulty, would have significant active 
function difficulty.  Floor and ceiling effects were assessed in the study population by 
considering the percentage of participants at either extreme of the subscales according 
to the criteria by Terwee and colleagues (Terwee et al. 2007). 
 
Construct validity 
Construct validity was evaluated by comparing the ArmA with components of the 
LASIS and the DASH.  The LASIS and DASH were divided into their active and 
passive function items and the relevant items were correlated with the relevant sub-scale 
of the ArmA.  All scales used are ordinal and therefore do not meet the criteria for the 
application of parametric tests.  Comparisons were therefore undertaken using the 
Spearman rank order correlation coefficient.   
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Convergent validity was tested in the passive function sub-scale of the ArmA by 
comparing it with the LASIS passive items and a high positive correlation was 
expected.   Convergent validity was tested in the active function sub-scale of the ArmA 
by comparing it with the LASIS and DASH active function items.  A high positive 
correlation was expected with both. 
 
Divergent validity was evaluated by comparing the ArmA passive function sub-scale 
with the LASIS and DASH active function items.  No significant correlation was 
expected.  Divergent validity was tested in the active function sub-scale of the ArmA by 
comparing it with the LASIS passive function items, with no significant correlation 
expected. 
 
Unidimensionality and scaling 
The dimensionality of the ArmA sub-scales were initially evaluated using principal 
component analysis.  The results from principal component analysis were evaluated by 
initially considering Eigenvalues above 1 according to the criteria by Kaiser (1960).  
Following evaluation of Eigenvalues, Scree plots were then examined to support the 
findings.  However to confirm these findings and to provide more objective criteria for 
the acceptance of the components identified, a Monte Carlo analysis was carried out 
according to the method by Horn (1965).   
 
Mokken analysis (monotone homogeneity) was also applied to confirm the constructs of 
the ArmA (see Chapter 3).  Mokken analysis was then applied in a preliminary 
evaluation of the ordinal structure of the items in the ArmA sub-scales. 
 
Internal consistency 
Cronbach’s alpha was used to evaluate internal consistency applying the criteria of 
Terwee and colleagues (Terwee et al. 2007).  A positive rating for internal consistency 
was given when ratings for Cronbach’s alpha were between 0.70 and 0.95 (Terwee et al. 








Reproducibility of ArmA was evaluated using Quadratic Weighted Kappa coefficient 
for test re-test reliability.  Time 1 (Baseline) data were compared with data recorded at 
Time 2 (one day later).   
 
Responsiveness 
Responsiveness of the ArmA was evaluated between Time 1 (baseline) and Time 3 (8 
weeks) following BTX injection.  Responsiveness was determined by comparing the 
ArmA detection of functional improvement with the Clinicians Categorisation of 
Response (CCR) in the passive and active function sub-scales.  Change in the ArmA at 
Time 3 (8 weeks) was compared between responder and non-responder categories using 
the non-parametric Mann-Whitney U test.  It was expected that the ArmA would 
identify a significant difference between the responder and the non-responder groups for 
passive function as defined by the CCR at Time 3 (8 weeks) following baseline.  
Responsiveness was further evaluated between responders and non-responders at Time 
4 (16 weeks) to further support the findings and as initial evidence of longitudinal 
validity. 
 
To enable comparison with other measures of upper limb function, effect size and 
standard response mean were calculated for the ArmA sub-scales, LASIS active and 
passive items, Barthel Index and DASH active items.  Effect size and standard response 
mean are commonly used with ordinal scales despite being parametric techniques (also 
see Chapter 3, Section 3.3.3.7; page 109).  Due to the acknowledged limitations of this 
parametric approach, positive and negative rank differences are also presented for each 
measure from baseline to 8 weeks.   
 
Interpretability 
Minimal Important Change (MIC) was calculated using two methods; a criterion-based 
method and a distribution-based method (also see Chapter 3, Section 3.3.3.8; page 111).  
The criterion-based method was produced by calculating the mean change in ArmA 
passive and active sub-scales in the responder group.  The distribution-based method as 
recommended by (Norman et al. 2003) was calculated by using half the baseline (Time 
1) standard deviation for ArmA as an estimate of MIC.  The calculation of MIC again 
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uses parametric assumptions and therefore can only provide a preliminary indication of 
interpretability for the ArmA.  Re-evaluation of MIC will be needed once Rasch 
analysis has been applied to establish the interval scaling properties of the ArmA using 
a logit scale.  Preliminary predictions of MIC were further examined by calculation of 
sensitivity and specificity for a 1-point change in ArmA, a 2-point change and a 3-point 
change according to the classification of response by CCR. 
 
Feasibility  
Feasibility is concerned with ensuring that outcome measures can a) be practical to use 
in routine practice and b) retain their psychometric properties, thus ensuring utility 
(Slade 2002b).  Feasibility is evaluated using a self-completed questionnaire 
administered following ArmA completion.  Patients and carers rated the ease of use, 
relevance, and value in the clinical situation of the ArmA.   
 
7.3.3 Analysis – Evaluation of functional change: A cohort study 
Evaluating spasticity intervention using the ArmA  
In order to compare change between baseline and both outcome evaluation points the 
Friedman test was applied (Altman 1991) (p. 334-6).  The Friedman test is a non-
parametric test of significance for three or more conditions for same or matched subject 
designs.  The Friedman test can only be used to identify general differences between 
groups, and does not indicate if one group has improved compared to the other.  The test 
is therefore always two tailed.  The Wilcoxon test was then applied following the 
Friedman test as per the recommendations of Altman (Altman 1991) (p. 203-5).  The 
Wilcoxon test was used to compare Baseline to Time 3 (8 weeks), Baseline to Time 4 
(16 weeks) and Time 3 (8 weeks) to Time 4 (16 weeks) separately.   




7.4 Results - Psychometric evaluation 
7.4.1 Demographics 
A total of 103 patients were screened to participate in the psychometric evaluation (63 
Group 1, 40 Group 2).  Of those patients approached in Group 1, four did not have BTX 
intervention after full assessment and were excluded and one declined to participate.  In 
Group 2, six of the 40 patients initially approached declined to participate. 
 
A total of 92 patients were recruited at baseline, 58 in Group 1 and 34 in Group 2.  
Table 7.3 shows the response rates at each time point. 
 
Table 7.3 Response rate at each time point 
Time Point Group 1 Group 2  Combined 
T1 – Start of baseline assessment (day 0) 58 (100%) 34 (100%) 92 (100%) 
T2 – 1 Day following baseline 44 (76%) 34 (100%) 78 (85%) 
T3 – 8 Weeks follow-up 53 (91%) n/a n/a 
T4 - 16 weeks follow-up 
 
48 (83%) n/a n/a 
n/a = Not applicable  
 
The study sample is described in Table 7.4. 




Table 7.4 Demographic characteristics of the study population (n=92) 
Groups 
 
Group 1 (n=58) Group 2 (n=34) Combined (n=92) 
Mean age (years) 47 (SD=17.5) 42 (SD=15.8) 44.5 (SD=16.7) 
Male/female ratio 32:26 22:12 54:38 
DIAGNOSIS 
 
   
Stroke 30 (52%) 18 (52%) 48 (52%) 
Right hemisphere 13 (22%) 10 (28%) 23 (25%) 
Left hemisphere 17 (30%) 8   (24%) 25 (27%) 
Acquired brain 
injury 
22 (38%) 6   (19%) 28 (31 %) 
Traumatic  16 (28%) 5   (15%) 21 (23%) 
Anoxic 6   (10%) 1   (3%) 7   (8%) 
Other  6   (10%) 10 (29%) 16 (17 %) 
Multiple Sclerosis 4 (6%) 2 (6 %) 6 (7%) 
Motor neurone disease 1 (2%)  1 (1%) 
Encephalitis 1 (2%)  1 (1%) 
CNS Tumour  4 (11%) 4 (4%) 
Spinal cord injury  2 (6%) 2 (2%) 
Vasculitus  1 (3%) 1 (1%) 
Critical care 
neuropathy 
 1 (3%) 1 (1%) 
 
Group 1 participants had a median Barthel Index score of 5.0, (inter-quartile range 0-15) 
with a high level of disability and dependence in ADL.  Group 2 participants had a 
median Barthel Index score of 14, (inter-quartile range 10-15) with a lower level of 
disability and dependence. 
 
Entry of data 
Double entry of all data (excluding MAS for which a sample of 20 participants was 
used) identified minimal errors between the two data sets, which are summarised in 
Table 7.5.   
 
Table 7.5 Errors found and corrected following double entry for each measure 
Time 
point 









34 (0.5%) 71 (3.1%) 8 (0.1%) 3 (1.6%) 2 (1.6%) 0 (0%) 
 
Overall, data entry error was 3.3% before correction.  Errors were resolved by referring 
back to the original paper copies of the data. 





Table 7.6 displays the return rate for ArmA, LASIS, DASH, GAS and CCR  at each 
time point.   
Table 7.6 Return rate for ArmA, LASIS, DASH, GAS and CCR 








Groups 1 and 2 (n=92)     
ArmA 92 (100%) 78 (85%) - - 
Group 1 only (n=58)     
ArmA 58 (100%) 44 (76%) 51 (88%) 39 (67%) 
LASIS  57 (98%) - 51 (88%) 39 (67%) 
DASH  58 (100%) - 50 (86%) 37 (64%) 
GAS  58 (100%) - 53 (91%) 47 (81%) 
CCR  - - 52 (90%) 46 (79%) 
 
The missing ArmA measure data at Time 2 were due to postal questionnaires not being 
returned by participants.  Missing data in returned measures was 1.4%.  The chi-square 
test was applied at all time points to evaluate if demographic differences could explain 
the reason for missing data but none were found.  Imputation methods were considered 
but not applied because of the risk of over emphasising the relationship between data 
points for psychometric purposes.  Case-by-case exclusion of data for each analysis was 
applied.  
  
Completion of the ArmA 
Table 7.7 presents the person who completed the ArmA; patient (professional assistance 
is also indicated), carer or combined (both patient and carer undertaking completion 
together). 
Table 7.7 Person completing the ArmA (patient, carer or combined) 








Patient alone 53 52 21 20 
(supported by a 
professional) 
(11) (5) (8) (6) 
Carer alone 31 19 25 20 
Combined patient and 
carer completion 
8 7 7 7 
 




Psychometric evaluation of the ArmA incorporated comparison with a number of 
different measures.  The descriptive statistics for these measures or sub-sections of 
those measures are shown in Table 7.8.   



















12 (6.2-17) 13 (6-17) - - 
ArmA  
Active 










14 (10-18) - 13 (7-17) 11 (7-15) 
ArmA  
Active 
52 (48.7-52) - 51 (48-52) 51 (48-52) 
Barthel 
Index 












105 (100-105) - 105 (99-105) 105 (94.7-105) 
Modified 
Ashworth 
4 (3-6) - 2 (1-3) 2 (2-4) 
Score ranges: ArmA Passive 0-28; Active 0-52, Barthel 0-20, LASIS Passive 0-36; Active 0-12, 
DASH Active 0-145, Modified Ashworth 0-5 (additional point +1). 
 
7.4.2 Ceiling and floor effects 
No ceiling or floor effects were identified in the Time 1 ratings on the passive function 
sub-scale.  Scores were distributed over the range of the measure from 0 to 28, with an 
increased frequency in the centre of the scale.  The modal score was 13, rated by 10 
(11%) participants as shown in Figure 7.2.   
 
Chapter 7 Evaluation of ArmA properties and application 
 
 209 























N = 92; Median = 12; Inter-quartile range = 6.2-17; Kolmogorov-Smirnov Z = 0.619; P = 0.84 
 
 
In the active function sub-scale, a complete range of scores was produced at Time 1 
from 0 to 52.  However a ceiling effect occurred with 37% of scores for active function 
at the maximum point on the scale (52) shown in Figure 7.3, according to the criteria by 
Terwee and colleagues (Terwee et al. 2007).   
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N = 92; Median = 48.5; Inter-quartile range = 35.5-52; Kolmogorov-Smirnov Z = 2.202; P = 0.003 
 
The ceiling effect in the active function sub-scale became apparent during the initial 
phase of recruitment for Group 1 as 34 participants initially recruited were reporting 
maximum difficulty.  This ceiling effect although reduced with the addition of Group 2, 
as expected was not entirely eradicated.   
 
7.4.3 Construct validity 
Construct validity was evaluated at Time 1 (baseline) by correlation of passive and 
active function sub-scales of the ArmA with the LASIS and DASH passive and active 
function items shown in Table 7.9.   
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Table 7.9 Correlation matrix between baseline ArmA (n=58), LASIS (n=57) and 
DASH (n=58). 
Measure ArmA Passive ArmA Active 
LASIS Passive items (n=57) Rho = 0.5* Rho = 0.23 
LASIS Active items (n=57) Rho = 0.02 Rho = 0.48* 
DASH Active items (Items 1-21) (n=58) Rho =-0.01 Rho = 0.63* 
Key:  All correlations used Spearman rank order correlation coefficient, *Significance P < 0.01 
 
 
Convergent validity was shown by the significant correlation between the ArmA 
passive function sub-scale and the LASIS passive function items.  In the active function 
sub-scale convergent validity was again shown by significant correlation between the 
ArmA active function items with the active function items from LASIS and DASH.   
 
Divergent validity was shown by non-significant correlations of the ArmA passive 
function sub-scale with DASH and LASIS active items.  The ArmA active function sub-
scale also showed a non-significant correlation with LASIS passive function items.   
 
In summary, the passive function sub-scale of the ArmA was found to correlate with 
passive function items in other measures and not to correlate with active function items.  
The active function sub-scale correlated with active function items such as DASH active 
items, but did not correlate with the passive function items.  Construct validity is 
supported as per the recommendations of Terwee and colleagues (Terwee et al. 2007). 




7.4.4 Unidimensionality and scaling 
 
Principal component analysis 
The passive function sub-scale had one component with an Eigenvalue above 1 using 
Kaiser’s criteria (Kaiser 1960), which accounted for 54% of the variance while the 
second component accounted for only 12% of the variance shown in Table 7.10. 
 
Table 7.10 Passive function; variance explained following principal component 
analysis (n=92) 
Component Initial Eigenvalues 






1 3.79 54 54 1.41 
2 0.88 12 67 1.22 
3 0.68 10 76 1.08 
4 0.63 9 85 0.97 
5 0.46 6 92 0.88 
6 0.29 4 96 0.78 
7 0.27 4 100 0.64 
*Monte Carlo analysis according to Horn’s method. 
 
These results indicate that the first component has a much larger influence and suggests 
a relatively coherent single construct, which has been interpreted as summarising 
passive function.  Table 7.11 displays loading of the individual measurement items onto 
the single principal component with an Eigenvalue above 1. 
 
Table 7.11 Passive function item loadings onto the principal component  
Item  Loading 
1. Cleaning palm 0.876 
2. Cutting finger nails 0.716 
3. Putting on a glove 0.642 
4. Cleaning armpit 0.801 
5. Putting arm through sleeve 0.817 
6. Putting on a splint 0.636 
7. Position arm in sitting 0.622 




Figure 7.4 shows a Scree plot of the principal components for the passive function sub-
scale. 
 
















The Scree plot supports a single component interpreted as passive function.  In addition 
a Monte Carlo analysis according to Horn’s method of parallel analysis was undertaken 
and confirmed a single principal component (Horn 1965) (see Table 7.10). 
 
The active function sub-scale had two components with an Eigenvalue above 1 using 
Kaiser’s criteria (Kaiser 1960), which in part reflected the narrower spread of scores 
within this sample.  However, the first component accounted for 71% of the variance 
while the second accounted for only 8% and was only just above 1.  On conducting a 
Monte Carlo analysis according to Horn’s method, only the first factor was retained 
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Table 7.12 Active function; analysis of variance following principal component 
analysis (n=92) 
Component Initial Eigenvalues 






1 9.26 71 71 1.68 
2 1.01 8 79 1.50 
3 0.56 4 83 1.36 
4 0.48 4 87 1.25 
5 0.41 3 90 1.14 
6 0.35 3 93 1.06 
7 0.25 2 95 0.97 
8 0.17 1 96 0.88 
9 0.14 1 97 0.79 
10 0.12 0.9 98 0.72 
11 0.10 0.74 99 0.63 
12 0.08 0.64 99 0.55 
13 0.05 0.41 100 0.46 
*Monte Carlo analysis according to Horn’s method. 
 
These results suggest that the first component corresponds with the construct of active 
function.  Table 7.13 displays loading of the individual measurement items onto the two 
principal components with Eigenvalues above 1. 
 




Table 7.13 Active function item loadings onto first and second principal 
components 








1. Buttons on clothing 0.864 0.047 
2. Pick up glass/bottle 0.852 0.125 
3. Use a key in lock 0.889 -0.080 
4. Write on paper 0.832 -0.316 
5. Open a jar 0.858 0.059 
6. Eat with knife & fork 0.856 -0.020 
7. Hold object & use other hand 0.724 0.497 
8. Effect of arm on balance when walking 0.523 0.726 
9. Dial number on phone 0.930 -0.106 
10. Tuck in shirt 0.935 -0.021 
11. Comb hair 0.881 -0.141 
12. Brush teeth 0.870 -0.208 
13. Drink from cup 0.875 -0.185 
 
The individual items load strongly onto the first component and generally weakly onto 
the second component.  The item loadings therefore support the interpretation of the 
first component representing active function.  Examination of the Scree plot (see Figure 
7.5) for these data also further support a single principal component interpreted as active 
function.   





















To further support single principal components for the active and passive function sub-
scales, analysis was undertaken on the combined items from both sub-scales.  In 
addition, Promax rotation was also performed with Kaiser normalisation to support the 
interpretation of a single principal component for each sub-scale. 
 
Examination of the Eigenvalues for both sub-scales combined produces three 














Table 7.14 Analysis of variance following principal component analysis for active 
and passive sub-scales combined (n=92) 
Component Initial Eigenvalues 






1 10.75 54 54 1.95 
2 2.44 12 66 1.74 
3 1.21 6 72 1.60 
4 0.80 4 76 1.50 
5 0.72 4 80 1.40 
6 0.65 3 83 1.29 
7 0.51 3 86 1.21 
8 0.47 2 88 1.11 
9 0.44 2 90 1.04 
10 0.40 2 92 0.97 
11 0.31 1 93 0.90 
12 0.28 1 94 0.83 
13 0.23 1 95 0.77 
14 0.20 1 96 0.71 
15 0.16 1 97 0.65 
16 0.12 1 98 0.59 
17 0.10 1 99 0.53 
18 0.08 0.4 99 0.47 
19 0.07 0.3 99 0.40 
20 0.05 0.3 100 0.34 
*Monte Carlo analysis according to Horn’s method. 
 
Three components had Eigenvalues above 1, however a Monte Carlo analysis was again 
conducted and confirmed two principal components when comparing the random values 
with those produced from the data.  Table 7.15 displays the loading of the individual 
items onto the first and second components.   
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Table 7.15 Item loadings onto first and second principal components for combined 
active and passive function sub-scales 








1. Cleaning palm 0.607 0.609 
2. Cutting finger nails 0.494 0.469 
3. Putting on a glove 0.542 0.327 
4. Cleaning armpit 0.545 0.563 
5. Putting arm through sleeve 0.522 0.651 
6. Putting on a splint 0.461 0.463 
7. Position arm in sitting 0.454 0.468 
8. Buttons on clothing 0.848 -0.154 
9. Pick up glass/bottle 0.847 -0.108 
10. Use a key in lock 0.869 -0.187 
11. Write on paper 0.795 -0.289 
12. Open a jar 0.850 -0.116 
13. Eat with knife & fork 0.829 -0.216 
14. Hold object & use other hand 0.718 -0.047 
15. Effect of arm on balance when walking 0.559 -0.215 
16. Dial number on phone 0.905 -0.233 
17. Tuck in shirt 0.919 -0.176 
18. Comb hair 0.861 -0.204 
19. Brush teeth 0.832 -0.302 
20. Drink from cup 0.837 -0.296 
 
Figure 7.6 shows the Scree plot of the principal components for the combined passive 
and active function sub-scales. 
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Figure 7.6 Scree plot of principal components for active and passive function sub-




















Promax rotation was performed on the combined scales and shown in Table 7.16. 




Table 7.16 Item loadings for combined active and passive function sub-scales 
following Promax rotation with Kaiser normalisation. 








1. Cleaning palm 0.445 0.860 
2. Cutting finger nails 0.368 0.681 
3. Putting on a glove 0.449 0.615 
4. Cleaning armpit 0.396 0.784 
5. Putting arm through sleeve 0.353 0.830 
6. Putting on a splint 0.338 0.653 
7. Position arm in sitting 0.329 0.651 
8. Buttons on clothing 0.860 0.493 
9. Pick up glass/bottle 0.848 0.524 
10. Use a key in lock 0.889 0.484 
11. Write on paper 0.841 0.360 
12. Open a jar 0.853 0.521 
13. Eat with knife & fork 0.856 0.435 
14. Hold object & use other hand 0.708 0.476 
15. Effect of arm on balance when 
walking 
0.492 0.548 
16. Dial number on phone 0.934 0.477 
17. Tuck in shirt 0.934 0.527 
18. Comb hair 0.884 0.466 
19. Brush teeth 0.880 0.377 
20. Drink from cup 0.883 0.385 
Bold indicates the highest loading of each item onto one of the two components 
 
The results following Promax rotation were then plotted in two-dimensional space 
shown in Figure 7.7. 




Figure 7.7 Component plot in two-dimensional space for active and passive 





































The results following Promax rotation support two principal components with items in 
two groups on the plot in two-dimensional space.  However, one item (a81) “difficulty 
with balance when walking due to your arm”, is more closely related to passive function 
rather than active function.  Principal component analysis suggested unidimensional 
sub-scales for passive and active function although this is a preliminary evaluation 
requiring further confirmation.   
 
Mokken Analysis 
The items in the passive function sub-scale produced an overall H coefficient for the 
scale of 0.48 with no individual item H-coefficients below 0.3 shown in Table 7.17.  




Table 7.17 Mokken Analysis – passive function sub-scale (n=92) 
Item Summary per item 
Mean Item H 
1. Cleaning palm 1.3 0.60 
2. Cutting finger nails 2.2 0.48 
3. Putting on a glove 1.6 0.53 
4. Cleaning armpit 1.2 0.40 
5. Putting arm through sleeve 1.6 0.55 
6. Putting on a splint 2.2 0.43 
7. Position arm in sitting 1.5 0.42 
 Scale H 0.48 
 Rho 0.85 
 
van Schuur identifies that no item in a unidimensional scale should have an item H 
below 0.3, which is satisfied in the passive function sub-scale (van Schuur 2003).  The 
overall H coefficient for the passive function total scale of 0.48 fits van Schuur’s criteria 
for a moderately strong unidimensional scale (Molenaar et al. 2000; van Schuur 2003).  
Only one item, item 6, had a crit value above 40 (actual value 43) outside the 
recommended range of crit values (Molenaar et al. 2000) indicating possible violations 
of monotonicity.  Although in this evaluation the aim was not to confirm double 
monotonicity, removal of items was explored.  Removal of items 7 and 6 resulted in a 5 
item scale with an overall item H of 0.56 indicating a strong scale and highest crit value 
of 15 indicating no violations of double monotonicity. 
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The items in the active function sub-scale yielded an overall H coefficient for the scale 
of 0.71 shown in Table 7.18.   
 
Table 7.18 Mokken Analysis - active function sub-scale (n=92) 
Item Summary per item 
Mean Item H 
1. Buttons on clothing 2.5 0.51 
2. Pick up glass/bottle 3.1 0.64 
3. Use a key in lock 3.4 0.73 
4. Write on paper 3.1 0.72 
5. Open a jar 3.3 0.73 
6. Eat with knife & fork 3.2 0.72 
7. Hold object & use other hand 3.2 0.79 
8. Effect of arm on balance when walking 3.4 0.69 
9. Dial number on phone 3.3 0.72 
10. Tuck in shirt 3.3 0.80 
11. Comb hair 3.3 0.73 
12. Brush teeth 3.2 0.74 
13. Drink from cup 3.4 0.76 
 Scale H 0.71 
 Rho 0.97 
 
The overall H coefficient for the active function total scale of 0.71 fits van Schuur’s 
criteria for a strong unidimensional scale (Molenaar et al. 2000; van Schuur 2003).  The 
item with the third lowest H index was again “difficulty with balance when walking due 
to your arm”.  No item, had a crit value above 40 outside the recommended range of crit 
values (Molenaar et al. 2000) indicating no violations of monotonicity although this is 
likely, at least in part, to be due to the ceiling effect for this group. 
 
Following Mokken analysis the unidimensionality of the two sub-scales is supported, 
although should be seen as preliminary evaluation due to the limited number of 
participants and the ceiling effect present in the active function data.  However, the 
passive function sub-scale appears to be a unidimensional scale satisfying the monotone 
homogeneity model in its current form and may conform to double monotonicity 
(possibly with removal of items 6 and 7) when further evaluation is undertaken. 
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7.4.5 Internal consistency 
Cronbach’s alpha for passive function at Time 1 (baseline) was 0.85.  This is within the 
range of 0.7 to 0.9 proposed by Nunnally and Bernstein (Nunnally and Bernstein 1994).  
The result also conforms to the quality criteria proposed by Terwee and colleagues 
(Terwee et al. 2007).  Table 7.19 shows that internal consistency also remains high with 
the sequential removal of each item.  
 
Table 7.19 Internal consistency – passive function (n=78) 
Item Removed Alpha Median Range I.Q. Range 
1. Cleaning palm 0.80 2 0-4 1-2 
2. Cutting finger nails 0.83 2 0-4 1-4 
3. Putting on a glove 0.84 3 0-4 2-4 
4. Cleaning armpit 0.84 2 0-4 1-3 
5. Putting arm through sleeve 0.81 2 0-4 1-3 
6. Putting on a splint 0.84 2 0-4 0.75-3 
7. Position arm in sitting 0.81 2 0-4 0-2.25 
Total (all items included) 0.85    
 
Cronbach’s alpha for active function at Time 1 (baseline) was 0.96 and reduced to 0.95 
following the removal of two items shown in Table 7.20.  
 
Table 7.20 Internal consistency – active function (n=78) 
Item Removed Alpha Median Range I.Q. Range 
1. Buttons on clothing 0.97 2 0-4 0-3 
2. Pick up glass/bottle 0.95 4 0-4 1-4 
3. Use a key in lock 0.95 3 0-4 1.75-4 
4. Write on paper 0.96 3 0-4 1-4 
5. Open a jar 0.96 3.5 0-4 2-4 
6. Eat with knife & fork 0.96 3 0-4 1-4 
7. Hold object & use other 
hand 
0.96 2.5 0-4 1-4 
8. Effect of arm on balance 
when walking 
0.96 3.5 0-4 1.75-4 
9. Dial number on phone 0.96 3 0-4 1.75-4 
10. Tuck in shirt 0.96 3 0-4 2-4 
11. Comb hair 0.96 3 0-4 2-4 
12. Brush teeth 0.96 2 0-4 2-4 
13. Drink from cup 0.96 4 0-4 2-4 
Total (all items included) 0.96    
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The active function sub-scale result indicates high internal consistency but is also 
indicative of item redundancy according to Terwee and colleagues (Terwee et al. 2007).  
However, the more plausible explanation for high internal consistency is the fact that 
many participants rated active function difficulty at maximum, thus producing the 
ceiling effect.  Despite the ceiling effect, a full range of scores for all items in both 
passive and active function sub-scales was found in the data (see Tables 7.19 and 7.20).  
Medians were in the middle of the scale for the passive function items, but with a 
tendency towards the higher end of the scale for the active function items indicating 
more difficulty for many subjects.   
 
In summary, Cronbach’s alpha for the passive function and active function subscales 
showed high internal consistency.  Mokken analysis also produces a version of internal 
consistency in the form of the overall Rho for the sub-scales (van Schuur 2003).  The 
Rho for both sub-scales was greater than 0.80 supporting internal consistency using this 
method in addition to Cronbach’s alpha (see Tables 7.17 and 7.18). 
7.4.6 Test re-test reliability and agreement 
Quadratic Weighted Kappa coefficients for the passive function scale were between 
0.71 and 0.90.  Percentage agreement ranged between 91.99 and 97.52; both Kappa 
coefficients and percentage agreement are shown in Table 7.21.   
 
Table 7.21 Test re-test reliability (Time 1 to Time 2) passive function (n=78). 












0.82 0.1119 Almost perfect 
2. Cutting 
finger nails 
93.83 0.74 0.1130 Substantial 









0.80 0.1107 Almost perfect 
5. Putting arm 
through sleeve 
96.31 0.75 0.1123 Substantial 




0.90 0.1132 Almost perfect 
7. Position arm 
in sitting 
96.47 0.86 0.1125 Almost perfect 




The Kappa coefficient for passive function conformed to “substantial” or “almost 
perfect” criteria for all items according to Landis and Koch (Landis and Koch 1977). 
 
Quadratic Weighted Kappa coefficients for the active function scale were between 0.70 
and 0.94.  Percentage agreement ranged between 92.15 and 98.72; both Kappa 
coefficients and percentage agreement are shown in Table 7.22.   
  
Table 7.22 Test re-test reliability Time 1 to Time 2 active function (n=78). 






Landis and Koch 
interpretation 
1. Buttons on 
clothing 
96.23                  0.94 0.1126 Almost perfect 
2. Pick up 
glass/bottle 
96.23      
             
0.89 0.1130 Almost perfect 
3. Use a key in 
lock 
96.79 0.76 0.1130 Substantial 
4. Write on paper 95.11   
                
0.79 0.1130 Substantial 
5. Open a jar 94.87    
               
0.81 0.1132 Almost perfect 
6. Eat with knife 
& fork 
94.79                  0.81 0.1131 Almost perfect 
7. Hold object & 
use other hand 
97.52                  0.87 0.1131 Almost perfect 
8. Effect of arm 
on balance when 
walking 
98.72                  0.86 0.1128 Almost perfect 
9. Dial number 
on phone 
97.20                  0.78 0.1132 Substantial 
10. Tuck in shirt 97.28    
               
0.88 0.1131 Almost perfect 
11. Comb hair 92.15      
             
0.86 0.1130 Almost perfect 
12. Brush teeth 96.39  
                 
0.70 0.1127 Substantial 
13. Drink from 
cup 
96.55    
               
0.85 0.1118 Almost perfect 
 
Weighted Kappa coefficients for the active function sub-scale also conformed to 
“substantial” or “almost perfect” agreement criteria according to Landis and Koch 
(Landis and Koch 1977) (see Table 7.22).  Again, the tendency towards ceiling effect in 
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the active function sub-scale has probably over emphasised the degree of agreement.  
Using the criteria of Landis and Koch both sub-scales are given a positive rating for 
reliability according to Terwee and colleagues (Terwee et al. 2007).   
7.4.7 Responsiveness 
Primary classification of response following intervention (BTX and PT) at Time 3 (8 
weeks) was determined by CCR.  As further evidence of responsiveness and 
longitudinal validity, response at Time 4 (16 weeks) is also presented.  The 
categorisation of response identified by CCR and corroborated by individual goal 
attainment recorded by GAS (goals achieved as predicted or over achieved), is 
presented in Table 7.23. 
Table 7.23 Response identified at 8 and 16 weeks by CCR and GAS. 
Measure 8 Weeks 16 Weeks 
CCR (n=52) (n=48) 
Responders 41 36 
Non-responders 11 12 
Unknown 6 10 
GAS (n=53) (n=47) 
Responders 42 36 
Non-responders 11 11 
Unknown 5 11 
 
The number of responders identified by CCR and GAS was similar with 41 and 42 
respectively at Time 3 (8 weeks).  The same participants were identified by both CCR 
and GAS, apart from one participant who did not have CCR recorded by his treating 
therapists.  At Time 4 (16 weeks) both CCR and GAS identified the same 36 
participants as responders.   
 
The responsiveness of the ArmA passive and active function sub-scales was evaluated 
by comparing responders with non-responders for passive and active sub-scales at Time 
3 (8 weeks) using the Mann-Whitney U test.  To further support these findings and 
provide evidence of longitudinal validity, the evaluation was repeated at Time 4 (16 
weeks).  To allow comparison of the ArmA with the other measures, responsiveness of 
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LASIS passive items, LASIS active items, Barthel index and DASH active items, were 
also evaluated.  The results of these analyses are shown in Table 7.24. 
 
Table 7.24 Responder Vs non-responder change in the ArmA, LASIS, Barthel and 
DASH (n=51). 
Measure Responders Vs non-responders 
(8 weeks) 
Responders Vs non-responders 
(16 weeks) 
ArmA passive  U = 98.5; p = 0.01 U = 29.5; p = 0.003 
ArmA active U = 163.5; p = 0.35 U = 77.5; p = 0.21 
LASIS passive items U = 127.0; p = 0.07 U = 263.5; p = 0.20 
LASIS active items U = 167.0; p = 0.39 U = 210; p = 0.17 
DASH active items U = 176.5; p = 0.92 U = 136.0; p = 0.47 
Barthel Index U = 200.5; p = 0.17 U = 117.5; p = 0.06 
Significant results in bold 
 
The ArmA identified a significant difference between responder and non-responder 
groups for the passive function sub-scale at Time 3 (8 weeks) for primary evaluation of 
responsiveness and at Time 4 (16 weeks).   A significant difference was not shown for 
the active function sub-scale.  The other measures did not show a significant difference 
between responders and non-responders at Time 3 (8 weeks) or Time 4 (16 weeks).  For 
graphical representation of individual patient level change in the ArmA passive function 
sub-scale at baseline, 8 weeks and 16 weeks see Appendix 19. 
 
Cohen’s effect size and standard response mean were also calculated for ArmA, LASIS, 
Barthel Index and DASH active items shown in Table 7.25.  As already discussed in 
chapter 3, the ordinality of the data brings into question the use of these methods with 
the ArmA data.  However, these methods have been used here to allow comparison 
between the different measures applied in the evaluation, to inform discussion of 
findings and the relationship of the ArmA to other measures.   
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Table 7.25 Effect size and standard response mean of the ArmA sub-scales, LASIS 
active and passive items, Barthel Index and DASH active items (n=51). 
Measure Effect Size Standard 
Response Mean 
ArmA passive  0.29 0.30 
ArmA active 0.21 0.16 
LASIS passive 0.23 0.20 
LASIS active 0.04 0.03 
DASH active 0.07 0.08 
Barthel 0.07 0.12 
 
Cohen’s effect size and standard response mean were small for the LASIS active items, 
Barthel Index, and the DASH active items.  Although somewhat greater for the ArmA 
active and passive function sub-scales and LASIS passive items, they were still low.  
Given the non-parametric nature of the data, the number of positive and negative rank 
differences are also presented for each measure from baseline to 8 weeks (see Figure 
7.8).   

















The distribution of data was assessed using the Kolmogorov-Smirnov test (also see 
section 7.4.2, Ceiling and floor effects; pages 208-210) and was normal for ArmA 
passive function (Z = 0.619; P = 0.84) and LASIS passive items (Z = 1.192; P = 0.12).  
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Distribution was not normal for ArmA active function (Z = 2.202; P = 0.003), LASIS 
active function items (Z = 2.300; P = 0.003), DASH active function items (Z = 2.498; P 
= 0.003) or Barthel index (Z = 1.471; P = 0.026).  The results again support greater, yet 
still small change in the ArmA passive function sub-scale and the LASIS passive 
function items.  However given the limitations of the sample for active function and the 
non-parametric nature of the data, conclusions about the responsiveness are preliminary. 
7.4.8 Interpretability 
Minimal Important Change (MIC) was calculated using: a criterion-based method and a 
distribution-based method (see Interpretability, page 203).  The results of calculating 
MIC using both these methods for the passive and active sub-scales are presented in 
Table 7.26. 
Table 7.26 Minimal Important Change calculated using criterion and distribution 
methods (n=51). 
Sub-scale Criterion-based method Distribution-based method 
ArmA passive  2.5 3.0 
ArmA active 1.1 2.5 
 
Given that no significant difference was identified between the responder and non-
responder group for active function the calculated MIC has limited meaning and will 
require further evaluation.  The ArmA passive function MIC will also need further 
evaluation once fundamental measurement properties have been demonstrated to allow 
confidence in the results of this parametric approach.   
 
To evaluate these preliminary predictions of MIC, sensitivity and specificity was 
calculated based on grouping of responders by CCR at 8 weeks for ArmA passive 
function (see Interpretability, page 203).  Calculation was undertaken for a 1-point 
change in ArmA, a 2-point change in ArmA and a 3-point change in ArmA.  The results 
are presented in Table 7.27. 
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Table 7.27 Sensitivity and Specificity of the ArmA according to classification of 
CCR at 8 weeks. 
Change from Baseline 1 point change 2 point change 3 point change 
Sensitivity 0.69 0.55 0.45 
Specificity 0.58 0.91 0.91 
Positive predictive value 0.63 0.45 0.37 
Negative predictive value 0.37 0.55 0.63 
 
These results indicate optimal sensitivity was achieved with a 1-point change in ArmA, 
but that specificity was improved with a 2-point change in ArmA. 
7.4.9 Feasibility 
Ease of completion was rated as Very easy, Easy or Moderate (on a scale from Very 
easy to Very difficult) by 90% of patients or carers, shown in Table 7.28. 
Table 7.28 Ratings for ease of the ArmA completion (n=56) 
Ease of Completion Number  
(Percentage) 
Very easy 15 (26 %) 
Easy 26 (45 %) 
Moderate 11 (19 %) 
Difficult 3 (5 %) 
Very Difficult 1 (2 %) 
Missing 2 (3 %) 
 
The ArmA was completed in 83% (n=48) of respondents in 10 minutes or under, 
presented in Table 7.29.   
Table 7.29 Ratings for time taken by patients and carers to complete the ArmA 
(n=56) 
Time to complete Number  
(Percentage) 
Under 5 minutes 27 (47%) 
5-10 minutes 21 (36%) 
11-15 minutes 3 (5%) 
16-20 minutes 3 (5%) 
Over 20 minutes  2 (3%) 
Missing 2 (3%) 
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Only two questionnaires took more than 20 minutes to complete (see Table 7.29).  The 
small numbers of participants (n=10) taking more than 10 minutes to complete the 
ArmA may have been due to confusion between the ArmA and the whole questionnaire 
pack (including all the other measures) for this minority of subjects.   
 
Relevance of the overall scale was rated by 77% of respondents as Very relevant to 
Moderately relevant.  The active function sub-scale was rated as Very useful to 
Moderately useful by 71% of respondents and the passive function subscale by 88% of 
respondents shown in Table 7.30.   
Table 7.30 Ratings of relevance or usefulness by patients and carers (n=56) 






Very Relevant/ useful 
 
15 (26%) 13 (22%) 16 (28%) 
Relevant/ useful 
 
17 (29%) 18 (31%) 19 (33%) 
Moderate 
 
13 (22%) 10 (17%) 15 (26%) 
Little relevance/ 
usefulness 
8 (14%) 11 (19%) 4 (7%) 
No relevance / usefulness 
 
3 (5%) 4 (7%) 2 (3%) 
Missing 
 
2 (3%) 2 (3%) 2 (3%) 
 
In table 7.30 relevance or usefulness of the ArmA are given in the left hand column.  
Relevance is rated for the whole ArmA (passive and active function sub-scales); 
usefulness is rated for active function and passive function sub-scales individually.  
Although over a quarter of respondents (26%) said the active function sub-scale was of 
little or no relevance (due primarily to the dependency of the group), only 10% said this 
of the passive function sub-scale.  
 
In summary, completion of ArmA was rated as Very easy to Moderately easy by 90 % 
of respondents and 83% of respondents completed the ArmA in 10 minutes or under.  
The passive and active function sub-scales of the ArmA are feasible to use for 
respondents as a self-completion questionnaire.   




7.5 Results - Evaluation of functional change: A cohort study 
7.5.1 Interventions applied 
The cohort study involved Group 1 (G1) participants only.  Injection of BTX was 
undertaken to muscles acting over the shoulder, elbow, wrist and hand.  All participants 
received BTX intervention shown in Table 7.31.   
 
Table 7.31 BTX intervention categorised by joint. 
BTX intervention  
 Shoulder Elbow Wrist/Hand 
Number of patients 
injected per region 
 
9 (15%) 26 (45%) 29 (50%) 
Muscles injected Pectoralis Major Brachialis FDS 
Infraspinatus Brachioradialis FDP 
Latissimus Dorsi Biceps Brachii FCU 
 Triceps Brachii FCR 
  FPL 
 
Dose range Dysport 150-1000u 150-1000u 300-1000u 
Botox - 50-200u 100-200u 
FDS - Flexor Digitorum Superficialis; FDP -Flexor Digitorum Profundus; FCU - Flexor Carpi 
Ulnaris; FCR -Flexor Carpi Radialis; FPL - Flexor Policis Longus 
 
In some patients, injections were applied to muscles acting over two joints.  Dysport and 
Botox BTX-A products were applied, although no Botox injection was applied to 
muscles of the shoulder (see Appendix 18 for details of BTX dose for each participant). 
 
All participants also received PT interventions shown in Table 7.32.   




Table 7.32 Physical therapy interventions. 
 Therapy intervention categories 
 























(4-8 hrs Daily) 













































Functional Electrical Stimulation (FES); Modified Constraint Induced Movement Therapy (MCIMT). 
 
Injection of BTX was undertaken in conjunction with PT interventions, which were 
assigned to the six categories shown in Table 7.32.  The most common PT interventions 
applied were splinting and passive stretch in 34 (59%) patients for both interventions.  
PT interventions were rarely provided in isolation, with most participants receiving at 
least two interventions in combination (mean number of interventions 1.7).  In 17 (29%) 
participants single physical therapy interventions were provided, in these instances 
intervention was most commonly splinting to maintain range of movement (see 
Appendix 18 for details of PT dose for each participant).   
7.5.2 Descriptive statistics 
The clinical and demographic characteristics of participants were presented previously 
in Table 7.4 (page 206).  Group 1 participants had a mean Barthel Index score of 7.0, 
(SD 7.7) indicating a high level of disability and dependence in ADL.   
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The ArmA, MAS, LASIS and DASH active ratings at Times 1, 3 and 4 are shown in 
Table 7.8 (page 208).  A reduction in median ArmA passive function score from 
baseline to 8 and 16 weeks suggests reduced difficulty in performing passive function 
tasks (i.e. caring for the affected upper limb).  The median MAS score also reduced 
from Time 1 (baseline) to Time 3 (8 weeks) and Time 4 (16 weeks) indicating a 
reduction in median spasticity.  Change in LASIS passive function median score is also 
shown from Time 3 (8 weeks) to Time 4 (16 weeks), but no change in LASIS active 
function or DASH active function.  A single point change is shown in ArmA active 
function median score from baseline to 8 weeks and maintained at 16 weeks. 
 
7.5.3 Evaluation of functional change 
ArmA passive function was compared between Time 1 (baseline), Time 3 (8 weeks) and 
Time 4 (16 weeks) and is displayed in Figure 7.9. 
 
























Box plots for passive function ArmA, following the Wilcoxon signed-ranks test, are 
shown across time points.  Difficulty in passive function is reduced at 8 weeks and 
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appears to reduce further at 16 weeks.  The range for all three-time points overlap due to 
variation within the group.  Data are presented for 38 participants due to missing data at 
16 weeks. 
 
Composite Modified Ashworth was also compared between Time 1 (baseline), Time 3 
(8 weeks) and Time 4 (16 weeks) and is displayed in Figure 7.10. 
 





































Box plots for composite MAS, following the Wilcoxon signed-ranks test, are also 
shown at each time point.  According to these measures, spasticity is reduced at 8 weeks 
and although still reduced increases again at 16 weeks.  The ranges do not overlap 
between Time 1 (baseline) and Time 3 (8 weeks) but do overlap between Time 3 and 
Time 4.  Data are presented for 44 participants due to missing data. 
 
The Friedman test was applied to compare change between Time 1 (baseline), Time 3 (8 
weeks) and Time 4 (16 weeks) for ArmA passive and active function, composite 
Modified Ashworth score measuring spasticity, LASIS passive and active function 
items and DASH active function items.  The Wilcoxon test was then applied as per the 
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recommendations of Altman (Altman 1991)(p. 203-5)  to compare Baseline to Time 3 
(8 weeks) and Baseline to Time 4 (16 weeks) separately and shown with the results for 
the Friedman test in Table 7.33.   
 
Table 7.33 Change in the ArmA, MAS, LASIS and DASH from baseline to 8 weeks 
(n=51) and baseline to 16 weeks (n=38). 
Measure Friedman test 
Baseline to 8 and 
16 weeks 
Wilcoxon 
Baseline to 8 weeks 
Wilcoxon 

































= 1.4 Z = -0.7 Z = -1.4 
  ***Significant at P < 0.005; **Significant at P < 0.01; *Significant at P < 0.05 
 
The results for the Friedman test show a significant decrease between Time 1 (baseline) 
and Time 3 and Time 4 (8 and 16 weeks) for the ArmA passive function sub-scale (X
r2 
11.9; n = 51; p < 0.005).  Due to the highly significant result from the Friedman test the 
risk of type one error was deemed small and the Wilcoxon test was applied.  A 
significant difference was also identified for composite Modified Ashworth (X
r2 
66.6; n 
= 51; p < 0.005) and in LASIS passive function items (X
r2  
= 6.4*; n = 51; p < 0.05).  No 
significant difference was identified for the ArmA active function sub-scale (X
r2 
0.5; n = 
51; p > 0.05), LASIS active function items or DASH active function items.   
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A significant difference was identified between Time 1 (baseline) and ArmA passive 
function at Time 3 (8 weeks), with improvement in passive function (Z -2.1; n = 51; p < 
0.05).  Comparison of Time 1 (baseline) to Time 4 (16 weeks), showed that the 
difference from baseline was maintained (Z - 2.6; n = 52; p < 0.01), and did not show a 
statistically significant change from 8 weeks (Z -1.0; n = 51; p > 0.05).  Significant 
difference was also identified for composite Modified Ashworth scores between Time 1 
(baseline) and Time 3 (8 weeks) (Z -6.0; n = 51; p < 0.005), Time 1 (baseline) and Time 
4 (16 weeks) (Z -5.3; n = 44; p < 0.005) and 8 weeks to 16 weeks (Z -3.6; n = 44; p < 
0.005). 
 
These results indicate that passive function is improved following BTX administration 
and PT intervention by 8 weeks and is maintained at 16 weeks despite the physiological 
effects of the BTX gradually reducing over this time period.  The passive function sub-
scale of the ArmA showed significant change at 8 weeks post intervention, which was 




Table 7.34 summarises the development (Chapters 4, 5, and 6) and evaluation of the 
ArmA (Chapter 7) in relation to the Quality Criteria produced by Terwee and colleagues 
and additional elements for evaluation of dimensionality, measurement scaling and 
feasibility.   
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Table 7.34 Summary of ArmA psychometric properties. 
Attribute Criteria Evaluation 
Validity The degree to which the instrument measures what it purports to measure 
Face Confirmed during pilot testing with patients and carers before main psychometric evaluation and during item selection by inclusion 
of patient identified items. 
Content Aim; population and target concepts: The ArmA was designed to provide a low burden measure of difficulty in active and passive 
arm function for patients undergoing spasticity management in the upper limb.   
Item selection and reduction; Item selection used a systematic review and patient selected items.  Item reduction was undertaken 
using a Delphi consensus process with specialist clinicians and confirmed with a wider consultation. Pilot testing was undertaken 
by patients and carers, feedback was provided on content and presentation.   
Interpretability of items: Items included in the questionnaire are short and simple and were developed in accordance with 
recommendations on language.  Understanding was confirmed during pilot testing (Terwee et al. 2007). 
Criterion-
related 
Not testable - no accepted gold standard measure for comparison currently exists.  Comparison using direct observation or activity 
analysis is impractical and raises problems of bias due to the presence of the observer. 
Construct 
(Concurrent) 
Convergent: Passive function sub-scale correlated with passive function items from LASIS (Rho 0.5) and active function was 
correlated with active function items from LASIS (Rho 0.48) and active function items from DASH (Rho 0.63).   
Divergent: Passive function did not significantly correlate with DASH active items and LASIS active items. The active function 
subscale was not correlated with LASIS passive function items. 
Construct validity is supported as per the recommendations of Terwee and colleagues with all correlations supporting the 
relationship of ArmA as predicted to the comparison measures (Terwee et al. 2007). 
 Unidimensionality Principal component analysis indicated one main component in each of the subscales and Mokken analysis confirmed the 
unidimensionality of the sub-scales - H index for the passive function 0.48 (rho 0.85) and active function 0.71 (rho 0.97).   
Scaling   
Mokken Analysis using a monotone homogeneity model confirmed preliminary ordinal scaling properties in the passive function 
sub-scale.  H index for the passive function was 0.48 indicating a medium scale (between 0.4 and 0.49) to differentiate persons. 
Reproducibility The degree to which the instrument is free from random error 
Agreement Percentage agreement ranged between 91.99 - 96.87 for the passive function scale and 92.15 - 97.52 for the active function scale. 
Test re-test 
Reliability 
Quadratic Weighted Kappa coefficients for the passive function sub-scale were between 0.71 - 0.90 and 0.70 - 0.94 for the active 
function sub-scale, constituting a positive rating for reliability (above 0.70 for Quadratic-weighted Kappa (Terwee et al. 2007)).  




Responsiveness Ability to detect change over time where actual changes occur 
Change: Baseline 
prior to intervention 
and follow-up 8 
weeks 
In this evaluation, a significant difference was identified between responders and non-responders using the ArmA passive function 
sub-scale at 8 weeks (U=98.5, P = 0.01), but not the active function sub-scale.   
SRM and ES were greater for ArmA than other measures but still low. 
Interpretability The degree to which easily understood meaning can be assigned to the quantitative scores 
Clinical meaning MIC was calculated using a criterion based method (2.5) and a distribution based method (3.0) for the passive function sub-scale.  
The higher of the two results (3.0) is accepted as the preliminary value of MIC, requiring further evaluation with interval scaling. 
Floor/ceiling effects  No significant floor or ceiling effects in the passive function sub-scale, but >15% ceiling effect in the active function sub-scale in 
the patient group used in this evaluation. 
Feasibility and 
Burden 
The time, effort or other demands of completing the measure 
Time to 
administer 
The ArmA was completed in 10 minutes or under by 83% of respondents.   
Ease of use  Ease of completion was rated as very easy, easy or moderate by 90 % of patients or carers.   
Relevance Relevance of the overall scale was rated by 77% of respondents as very relevant to moderately relevant.   
The active function sub-scale was rated as very useful to moderately useful by 71% of respondents and the passive function 
subscale by 88% of respondents. 
Acceptability Completion of ArmA was rated as very easy to moderate by 90% of respondents and 77% of respondents rated it as relevant with a 
mean time for completion of between 5-10 minutes.   
Value The passive function subscale was rated by 88% of respondents as useful (very useful, useful or moderately useful). 
The active function subscale was rated by 71% of respondents as useful (very useful, useful or moderately useful).   
Alternative modes of administration The ArmA has been administered, during testing, as a self-completion questionnaire or as an interview (face-to-face or over the 
telephone).  Only a small minority completed by interview or telephone and further validation of these methods will be needed. 
Cultural and language adaptations None currently available 
MIC - Minimal Important Change; SRM – Standard Response Mean; ES – effect Size 
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The ArmA provides a valid and reliable measure of difficulty in passive arm function 
for spasticity management intervention in the hemiparetic upper limb.  However, the 
fundamental measurement properties of the ArmA need further evaluation for passive 
and active sub-scales.  Further establishment of measurement properties with Rasch 
analysis will allow further subsequent analysis of properties such as MIC.  The 
evaluation of the active function sub-scale has been significantly limited by the ceiling 
effect seen in the study group and requires further evaluation in a more able study 
population.   
 
The psychometric evaluation is discussed in Section 7.6.1 and the evaluation of 
functional change (cohort study) is discussed in Section 7.6.2. 
 
7.6.1 Evaluation of the psychometric methods 
While key psychometric concepts have been addressed, some limitations to the methods 
became apparent through the evaluation process.  Moreover, some properties would also 
benefit from further evaluation.   
7.6.1.1 Construct validity 
Construct validity is supported, with confirmation of predicted moderate correlations of 
the ArmA with comparison measures.  The use of DASH as a comparison measure for 
construct validity can be criticised due its lack of validation in individuals with 
neurological impairment.  However, its potential strength for measurement of active 
function is in its design for self-completion in common with the ArmA.  It also contains 
a number of very relevant items for patients with hemiparesis.  Conversely, DASH 
contains a number of much higher-level functional items, which were unlikely to show 
change in all but the most able participants with impairment of neurological origin.  
Other alternatives such as MAL-14, MAL-26  or MAL-28 are not currently designed for 
self-completion.  Both MAL-14 and MAL-28 were pilot tested in standard format and 
an adapted form for self-completion, before construction of the measures pack.  In both 
versions of MAL respondents are asked to score both ‘Quality of Movement’ and 
‘amount of use’ for the affected upper limb as per the instructions for this measure.  In 
the pilot testing, these concepts were difficult for patients and carers to understand, 
which was particularly apparent for ‘quality of movement’ which was often not 
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completed.  The decision not to use the MAL in the ArmA validation was made on this 
basis.   
 
In the evaluation by van der Lee and colleagues (2004) correlations were identified 
between the MAL-14 and the Action Research Arm Test (ARAT) at baseline, which 
was a similar approach to that taken for convergent validity with the ArmA.  However, 
a weakness in the approach for the ArmA is the use of items, taken from measures, for 
comparison (e.g. passive function items from LASIS) rather than use of the whole 
measure.    This method was necessary to compare relevant items with the sub-scales of 
the ArmA, since other measures exactly matching the ArmA sub-scales (i.e. ‘gold-
standard’ measures) could not be found (see Chapter 4).   
 
Uswatte and colleagues also examined construct validity for the MAL-14 using 
accelerometer recordings (Uswatte et al. 2005).  Accelerometers were worn for three 
days at baseline and at the point of outcome evaluation.  Pearson correlations were 
identified between accelerometer recordings and baseline MAL-14 and change in MAL-
14 (Uswatte et al. 2005).  This has parallels with the approach taken in the ArmA, in 
evaluating hypothesised change over time, but differences in the manner of 
measurement.  However, in ArmA the statistical method of Spearman correlation was 
used because of the non-parametric nature of the data, which would seem a more 
appropriate method as per the criteria of Terwee and colleagues (2007) than Pearson 
correlation used for evaluation of MAL-14. 
 
In the evaluation of MAL-28 by Uswatte and colleagues, extensive use was made of 
accelerometers placed on each wrist to record participants function (Uswatte et al. 
2006).  Correlations were identified between MAL-28 and accelerometer recordings of 
the affected upper limb.  Convergence was also seen with MAL-28 and the Stroke 
Impact Scale – hand function section completed by both patients and carers.  
Divergence was identified between accelerometer recordings on the unaffected upper 
limb and the Stroke Impact Scale – mobility section completed by patients.  However 
caregiver completed MAL-28 did correlate with accelerometer recordings for the 
unaffected hand.  Use of accelerometer recording is possibly the next best method to 
direct observation of activity but is still time consuming, requires significant 
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commitment from the participant and can still only record information over a limited 
time period (72 hours for MAL-28).  Further evaluation of the ArmA could include 
comparison with accelerometer recordings, which should give further evidence for 
construct validity, but may have limited value as construct validity is now well 
supported. 
7.6.1.2 ArmA sub-scale unidimensionality and scaling properties 
Unidimensionality was initially examined using Principal Components Analysis (PCA) 
and then further evaluated using Mokken analysis.  Mokken analysis confirmed 
unidimensionality, with an H coefficient for the passive and active items and total sub-
scales of greater than 0.3, as recommended by van Schuur (van Schuur 2003).   
 
In the passive function sub-scale Principal Components Analysis (PCA) loading was 
consistent on this sub-scale (see Table 7.11; page 212).  Following Mokken analysis a 
moderate unidimensional scale was identified conforming to monotone homogeneity.  
Further reduction of items to improve measurement properties was not considered at 
this stage, however possible violations of double monotonicity were identified in Item 6 
(putting on a splint) and Item 7 (positioning the arm) of the passive function sub-scale.  
Removal of these items resulted in a strong unidimensional scale conforming to double 
monotonicity.  However, given the preliminary nature of the evaluation and the limited 
sample size (n=92) for this analysis, items were not excluded at this stage. 
 
During the selection of the ArmA items in Chapter 7, item 8 (active function) - ‘Effect 
of arm on balance when walking’ - was considered for inclusion in both sub-scales.  
Since walking is an active function it was included in the active function sub-scale but 
could have been included under passive function.  This is because the influence of the 
arm on walking is usually passive in the form of increased spasticity or associated 
reaction due to the effort of walking.  The upper limb can impact on walking and 
balance either because expression of spasticity increases due to effort and therefore 
alters the posture of the body, or because it acts as a weight with no active movement 
which can also alter posture.   
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Following rotation, PCA indicated this item, to be closest to the passive function sub-
scale than the active function sub-scale (see Figure 7.7; page 221; item a81).  This item 
was the third lowest performing item following Mokken analysis of the active function 
sub-scale (item 8; see Table 7.18; page 223).  However, the active function sub-scale 
evaluation, was limited due to the ceiling effect in this sub-scale and will require further 
evaluation.   
 
The ArmA is a measure of difficulty with passive and active function.  This is more 
straightforward for the passive function sub-scale, where measurement is confined to 
the affected upper limb.  However for the active function sub-scale some items are 
unimanual, other items are bimanual, and the impact of hemiplegia may change what is 
normal function for the patient.  Although a reflective measure of difficulty with active 
function is still produced, the unaffected upper limb may carry out some tasks 
unilaterally, particularly if this limb is dominant.  This will result in some items scored 
as having ‘no difficulty’ by being performed by the unaffected limb, while performance 
of the task by the affected limb is not possible.  Measuring overall difficulty with active 
function provides a true indication of function, but individual items are not reflecting 
only the performance of the affected upper limb.  An additional question has therefore 
been added to the active function questions to ask if the affected limb carries out each 
item or if it is done by both limbs (see Appendix 22).  Understanding which limb is 
used when performing each item is useful from a clinical perspective for treatment 
planning rather than measuring overall difficulty with active function and may enable 
additional analysis for research.  The instructions were not just changed to allow use of 
the affected limb only, because ArmA is a measure of function not just affected arm 
use. 
 
Following this evaluation of the ArmA, one previously excluded passive function item 
has been identified which merits further consideration regarding its place in the 
measure.  During item reduction, ‘cleaning around the affected elbow’ was removed 
during the first round of Delphi consultation.  This item was removed on the 
recommendation of eight members of the consultation group because the item was 
possibly not fully understood.  However, from a clinical perspective ‘Ease of elbow 
crease hygiene’ continued to be set as a goal for participants in the cohort study (n=6).  
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Based on this finding, consideration could be given to including this item in the passive 
function sub-scale and evaluating the scaling properties of the modified measure.  This 
finding emphasises the need for a multi-modal approach to item reduction, which could 
have been strengthened by further referring to the goals of clinical intervention before 
psychometric testing. 
 
Additional work might also be explored in the future to ensure that dimensionality and 
measurement structure of the ArmA remain consistent across time points rather than just 
the baseline time point.  This has particular relevance if the measure is to be used for 
before and after intervention studies as is proposed with ArmA.  Using a latent variable 
model (LVM) this could be addressed by examining longitudinal construct validity and 
one method to evaluate it would be reviewing the factorial structure of the ArmA at the 
different time points using confirmatory factor analysis.  An alternative approach using 
IRT would be the application of Rasch analysis examining differential item functioning 
at each time point. 
 
Another issue highlighted during the ArmA development and evaluation is the 
complexity of scoring the passive function sub-scale and the possible effects on 
dimensionality and validity.  The passive function sub-scale may be scored by the 
patient alone (if they undertake all tasks), the patient and carer in combination (if tasks 
are undertaken in combination) or the carer alone (if only the carer is involved in 
carrying out the tasks).  This presents difficulties because patient and carer information 
may be different and an alternative approach would be to collect two scores (patients 
and carers).  However, in many instances both patient and carer are involved in carrying 
out the task and a single score to represent the tasks difficulty is desirable for analysis 
and comparison.  A combined score may actually also be more representative of the 
manner in which the task was completed.  The combining of the score could be 
considered to be creating a further dimension giving a possible three (patient completed, 
carer completed and combined completed).  This issue deserves further exploration in 
future work. 
 
In practice, in this thesis, a pragmatic approach has been taken with scoring of the 
ArmA by the person or persons carrying out the task.  Use of a simple solution in this 
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manner is important for clinical utility, but future work is needed to consider the 
relationship between these different scores in greater depth.  Possible methods could be 
confirmatory factor analysis and correlations between the two (or three) sets of scores 
(patient completed, carer completed and combined). 
7.6.1.3 Internal consistency 
Cronbach’s alpha for the passive function and active function subscales showed high 
internal consistency.  A theoretical risk of item redundancy was presented by the results 
for internal consistency in the active function sub-scale, with reference to the 
recommendations of Terwee and colleagues (Terwee et al. 2007).  However, as referred 
to in the results this issue appeared to be related to the ceiling effect seen in the study 
group in the active function scale. 
7.6.1.4 Test re-test reliability (Reproducibility) 
Test–retest reliability after 24 hours used quadratic-weighted Kappa and produced a 
positive rating for reliability conforming to the recommendations of Terwee and 
colleagues (Terwee et al. 2007).  Test re-test reliability was adequate with sufficient 
power to provide an indication of the reliability of the active and passive sub-scales.   
 
An evaluation of the clinimetric properties of the MAL was undertaken by van der Lee 
and colleagues for the assessment of arm use in hemiparetic patients (van der Lee et al. 
2004).  The evaluation assessed both the 26-item and 14-item MAL but only the 14-
item version results were reported.  Internal consistency was evaluated using 
Cronbach’s alpha and test re-test reliability was evaluated using a two week time 
interval during which no change was expected using the Bland and Altman ‘limits of 
agreement method’ (Bland and Altman 1986).  The Bland and Altman method, unlike 
weighted Kappa used for ArmA, is designed as a measure of absolute agreement for 
interval data.  A fundamental weakness in using this method is that it is a parametric 
approach, requiring interval level measurement, which has not been established for the 
MAL items.   
 
Uswatte and colleagues examined MAL-14 reliability in two groups of patients in two 
separate studies evaluating CIMT (Uswatte et al. 2005).  Cronbach’s alpha was used as 
in ArmA evaluation, for internal consistency and indicated that MAL-14 was internally 
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consistent.  Test re-test reliability was evaluated using Pearson correlation, which is 
considered by Terwee and colleagues to be insufficient because systematic differences 
are not taken into account.  Pearson correlation will therefore usually produce ratings 
higher than actual reliability calculated using other methods.  The evaluation of test re-
test reliability in ArmA using the weighted Kappa coefficient is a more robust method 
of demonstrating test re-test reliability and is supported by both Terwee and colleagues 
and Streiner and Norman (Streiner and Norman 2003; Terwee et al. 2007).   
7.6.1.5 Responsiveness to change 
A significant difference was seen between responder and non-responder groups in 
ArmA passive function but not in ArmA active function nor in LASIS, Barthel Index or 
DASH.  Preliminary effect sizes (ES) and standard response means (SRM) were 
calculated for the ArmA, to enable comparison with the other measures.  Calculation of 
ES and SRM was undertaken with the acknowledged limitation of not having 
established interval scaling.  The ESs and SRMs were greater for the ArmA sub-scales 
(passive 0.29 and 0.30 and active 0.21 and 0.16 respectively) than for the other 
measures.  However, these results for the ArmA were still relatively low.  The values 
for the ArmA active function sub-scale are explained by the lack of changes seen or 
expected in the study group as a whole.  However the results for the passive function 
sub-scale are disappointing and require further exploration once interval scaling has 
been established using Rasch analysis for the ArmA in a larger study population. 
 
The difference in responsiveness, (ES and SR) between the LASIS and the ArmA is 
surprising since they both contain a number of similar passive function items.  However 
there are also different items in the ArmA and the LASIS.   The LASIS total score also 
incorporated both the carer and the patient score in this analysis and may have led to 
confusion between patients and carers regarding who should be completing items, 
having already completed the ArmA in some cases.  Patients and carers were not 
specifically asked about their understanding of LASIS completion so it is difficult to 
determine if this was the case.  One issue with LASIS that may also have made a 
difference was asking the patient or carer if the particular item was difficult with a 
yes/no response before rating the item on the scale.  This appeared in some instances to 
lead patients and carers to say that an item was difficult but then not completing the 
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scale resulting in missing data.  Patients and carers may also have indicated that an item 
was not at all difficult, when in fact it was mildly difficult in some cases. 
 
The approach taken of comparing change in the ArmA with an overall rating of 
response to intervention by clinicians is similar to that taken by other authors e.g. van 
der Lee et al. 2004.  Responsiveness to change in MAL-14 was also evaluated by van 
der Lee and colleagues by comparing change with that in ARAT and a global rating of 
change (GRC) by patients after two weeks.  No significant positive correlation was 
found between MAL-14 and ARAT or GRC.  The approach taken in evaluation of 
responsiveness was similar in the ArmA with rating of response by clinicians compared 
with change demonstrated by the ArmA.  The ArmA and LASIS (passive items) in BTX 
intervention, measure very similar functional issues, while MAL-14 and ARAT measure 
patient-reported every day function and clinic-performed functional tasks respectively.  
While a relationship should exist between every day function and functional tasks 
performed in a clinic, differences will also be present (as discussed in Chapter 1), which 
may account for the lack of correlation observed in the van der Lee study (van der Lee 
et al. 2004).  
 
Responsiveness of the ArmA measure has been evaluated for the passive function sub-
scale but evaluation of the active function sub-scale is needed in a patient group 
showing change in this domain.  Qualified support is provided for passive function 
responsiveness, but this requires further evaluation in future work. 
7.6.1.6 Interpretability 
A significant difference was identified between responders and non-responders for the 
passive function sub-scale and therefore MIC was calculated.  However, interval scaling 
has not been demonstrated for the ArmA and will need further evaluation in future 
stages of development and evaluation.  A change of two or more points on ArmA, was 
deemed a preliminary indication of clinical significance taking into account calculations 
of MIC and evaluation of sensitivity and specificity.  Absence of change in the active 
function sub-scale was expected once initial data collection had begun, due to the lack 
of active function goals for intervention in this sample. 
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The establishment of MIC for the passive function sub-scale is important in using the 
ArmA in clinical practice to indicate meaningful change following intervention and 
enabling decisions about clinical effectiveness.  The MIC will need to be further 
explored in the ArmA once interval scaling properties have been established using 
Rasch analysis before a figure can be effectively applied. 
7.6.1.7 Feasibility 
If measures are to be applied in clinical practice they must be practical to apply in the 
setting in which they will be used.  Feasibility is concerned with ensuring that outcome 
measures can be both practical to use in routine practice and retain their psychometric 
properties (Slade 2002b).   
 
Some limitations arise from assessing feasibility as a component of a psychometric 
study.  A psychometric study uses a design to allow evaluation of the measure or 
includes this evaluation within another research study, while feasibility by definition 
should be evaluated in normal clinical practice.  The ArmA evaluation required a 
research design but this was applied in normal clinical practice situations for spasticity 
intervention.  Patients were receiving standard treatment and the evaluation of 
feasibility in this context was adequate.  However, limitations do arise from this 
compromise between normal clinical practice and the need to present the ArmA 
alongside a number of other measures in the questionnaire pack.  Feasibility evaluation 
in a non-experimental patient group would confirm the current feasibility findings.  
More detailed evaluation of feasibility could have been useful, but given the burden of 
the questionnaire pack (including the ArmA, LASIS, DASH, Barthel Index and the 
feasibility questionnaire), it was decided not to increase the size and complexity of the 
feasibility questionnaire further. 
 
The psychometric evaluation of the ArmA has been discussed and compared with 
findings for MAL, ABILHAND, LASIS and DASH.  Table 7.35 provides a summary of 
the quality of the psychometric properties of these four (including four versions of 
MAL) measures.  
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Table 7.35 Comparison of psychometric evaluation for the ArmA with the MAL, ABILHAND, LASIS and the DASH. 
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Following development and psychometric testing, the ArmA preliminary findings have 
been inserted into the theoretical hierarchy of measurement items produced following 
the systematic review.  The insertion of the ArmA into this hierarchy enables 
comparison of items with those in other measures.  The ArmA measure items overlap 
with the LASIS and include many of the same passive function items.  It also has items 
in common with all four versions of the MAL and has some items in common with the 
ABILHAND, but does not cover the most complex upper limb tasks (see Table 7.36).   
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Table 7.36 Comparison of items in the ArmA with those from the systematic 
review 










Passive Function Items 
Cleaning the palm affected hand 1 1      
Cutting fingernails affected hand 2 2  25*   4* 
Cleaning the affected elbow  3       
Cleaning the affected armpit  4 4      
Cleaning the unaffected elbow 5       
Putting arm through coat sleeve  6 5 1* 1*    
Difficulty putting on a glove  7 3      
Doing physiotherapy exercises to 
arm 
9       
Put on a splint  6      
Position affected arm comfortably  7      
Active Function Items 
Difficulty rolling over in bed 8       
Difficulty balancing standing  10       
Difficulty balancing walking 11 15      








    10
a 
Steady myself while standing   2 2    
Carry an object from place to 
place 
  3 3 23 12  
Pick up fork or spoon, use for 
eating 
 13 4 4 24 10  
Comb hair  18 5 5 25   
Pick up cup by handle   6 6 26 11  
Hand craft/card playing   7 7    
Hold a book for reading   8 8    
Use towel to dry face or other 
body part 
  9 9    
Pick up a glass  9 10 10 20 5  
Pick up toothbrush and brush 
teeth 
 19 11 11 21 6  
Shaving / make-up   12 12    
Use a key to open a door  10 13 13 22 7  
Letter writing/typing  11 14 14  8  
Poor coffee / tea    15    
Peel fruit or potatoes    16   3 
Dial number on the phone  16  17    
Open / close a window    18    
Open an envelope    19    
Take money out of a wallet or 
purse 
   20    
Undo buttons on clothing    21    












Undo a zip    23    








Other optional activity    26    














Tuck in a shirt/blouse  17      
Drink from a cup or mug  20      
Turn on a light with a light switch     1   
Open a drawer     2   
Remove item of clothing from 
drawer 
    3   
Pick up phone     4 1  
Wipe kitchen counter     5   
Get out of car     6   
Open refrigerator     7   
Open a door by turning a door 
knob 
    8 2  
Use a TV remote control     9   
Wash your hands     10   
Turn water on/off with faucet     11 4  
Dry your hands     12   
Put on your socks     13   
Take off your socks     14   
Put on your shoes     15   
Take off your shoes     16   
Get up from chair with arm rests     17   
Pull chair away from table before 
sitting 
    18   
Pull chair toward table after 
sitting 
    19   
Eat half a sandwich or finger food     28 3  
Use removable computer storage      9  
Hammer a nail       1 
Thread a needle       2 
Wrap gifts       5 
File nails       6 
Cut meat       7 
Peel onions       8 
Shell hazel nuts       9 
Open pack of chips (crisps)       12 
Sharpen pencil       14 
Spread butter       15 
Fasten ‘snap’ (press-stud)       16 
Take the cap off a bottle       18 
Open mail (post)       19 
Squeeze toothpaste       20 
Unwrap chocolate       22 
Wash hands       23 
Key:  
Items in the table are given the number at which they appear in order in the measure. 
Items in the LASIS and the ArmA included under passive function all asked respondents ‘how difficult’ a 
task was to undertake related to care of the limb by the patient him or herself or a career. 
* Items in the passive function section included in MAL-14, MAL-26 or ABILHAND could be done 
either passively or with more active involvement by the individual, with the focus being on active 




 refer to specific objects used for the functional items in a measure. 
 




7.6.2 Evaluation of functional change: A cohort study 
The application of the ArmA during the cohort study identified a small but significant 
improvement in passive function at 8 weeks, which was maintained at 16 weeks (see 
Table 7.33; page 237).  Change in passive function was also confirmed by LASIS.  
Passive function change corresponded with an initial decrease from baseline in 
spasticity recorded by MAS by 8 weeks followed by an increase in spasticity by 16 
weeks.  The reason for the implied maintenance of functional benefit in the presence of 
an increase in spasticity is not entirely clear, although the most plausible explanation is 
that PT intervention used in conjunction with BTX may be responsible.  Two other 
possible reasons for the results include; a) natural improvement over the period of BTX 
action in spasticity or b) inaccuracies in measurement of either function or spasticity.  It 
is unlikely that natural improvement in spasticity would occur over the 16-week period 
of the study, because this is a relatively short period in which to expect spontaneous 
improvement in spasticity presentation, which is not acute.  Natural improvement also 
does not explain the re-increase in spasticity (measured by MAS) seen at 16 weeks.  
Measurement inaccuracy is a possibility, but is also unlikely given the consistent pattern 
produced in a majority of participants and the concurrence between the ArmA and 
LASIS in function.   
  
The study has also demonstrated that the ArmA is able to identify change following 
intervention, which was not detected by the other measures used with the exception of 
LASIS for the overall analysis.  The LASIS passive function items demonstrated change 
when the Friedman test was applied overall, but not for the individual analysis at 8 and 
16 week outcome points.  The ArmA did however show significant differences between 
baseline and 8 and 16 weeks as well as differentiating responders and non-responders in 
the responsiveness evaluation unlike the LASIS.  These findings provide modest 
support for the use of the ArmA as a more responsive measure following focal spasticity 
intervention, than the other measures applied.  Utility of the ArmA seemed acceptable, 
in this preliminary evaluation, and in the context of being able to detect change, its 
further evaluation is supported. 
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The results of the cohort study also seem to indicate a trend to greater improvement in 
passive function towards 16 weeks from that seen at 8 weeks.  This pattern of 
improvement has been observed by other authors, such as Francis and colleagues, who 
identified maximal improvements in passive function occurring at some time after 
maximal improvements in spasticity in some patients (Francis et al. 2004).  One 
possible reason for the delayed improvement in passive function is the need for time for 
the PT interventions to take effect.   
7.6.2.1 Significance of passive function improvement 
Other authors have also identified sustained improvement in passive function following 
treatment with BTX and PT.  In a recent study by Shaw and colleagues a combination 
of BTX and PT interventions were applied (Shaw et al. 2010).  The experimental group 
received BTX and PT.  The control group received PT alone.  PT consisted of a 
stretching programme for all participants and a task-training programme for participants 
with an Action Research Arm Test (ARAT) score above four.  Spasticity was reduced in 
the intervention group at one month, but not 3 or 12 months compared to the control 
group.  Differences in active function improvement between the groups were not 
identified.  However, improvements were identified in individual passive function tasks 
at one, three and 12 months.  These results support the findings of the current cohort 
study in identifying a pattern of maintained improvement following BTX with the 
application of a PT maintenance programme.  Passive function improvement was not 
the primary outcome in this study and these improvements were therefore not 
emphasised in the findings.  Nevertheless improvements in passive function were 
significant and the focus on active function in this study illustrates the over emphasis 
active function improvement often receives in the literature and practice. 
7.6.2.2 Physical therapy interventions 
Specific evaluation of PT intervention in combination with BTX has been limited (see 
Chapter 1; section 1.3), and therefore comparisons of the cohort study with other work 
are restricted.  The following two studies are however briefly discussed in relation to the 
findings.   
 
Giovannelli and colleagues, in their randomised controlled trial with multiple sclerosis 
patients, identified that improvements in Modified Ashworth scores were significantly 
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greater in patients receiving physiotherapy than those who were not (Giovannelli et al. 
2007).  Unfortunately, the actual PT interventions are not specified in the reporting of 
this study.  The results from Giovannelli and colleagues have similarities to the findings 
in the cohort study, with spasticity maintained in their work until 12 weeks in the 
experimental group and in this cohort study until 16 weeks.   
 
Carda and colleagues undertook a case control study in patients who all had BTX 
intervention, investigating application of adhesive strapping of the wrist and fingers 
compared with electrical stimulation combined with a resting splint (Carda and Molteni 
2005).  This study again demonstrated a similar pattern of change in spasticity to that 
identified in this thesis.  Since Giovannelli et al (2007) and Carda and Molteni (2005) 
do not record changes in any measure of function, the timing of change in spasticity and 
in function cannot be compared.  
 
7.6.2.3 Recording of physical therapy intervention 
The study has also enabled the initial development of a system for recording PT 
interventions in a clinical practice setting for focal spasticity management in the upper 
limb.  This preliminary system of recording could now be formally refined, evaluated 
and compared to other similar classification systems developed, for example that by 
Donaldson and colleagues (Hunter et al. 2006; Donaldson 2007; Donaldson et al. 2009) 
and De Wit (De Wit et al. 2007).  However the complexity of constructing and 
developing treatment schedules should not be underestimated as emphasised in the work 
of DeJong and colleagues (DeJong et al. 2004; DeJong et al. 2005; Gassaway et al. 
2005) and emphasised by Jette in a commentary on the conclusions drawn from the 
work (Jette 2005).  The recommendation of developing a treatment schedule echoes that 
by the recently published botulinum toxin: international consensus statement (Sheean et 
al. 2010).  Further strengths, limitations and implications of the cohort study are 
discussed in Chapter 8. 




7.6.3 ArmA evaluation strengths and limitations  
Limitations in the study were;  
a) ceiling effects in the study population for active function;  
b) sample for psychometric evaluation  
c) feasibility evaluation within a psychometric study.   
 
However important strengths have been identified in; 
a) the resulting measures evaluation of passive function;  
b) the initial evaluation of feasibility and  
c) the potentially low burden for patients of completing the 
measure. 
7.6.3.1 Ceiling effects for active function 
The active function sub-scale could not be fully evaluated because of the limited 
changes in active function occurring in the main study group (Group 1).  This 
necessitated the addition of Group 2 to evaluate test-retest reliability and internal 
consistency of the active function sub-scale.  Ceiling effects may be a characteristic of 
the scale or may be a result of targeting the scale at a population, which is unlikely to 
change in the domain measured.  The ArmA has two sub-scales designed to address the 
second of these potential problems, with the knowledge that the majority of patients 
make passive function improvements, but a small minority also improve in active 
function (McCrory et al. 2009). 
  
The study population as a whole had very limited arm function, therefore ceiling effects 
occurred in the active function sub-scale.  Possible reasons for this ceiling effect might 
be that items in the active function sub-scale were too difficult and that all the items 
have a similar level of difficulty.  However, these explanations do not fit with the other 
information collected.  Goal setting for the majority of patients did not include active 
function goals indicating that improvement in active function for these patients was 
unlikely.  In addition, the clinical examination recorded for these patients did not record 
improvements in active function or selective movement following intervention.  As 
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these patients have very limited active function, the ceiling effect does not therefore 
necessarily indicate a deficit in the measure.   
 
Conceivably, if patients were very able a floor effect might be seen for difficulty in 
passive function with none of the passive function tasks being perceived as at all 
difficult (i.e. ceiling effect in passive function).  These actual ceiling and possible floor 
effects are the reason for the construction of the ArmA in two distinct sub-scales to 
capture this information.   
 
It might be argued, that given the very small number of participants improving in active 
function, measurement of active function following spasticity management intervention 
is not appropriate.  However, this would lead to an inability to detect improvement in 
active function in the small number of patients who do improve in this dimension.  
Improvements in active function are multi-factorial, involving not only management of 
focal spasticity, but also for example task specific training.  Nevertheless focal 
spasticity intervention may be a component in the overall improvement seen in a small 
minority of patients (rather than passive function improvement in the majority 
undergoing spasticity intervention) and recording this is therefore of clinical 
importance. 
7.6.3.2 Sample 
An overall limitation of the psychometric evaluation, was the sample size.  The sample 
size achieved (n=92), was smaller than the target of 100 participants identified at the 
outset of the study.  As discussed in section 7.3.1 (page 191), sample size for PCA is not 
clear.  However, the target for sample size based on currently available evidence was 
not met.  Future work should focus on increasing the participant numbers used for these 
evaluations to confirm the preliminary findings.  Despite this limitation, the passive 
function sub-scale psychometric properties have been evaluated as planned at the start 
of the study. 
 
The psychometric evaluation group (as with the goal setting analysis), were younger 
than the common age range associated with a general stroke population (mean age 
44.5).  However, these mean ages did reflect the age range of patients seen in specialist 
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rehabilitation services and the mean age of patients from the two services used for 
recruitment.  The age range in the development and evaluation groups used may reflect 
a theoretical limitation.  The practical implications however, are likely to be limited due 
to the significant disability in the psychometric study group (Barthel Index 7) and 
inclusion of patients with both significant communication issues and cognitive 
impairment, which are likely to be more important factors than chronological age. 
 
7.6.3.3 Feasibility 
Feasibility in this evaluation was focused on patients and carers who are the users of the 
measure.  Patients and carers were prioritised as the most important and appropriate 
sources of data.  Although the views of clinicians were obtained during the ArmA 
development and were used extensively in item reduction and confirmation.  They were 
not sought again formally during the testing of the ArmA.  Views from professionals 
may have been valuable in considering the impact of the ArmA in practice from the 
clinician’s perspective.  These data are currently being collected in the ongoing 
evaluation of the ArmA in clinical practice. 
7.6.3.4 Low burden of ArmA for patients, carers and clinicians 
In busy clinical environments, clinicians may be concerned that an additional outcome 
measure will add to their workload.  Previous work in patient reported outcome 
measures (Greenhalgh et al. 2005) and standardised measures in general practice 
(Meadows et al. 1998) have emphasised that introduction of outcome measures into 
practice require clinicians to have ownership of the use of such measures.  These studies 
also emphasise the need for measures to be feasible for use in clinical practice settings 
to ensure that they are acceptable to clinicians.  This is where patient reported outcome 
measures, such as the ArmA, have a potential strength by having a low impact on 
clinician time.  In the ArmA, the burden on patient and carers is also low.  This should 
ensure that it can be applied in routine practice for spasticity management as well as 
research.  In a previous survey of practice, routine use of outcome measures by clinical 
teams for spasticity management was shown to be variable (Turner-Stokes 2009a).   
Methods for improving use (such as the use of integrated care pathways) and self-report 
measures such as the ArmA, need to be considered. 
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7.7 Conclusions  
Based on this evaluation of the ArmA, psychometric properties of the passive function 
sub-scale were generally supported.  Further evaluation is required to confirm double 
monotonicity for ordinal scaling and to undertake Rasch analysis for interval scaling 
properties.  In light of the scaling limitations of this evaluation of the ArmA, further 
work to examine responsiveness and MIC will be needed for the passive function sub-
scale once fundamental measurement properties have been demonstrated.   
 
The active function sub-scale suffered from a ceiling effect in this group of patients with 
generally severe spasticity and disability.  Further evaluation of this sub-scale in a 
different group is indicated to evaluate all measurement properties, but in particular the 
scaling ability (ordinal and then interval) of this measure.  Evaluation may be needed, in 
particular for responsiveness, in a non-spasticity intervention group to gain sufficient 
data to fully evaluate the active function sub-scale. 
 
The ArmA can be completed by self-report as well as structured interview, making it 
useful for completion and return by post following clinic visits with a potentially low 
burden on clinician’s time.  The passive function sub-scale is now appropriate for 
preliminary application in clinical practice, however the active function sub-scale needs 
further evaluation before it is applied more widely. 




Chapter 8 Thesis discussion, future work, and conclusions 
8.1 Summary of findings 
The major components of discussion for the different strands of this thesis (systematic 
review and patient identified items, ArmA development, psychometric testing and 
cohort study) have been located in the relevant chapters.  This final chapter offers an 
overview of the key findings, general strengths and limitations of the thesis as a whole 
as well as methods and analytical techniques.  Plans for future research and possible 
methods for addressing the limitations in this thesis are also proposed.   
 
The clinical challenge leading to the development of this thesis involved re-
conceptualisation of measurement of upper limb function following spasticity 
management from the perspective of patients and carers.  A challenge arises from the 
need to measure passive and active function particularly in the context of everyday 
activities of relevance to focal spasticity intervention in the upper limb.  Self-report 
measures are a means of capturing the impact of intervention from the perspective of the 
individual in the context of their normal lives and also offer the possibility to obtain 
follow-up information at a distance. 
 
This thesis has made the following three key contributions to knowledge:   
 
Measurement 
The complexities of measurement have been explored in the context of variables that 
are not directly observable.  The need to establish clear dimensions as a basis for 
measurement has been addressed in this work and the clinically conceived dimensions 
of active and passive function have been supported.  Ordinal scaling of the ArmA 
passive function sub-scale has been partly evaluated, with further work identified in 
terms of ordinal scaling and in due course interval scaling using the Rasch analysis 
method. 
 
Additive conjoint measurement was discussed in this thesis and the need for 
measurement tools of latent variables to meet these requirements was established.  
However, the application of classical test theory approaches, latent variable methods 
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and an item response method to establish ordinal scaling, have been identified as useful 
preliminary steps in measure development and evaluation.  These methods result in a 
measure with partially established psychometric properties and a clear indication of 
current limitations and need for future work. 
 
Active and passive function 
The ArmA is a two-dimensional tool with two sub-scales evaluating active and passive 
function in the context of focal spasticity intervention.  The concept of difficulty with 
upper limb functional tasks has been applied in a self-report tool, capturing the patient 
and carer perception of upper limb passive and active function limitation due to 
spasticity.  While the concept of difficulty has introduced challenges, it has been 
successful in the central aim of recording a patient and carer perspective.  The 
combination of patient and carer scoring also has challenges, but for passive function 
has been effective in reflecting the impact for the combined patient/carer unit. 
 
The primary focus of measure development was the passive function sub-scale, which 
received the major theoretical focus.  Passive function has received limited attention in 
the literature and yet is important to evaluate in patients with hemiparesis undergoing 
focal spasticity intervention in the upper limb.  Passive function was expected to be the 
main area of improvement in the study group undergoing spasticity management 
interventions. 
 
Maintenance of passive function improvement 
The application of the ArmA during the cohort study identified that passive function 
was maintained from 8 weeks to 16 weeks post injection with BTX.  The reason for 
maintenance of functional benefit in the presence of increasing spasticity is not entirely 
clear.  One possibility is the positive effect of the physical therapy (PT) interventions 
provided in conjunction with BTX.  Other authors have identified changes in passive 
function maintained to 16 weeks and in one study up to one year following BTX 
intervention (Shaw et al. 2010).  It has also been suggested that, in some patients, 
maximal improvement in passive function may develop some time after maximal 
improvement in spasticity specifically following BTX intervention (Francis et al. 2004).  
There has been a focus on active function improvement in both clinical practice and 
Chapter 8 Thesis discussion, future work, and conclusions 
 
 263 
research (see Shaw et al 2010).  The cohort study has provided additional evidence that 
it is largely passive function improvements that are seen following focal spasticity 
intervention including BTX and PT. 
8.2 Strengths and challenges 
Overall, the work in this thesis has major strengths in addressing the challenges of a 
different approach to measurement of functional outcome in the hemiparetic arm 
following focal spasticity intervention.  The approach has been to re-conceptualise 
activity into passive and active function and evaluate against overall difficulty of 
everyday performance.  The following section (8.2.1) will initially discuss the strengths 
and challenges related to the methods and analytical techniques used in this thesis.  
Then in Section 8.2.2 the strengths and challenges that relate to the findings will be 
discussed. 
8.2.1 Strengths and challenges of the methods and analysis 
A systematic approach was used in developing the ArmA by applying a structured 
method of combining findings from the literature with findings from clinical practice 
(Chapters 4 and 5).  Consensus techniques were used to combine and confirm literature 
and practice findings in the selection of items.  A psychometric evaluation was 
subsequently applied to the resulting measure; evaluating distinct properties and using 
classical test theory as well as latent variable and item response techniques.   
8.2.1.1 General strengths 
The multi-methods approach, evidenced above, is a strength of this thesis and has 
allowed cross-confirmation of measurement properties giving increased rigour to the 
process.  A further strength comes from the use of reported ‘difficulty’ in passive 
function as a model for outcome evaluation.  The theoretical approach of recording task-
difficulty in function has been used in contrast to some existing measures, but in 
common with others such as DASH or LASIS.  Many measures administered at clinic 
appointments assess standardised versions of functional tasks (e.g. the Action Research 
Arm Test (Koh et al. 2006)) and, in some measures, items assessing function are mixed 
with those assessing impairments (e.g. the Motor Club Assessment (Wade 1992b) page 
147).   
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In the ArmA rather than an observer assessing individual task performance, patients 
(and/or carers) are asked to rate difficulty.  This approach has been used by other 
authors in the field e.g. (Bhakta et al. 2000a) and has particular relevance to passive 
function.  Passive function tasks are not necessarily performed by the patient, but can be 
performed by patient or carer.  As tasks are not active, difficulty in task performance is 
a particularly relevant concept.   
8.2.1.2 General challenges 
However, a challenge in this thesis has been evaluation of difficulty in active function.  
While the concept of difficulty works well in passive function, it does not apply as 
easily to active function, although it has been used in active function measures such as 
ABILHAND (Penta et al. 2001) and MAL (Uswatte et al. 2005).  When specifically 
related to the affected upper limb, measurement of active function may be complicated 
by both performance of bimanual and unimanual tasks and hand dominance (Jones 
1990; Alon et al. 2003).  A development following the psychometric evaluation is to 
record difficulty in active function for all items regardless of which limb is used 
(affected or unaffected).  Patients and carers are then asked to indicate for each task the 
limb used or that it was undertaken using both limbs.  The revised version of the ArmA 
is presented in Appendix 22.   
 
The modification to scoring the active function sub-scale should make the ArmA 
conceptually easier for patients and carers to complete.  It is still possible to review how 
 individual items change even if this involves a change of limb completing the task, for 
example as an affected dominant limb improves in active function.  Further evaluation 
will be required of the revised measure. 
 
Another challenge identified in Chapter 7 (Section 7.6.1.2; page 243-246), was the 
complexity of scoring the passive function sub-scale and possible effects on 
dimensionality and validity.  The passive function sub-scale may be scored by the 
patient alone, the patient and carer in combination or the carer alone (if only the carer is 
involved in carrying out the tasks).  This presents difficulties because patient and carer 
information may be different.  However, in many instances both patient and carer are 
involved in carrying out the task and a single score to represent the tasks difficulty was 
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decided upon because it more fully represented reality for patients and carers.  This 
issue deserves further exploration in future work. 
 
8.2.1.3 Strengths and challenges of development and psychometric evaluation  
The following section will discuss the strengths and challenges encountered during the 
development of the ArmA and its psychometric evaluation.   
  
Item Generation 
The use of the literature to generate items for possible inclusion in the ArmA, has 
strengths in utilizing the work of others evaluating upper limb function.  Items identified 
in this way are more likely to have face and construct validity.  However, as identified 
in the systematic review, all of the existing measures, excluding LASIS, address only 
active function.  This process is therefore unlikely to identify many passive function 
items.  The review of goals for focal upper limb spasticity intervention aimed to redress 
this imbalance because mainly passive function goals are set in this area.   
 
The use of the systematic review produced a large pool of active function items.  
However this approach risked reflecting the accepted wisdom and in particular may be 
prone to reflect the items identified by clinicians rather than patients and carers (Lomas 
et al. 1987).  Much discussion has been undertaken related to active function 
improvement specifically following BTX administration for focal spasticity (Bakheit 
2004a; Bergfeldt et al. 2006; Shaw et al. 2010).  However to date, improvements have 
generally been in passive function, with only a small minority of patients showing 
active function improvement with focal spasticity intervention including BTX (Shaw et 
al. 2010).  While measuring active function still seems important for detecting change in 
those patients who do make improvements in this area, passive function improvement is 
most relevant to measure for the majority of participants. 
 
The goal-setting review identified only two additional items, which were both passive 
function.  However, it enabled the confirmation of other items identified from the 
literature; all but one of these were passive function.  This analysis included goals set 
with a relatively small group (n=16) and could have been expanded further to explore 
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other items set as goals in this area.  To address the lack of active function goals, 
purposive sampling could be employed to identify more active function items, possibly 
in participants undergoing different focal interventions.  However, if applied in 
spasticity intervention, given that active function goals (as demonstrated by both the 
goal analysis and cohort study in this thesis) are set so infrequently, even this approach 
is unlikely to identify a large number of relevant new items.   
 
Other methods of item generation could have been applied, such as focus groups or 
interviews and have been discussed in Chapter 3.  However, the advantage of the goal 
setting analysis, came from focusing on the particular area of investigation, avoiding the 
problems associated with group interactions in eliciting patient and carer perspectives.  
Disadvantages include the clinician potentially influencing the patient in the goal setting 
process (Reed and Roskell-Payton 1997), and lack of reflection of a larger patient group 
in considering items (goals may be specific to that individual).  The sample reflected the 
patient population in specialist neurological rehabilitation services.  However, it may 
not be as relevant to other groups (e.g. an older post stroke population), and further 
evaluation will be required to determine applicability of the ArmA in other populations 
in which it may be used.  The restriction of goals to a very specific area for upper limb 
spasticity management, may have limited identification of active function items in 
particular.  However, this is balanced against the limited active function goals set in this 
area and the large number of active function items identified from the literature. 
 
Passive function items were identified in the literature, but only from one measure, the 
LASIS.  The goal setting analysis identified additional items, but only two.  This may 
result in very similar items for the passive function sub-scale, which may be more 
appropriate to the formation of a clinical ‘check-list’ rather than a measure due to the 
possibility of similar difficulty of the items.  A related issue is that clinical presentation 
of spasticity may vary between individuals and therefore the items that change 
following intervention may also vary.  This raises the issue of whether the ArmA is a 
clinical ‘check-list’ rather than a measurement scale.  While an individual patient’s 
clinical presentation can certainly vary, consistent problems do arise as evidenced in the 
goal-setting analysis and the subsequent goals set in the cohort study.  The item 
generation methods used have attempted to obtain the important items relevant to 
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passive function.  Other methods of item generation, as already discussed, could have 
added to this process for passive function.  Nevertheless, passive function items have 
been explored in some detail for dimensionality using two methods and the initial 
indication from preliminary Mokken analysis for scaling is that an ordinal scale is 
apparent. 
  
Item reduction – Delphi consultation 
Item reduction may take different forms, but in this thesis Delphi Consultation was used 
to obtain opinions of experts to identify the most important items reflecting the 
construct.  The Delphi consultation (three rounds of consultation) group consisted of 
clinicians and was then followed by a wider consultation to confirm the findings with a 
different and larger group of clinicians as well as patients and carers.  As discussed in 
Chapter 6 a possible limitation of prioritising the items using the Delphi process and 
wider consultation is that a set of items with a similar degree of difficulty may be the 
result, limiting the range of the scale.  While items measuring the same construct or 
dimension are desirable, if the items also have similar difficulty, a potential limitation to 
the breadth of the hierarchical scale may occur.  In this situation, items instead of 
forming a wide scale may cluster around one particular area of the dimension.  
However, preliminary evaluation of the ArmA indicates that it forms an ordinal scale.  
Passive function items for the upper limb also evaluate a relatively focused issue and 
therefore concerns over the breadth of the scale are likely to be more theoretical than an 
actual limitation.  
 
Ceiling effect 
In this thesis, for active function, the focus was on identification of items, which had 
low to moderate difficulty with fewer higher function items.  A ceiling effect was 
observed in the active function sub-scale during the evaluation.  One interpretation of 
this finding is that the active function items are still too difficult for the population 
tested (i.e. easier items may have detected change).  However, given that active function 
goals were set in a very limited number of participants, a more plausible explanation is 
that active function was not possible for the majority of the study group (i.e. the 
majority of participants were unable to perform active function).   
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The probability that the ceiling effect is a feature of the study population raises the 
question of whether the ArmA active function sub-scale is ‘well-targeted’.  Linacre has 
argued that if many patients are at the margins of a scale, then the measure should be 
considered not well targeted (Linacre 1994).  The implication is that either a larger 
study sample will be required to confirm measurement properties or better targeting of 
the measure to the sample will be needed to evaluate the measure.  Pallant and Tennant 
(2006) have emphasised the need, particularly in clinical practice, to ensure that 
measures are appropriately targeted at the population being assessed.  Good targeting is 
therefore seen as important for good measurement, as well as evaluation of such 
measures (Hagquist et al. 2009).  However, the very reason for construction of the 
ArmA with two sub-scales is to ensure that items are appropriately targeted at passive 
function, but that active function changes are recorded if they occur.  This may in part 
explain why, despite the lack of active function change in the study population, 74% of 
patients and carers valued the inclusion of the active function sub-scale. 
 
As already discussed in Chapters 1 and 7, while for the large majority of patients only 
passive function change will occur; for a small minority active function changes also 
take place.  A small, but not insignificant, proportion of patients (n=4) did in fact 
change in active function, which was detected by the ArmA.  This finding both supports 
the need to measure active function and the utility of the ArmA in detecting these 
changes when they occur.  In effect, assessment of active function in a spasticity 
intervention group is acting as a screening tool to identify those patients who are able to 
perform active function from the large majority who cannot.   
 
Construct Validity 
While correlations between the ArmA, LASIS and DASH were as expected, the positive 
correlations for passive function were moderate and higher correlations might have been 
expected between LASIS and ArmA passive function items.  However, some difference 
in items occurs between the ArmA and LASIS and the scoring methods differ, both of 
which may in part account for differences between the scores.  Despite correlations not 
being as strong as expected, the construct validity of the ArmA is supported, but would 
benefit from further evaluation in future work.  Further evaluation might involve 
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longitudinal construct validity using principal components analysis (PCA) as well as 
correlations with LASIS and DASH at the other time points in addition to baseline. 
 
The cohort study demonstrated that the passive function sub-scale of the ArmA showed 
significant change between baseline and outcome at 8 and 16 weeks, which was also 
shown to a lesser extent by the LASIS passive function items using the Friedman test.  
This gives preliminary support to the longitudinal construct validity of the ArmA 
passive function sub-scale. 
 
Dimensionality 
Principal components analysis was used initially to give an indication of the key 
constructs underlying the ArmA sub-scales.  The aim of PCA is to reduce the 
dimensionality of a data set consisting of a large number of interrelated items (Jolliffe 
2002).  A possible criticism could arise with the use of PCA as opposed to exploratory 
factor analysis (EFA) in terms of the appropriateness of this method.  While the purpose 
of EFA is to explore relationships between items, the purpose of PCA is to reduce 
dimensionality in the data.  The purpose of PCA and EFA may seem contrary to each 
other, but in effect the two methods are performing a similar function.  In this 
evaluation of the ArmA, where measure development has been based around two sub-
scales, the use of PCA is an appropriate method for exploring the dimensions within the 
measure.   
 
The method of PCA has also been applied in other studies examining the dimensions 
contained in rehabilitation measures (Bedard et al. 2001; O'Rourke and Tuokko 2003; 
Siegert et al. 2010).  As in this thesis, some studies have also combined this approach 
with other methods of confirming findings, such as Mokken analysis or confirmatory 
factor analysis (Siegert et al. 2010).  The combination of methods, using both a LVM 
and IRT approach, lends strength to the findings. 
 
Scaling 
The aim when developing a scale is to enable the differentiation between people using 
the sum of the items as a summary statistic.  Differentiation and consistent ordering of 
items is also desirable to infer directly from a participant’s score, their level of function 
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in practice.  In this thesis, Mokken analysis using monotone homogeneity was explored, 
however double monotonicity only received exploratory investigation.  Double 
monotonicity was not the main focus of evaluation because of the limited number of 
participants included in the psychometric evaluation; therefore expansion of the 
numbers included in this evaluation would have been valuable.  However, the current 
analysis has provided an indication of ordinal scaling properties for the passive function 
sub-scale, which will be explored further in subsequent evaluation of the measure. 
 
The preliminary evaluation of double monotonicity undertaken, indicated that two items 
could be removed to improve upon both the dimensionality and scaling properties of the 
passive function sub-scale.  There is a possible dilemma from a clinical perspective, 
where specific items give useful clinical information, but do not ‘fit’ the construct and 
scaling demonstrated by IRT approaches.  However, if they do not fit the construct or 
fail to demonstrate scaling properties, in the context of the whole scale or sub-scale, 
they cannot form part of the measure (also see Section 3.3.3.5; page 107).  An 
alternative, suggested in chapter 3, was the retention of such items to inform the clinical 
picture if they provide particularly important clinical information, but not to form part 
of the measurement scale.  
 
Another related issue, is the possibility that the ArmA could form a checklist rather than 
a measure.  This would mean that important clinical items (e.g. axillary hygiene) are 
recorded as single items solely for the specific clinical information they provide.  In the 
case of the ArmA passive function, preliminary scaling properties have been 
demonstrated and although following further evaluation, some items might be excluded; 
measurement with the remaining items seems possible.  Both passive and active 
function sub-scales require further evaluation and in the passive function sub-scale it is 
still possible, given an increase in sample size, that removal of items will not be 
required.  Nevertheless, the ArmA appears to form an ordinal scale for passive function 
based on current evaluation. 
 
Reliability (Reproducibility)  
In this evaluation of test-retest reliability, the time interval between self-completion of 
the ArmA at baseline and completion 24 hours later with postal return was relatively 
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short.  However, it is possible that patients and carers had some memory of completion 
of the ArmA the day before.  It may have been appropriate to increase the time between 
the first and second completion of the ArmA to reduce recall from previous completion.  
However, increasing the time interval may also have resulted in a poorer questionnaire 
return. 
 
The ArmA was completed at the ‘clinic’ in the first instance and then ‘at home’ and 
returned by post.  This could constitute completion under different conditions, 
introducing a potential confound for test-retest reliability.  However, as completion was 
by self-report on both occasions this was minimised.   
 
Responsiveness 
In the psychometric evaluation, a significant difference was seen between responder and 
non-responder groups in ArmA passive function, but not in ArmA active function nor in 
the LASIS, Barthel Index or DASH.  Therefore, a significant limitation in the evaluation 
of responsiveness for the active function sub-scale was the minimal change in active 
function seen in the study group, which prevented full evaluation of this sub-scale and 
active function responsiveness in particular.  However, strengths are seen in the ArmA 
passive function sub-scale detecting a response when the other measures were unable to 
show this.   
 
The ES and SRM, as already discussed (Chapter 7; Section 7.6.1.5; page 247) are based 
on parametric assumptions and are therefore preliminary as evaluated for an ordinal 
scale in this thesis.  However, these methods were used in common with the evaluation 
of many other scales to allow comparison.  The ES and SRM were larger for the ArmA 
passive function sub-scale than other measures used, but were still moderate, which has 
also been discussed in Section 7.6.1.5.   
 
Interpretability 
Calculation of MIC using both the criterion-based method and distribution-based 
method, use mean and standard deviation and are therefore parametric methods.  As 
already discussed in Chapter 7; Section 7.6.1.6 (page 248), this is a significant 
limitation that needs to be addressed in future work.  These methods arrive at a single 
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figure to indicate clinically meaningful change across the whole of the scale.  Interval 
scaling is therefore required to ensure that the amount of change that is clinically 
meaningful in the middle of the scale is also meaningful at the extreme ends of the 
scale.  Further work to evaluate the MIC will be needed on an interval version of the 
ArmA following Rasch analysis. 
 
Feasibility 
Limitations are apparent in the evaluation of feasibility because of the compromise 
between normal clinical practice and the need to present the ArmA alongside a number 
of other measures in the questionnaire pack.  As already discussed in Chapter 7; section 
7.6.1.7 (page 249), feasibility evaluation in a non-experimental patient group would 
confirm the current feasibility findings.  However, the psychometric evaluation was 
undertaken, as far as was possible, in a normal clinical practice setting and provides a 
strong indication of feasibility of the ArmA scale. 
 
8.2.1.4 Cohort study 
The cohort study using the ArmA revealed that passive function change occurs as 
expected following spasticity intervention and, importantly, that this is maintained as 
the direct effects of BTX subside.  This finding corresponds with findings from other 
authors such as Bhakta and colleagues (Bhakta et al. 2000a) and Francis and colleagues 
(Francis et al. 2004).  However, the small number of data collection points limits the 
resulting model of the relationship between change in spasticity and change in passive 
function.  This finding is therefore hypothesis generating rather than confirmatory.  
Section 8.3 includes proposed further research to strengthen this finding.   
 
The use of the International Classification of Functioning, disability and health (ICF) as 
a framework in the ArmA development ensures it maps onto the ICF.  The goals of 
intervention set during the cohort study in this thesis, are presented in summary, 
classified according to the ICF in Table 8.1. 
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Table 8.1 Classification of cohort study GAS goals to World Health Organisation ICF codes. 
Domain Goal Area Chapter Sub-category 1 Sub-category 2 
Body Functions 
 Pain reduction 2 – Sensory & 
Pain 
b280 – Pain 
 
 
 Enable passive range 
of movement 
7 – Neuro- 
musculoskeletal 
b735 - Muscle Tone,  
b710 - Mobility of joints 
 
Activities  
 Balance improvement 
during walking 
4 - Mobility d450 - Walking d4500 – Walking short distances 
Related: b735 Muscle Tone, b755 Balance 
 Enable active 
exercise (exercise 
programme) 
5 - Self-Care d570 – Looking after health d5702 – Maintaining ones health 
Related: b735 Muscle Tone, b710 Mobility of joints, 
b760 Control of voluntary movement functions 
 Enable hygiene/Self 
Care 
5 - Self-Care d520 – Caring for body parts d5208 – Caring for body parts, specified 
Related: b810 Protection of skin, b820 Repair of skin 
 Enable splint 
application 
5 - Self-Care d520 – Caring for body parts d5208 – Caring for body parts, specified 
Related: b735 Muscle Tone, b710 Mobility of joints 
 Enable postural 
management  
5 - Self-Care d520 – Caring for body parts d5208 – Caring for body parts, specified 
Related: b735 Muscle Tone, b710 Mobility of joints 
Other 
 Improve cosmesis of 
arm 
 Does not fit in an ICF category 
Key: Related : Body function domains related to achievement of activity goals 
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Goals in the cohort study 
Goals set during the cohort study were in the domains of body function and activity, 
with one goal set (improving arm cosmesis) which did not fit the framework of the ICF.  
The activity goal categories broadly matched those covered by the ArmA and were in 
mobility and self care ICF chapters.  This further supports the use of the ArmA in 
groups undergoing focal spasticity management intervention. 
 
Some differences exist in the goals set in the current cohort study and those set in the 
study by Turner-Stokes and colleagues (Turner-Stokes et al. 2010).  For example, the 
ArmA does not address community and social activities.  However, both community 
and social activities are primarily participation issues rather than activity as defined by 
the ICF.  The difference between the goals in the studies also possibly reflects the 
overall high level of impairment and dependency of the patient group studied in this 
thesis, compared with the groups studied in some other trials (Brashear et al. 2002; 
Turner-Stokes et al. 2010).   
 
The ArmA has been developed to address specific issues seen in focal spasticity 
intervention where active and passive improvements may be made.  Improvements in 
passive function have particular importance for patients with more severe neurological 
disability who will usually not improve in active function, but for whom ease of care is 
particularly important. 
 
8.2.2 Strengths and challenges of the findings 
The following section will address the strengths and challenges of the findings in the 
following three areas; application of the ArmA measure; the relationship of passive 
function to active function and physical therapy contribution to functional 
improvements in focal spasticity intervention. 
 
8.2.2.1 Application of the ArmA 
Most clinicians in rehabilitation practice will be familiar with the use and application of 
outcome measures.  While in some teams outcome measurement may be infrequently 
used, current standards of practice such as codes of professional practice (Chartered 
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Society of Physiotherapy 2008) and the Royal College of Physicians – Spasticity in 
adults: management using botulinum toxin, (Royal College of Physicians et al. 2009) 
emphasise the use of outcome measures.  The Darzi review, High Care Quality for All, 
places the use of clinical outcome measures firmly in the context of current policy 
direction for health care in general (Department of Health 2008).  Outcome measures 
are therefore central to rehabilitation practice, physical therapy intervention and 
decision-making about ongoing management (Playford et al. 2009; Wissel et al. 2009).  
Measuring function in clinical practice has been emphasised as a priority in spasticity 
management and other areas of rehabilitation practice because functional improvement 
is often a main goal (Royal College of Physicians et al. 2009; Wissel et al. 2009).   
 
Sheean was one of the first authors to refer to the terms active and passive function in 
the literature and used the terms to describe the different types of improvement seen 
clinically following spasticity intervention (Sheean 2001).  In the same paper Sheean 
posed the question “why is it difficult to show a functional benefit” following BTX 
intervention for spasticity?  In suggesting possible answers to this question, he proposed 
that it may be difficult to show functional benefit because of a lack of appropriate 
measures which are sensitive to change.  The cohort study has demonstrated that it is 
possible to show passive function change following spasticity intervention using the 
ArmA.   
8.2.2.2 Relationship of passive function to active function 
The cohort study has provided further confirmation that, as expected, improvements in 
passive function do not automatically lead to improvements in active function.  Passive 
function improvements relate more directly to reduction in spasticity, which allows 
improved passive movement of the affected upper limb, making care tasks easier.  
Improvements in passive function may be further augmented by physical interventions, 
which in the case of casting and splinting maintain or increase joint range through 
mechanical extension and longer duration ‘stretch’ (Lannin and Herbert 2003).    
 
Improvements in passive function therefore occur largely because of an increase in the 
available range of movement produced through spasticity reduction and increases in 
true range of movement due to stretch following physical interventions.  The changes 
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can directly influence passive function by increasing the ease of extending the affected 
limb for care tasks.  For example, cleaning the axilla of the affected upper limb will be 
easier following injection of BTX, combined with positioning of the upper limb, 
because it is then much easier to passively abduct the arm and clean the armpit. 
 
Improvements in active function rely on the mobility of the joint or limb and the ability 
to recruit movement and muscle strength in a selective manner allowing purposeful 
activity.  If joint range of movement is lost due to muscle being in a shortened position 
for a prolonged period of time (e.g. as a result of spasticity) then movement and 
function will be inhibited.  However, to improve active function, selective control by the 
patient will also need to produce purposeful movement.   
 
Selective control will not necessarily follow improved range of movement because it 
relies on potential for recovery dependent on the extent of the initial injury and the 
plasticity of the central nervous system.  The purpose of BTX is the weakening of 
muscle.  Therefore, direct improvement in active movement and therefore function is 
not possible.  Active function in the right circumstances may be progressed and 
developed by task practice, but the ability to engage in this type of practice is needed 
(Dettmers et al. 2005; Uswatte and Taub 2005).  Active function improvement will only 
be possible if some degree of control is present or can be re-learned to allow practice 
and secondary problems such as spasticity or contracture are prevented or reversed.  
Active function improvement may be particularly relevant in BTX intervention 
provided soon after initial neurological insult in selected patients (Cousins et al. 2010; 
Hesse et al. 2011), although this requires further evaluation. 
8.2.2.3 The contribution of physical therapy to functional improvements 
In addition to Modified CIMT (MCIMT) and task practice, the PT intervention 
categories in this thesis consisted of splinting (non-circumferential and removable 
orthotics), serial casting (circumferential removable and non-removable orthotics), 
positioning of the upper limb, and functional electrical stimulation (FES).  However 
interventions, which have an initial impact on passive function, deserve further 
evaluation in the context of management of spasticity in the hemiparetic upper limb 
(Bergfeldt et al. 2006).  Of particular interest for further evaluation are splinting (Lannin 
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and Herbert 2003; Lannin et al. 2007), serial casting and passive stretch (Hill 1994; 
Moseley et al. 2008).  Trials to evaluate these interventions should include a self-report 
measure such as the ArmA to assess passive function outcome in the context of real-life.   
 
Further exploration of the combination of BTX with ‘task practice’ such as Constraint 
Induced Movement Therapy (CIMT) (Taub et al. 1993; Dettmers et al. 2005) would be 
valuable.  However, ‘task practice’ is only appropriate in the small number of 
individuals undergoing BTX intervention for management of spasticity who have 
potential for improvement in active function.  There is therefore a stronger clinical need 
to explore application of task practice intervention in the total brain injury population 
rather than confining evaluation just to those undergoing spasticity management who 
will be a small minority.  Future development of the ArmA active function sub-scale 
could involve evaluation and validation in these wider applications. 
 
8.3 Future development of the ArmA measure 
The following section focuses on developments in ArmA evaluation and its application 
in addressing some of the research questions posed.  Future research and development 
broadly fits into two areas; further evaluation of the properties of the ArmA measure 
and further evaluation of upper limb interventions using the ArmA measure.   
  
8.3.1 Further evaluation of the ArmA measure 
Future research evaluating the ArmA measure should focus on three areas; 1) 
confirming changes made to the active and passive function sub-scales, 2) further 
evaluation of the measurement properties of the active and passive sub-scales using IRT 
methods and 3) evaluation of interval scaling and longitudinal construct validity of the 
ArmA using IRT and CTT methods. 
 
1) It is necessary to consider modifications to the active and passive function sub-scales 
(for further details see Section 7.6.1.2; page 243).  Further evaluation of the passive 
function and active function sub-scales will be ongoing using data from routine practice 
in our setting resulting in enlarging the current data set and allowing initial exploration 
of the changes made (Harrow Ethics committee 04/Q0405/81).   




2) Mokken analysis, should be re-applied using the double monotonicity model once a 
larger cohort of participants has been recruited to confirm the findings of the 
preliminary evaluation of the passive function sub-scale in this thesis.  The active 
function sub-scale requires evaluation of its dimensionality and measurement scaling 
properties by applying the ArmA in a more able group of participants not undergoing 
spasticity intervention.  Undertaking evaluation in patients not undergoing spasticity 
intervention will enable this work to be completed in a timely manner, rather than the 
extremely prolonged process if evaluated in those undergoing spasticity intervention.   
 
3) Following initial analysis of ordinal scaling using the double monotonicity model, the 
interval scaling properties of the ArmA can be evaluated using the Rasch method.  
Application of Rasch analysis, if applied in longitudinal data (e.g. baseline, 8 weeks and 
16 weeks as undertaken in this thesis), will in due course allow the evaluation of 
longitudinal construct validity and identification of minimal important change in the 
active and passive sub-scales.  Using latent variable methods, evaluation of the 
consistency of the measurement properties across the three time points can also be 
undertaken using confirmatory factor analysis.   
 
8.3.2 Further evaluation of functional improvement following spasticity 
management 
Bakheit and colleagues have identified changes in passive function maintained up to 16 
weeks (Bakheit et al. 2000; Bakheit et al. 2001).   Francis and colleagues also suggested 
that in some patients, maximal passive function improvement, may occur sometime 
after maximal improvement in spasticity following BTX intervention (Francis et al. 
2004).  These issues require further evaluation in due course. 
 
Passive function 
For improvement in passive function two areas of future research have been identified:   
 Which physical therapy interventions (see Appendix 18) and dosages are most 
effective in producing and maintaining passive function improvement?   
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 For what time period is it possible to maintain these improvements with physical 
therapy intervention? 
Active function 
For active function it is important to more fully understand which patients are likely to 
achieve active function improvement following BTX intervention and what 
combination of interventions are effective in producing that change.  For patients with 
active function goals the following research areas have been identified:  
 Which patients will benefit from spasticity intervention as a contribution 
towards active function improvement? 
 Which interventions to improve task performance are most effective in 
producing maximum improvement in active functional outcome? 
  
Before undertaking, a further investigation of these areas it will be necessary to develop 
an upper limb treatment-recording schedule to record, in a systematic manner, the 
physical therapy interventions provided to patients.  Donaldson has undertaken similar 
work in an investigation of conventional physiotherapy with functional strength training 
for rehabilitation of the upper limb after stroke (Hunter et al. 2006; Donaldson 2007; 
Donaldson et al. 2009) and related work has also been undertaken by De Wit (De Wit et 
al. 2007) (also see Section 7.6.2; page 254).   
 
8.4 Conclusions 
This thesis has made three main contributions to current knowledge.   
 Firstly, the ArmA, a new measure of active and passive function, with potential 
for both clinical and research use, was developed and underwent preliminary 
psychometric testing including evaluation of ordinal scaling.   
 Secondly, the complexities of measuring active and passive function as latent 
variables have been explored with reference to psychometric methods.   
 Thirdly, further evidence was generated indicating that improvements in passive 
function occur following BTX and PT interventions by 8 weeks and that these 
are maintained at 16 weeks despite a re-increase in spasticity as measured by the 
Modified Ashworth Scale (MAS).  Further exploration of these preliminary 
findings will inform future developments in clinical practice. 




The overall hypotheses (see Chapter 1; page 59) for the thesis were accepted, as 
follows: 
1. Items have been successfully identified from literature and clinical 
practice sources leading to acceptance of hypothesis 1. 
2. Reduction of these items using Delphi and wider consultation processes 
with patients, carers and clinicians has been successfully undertaken 
resulting in a draft measure and leading to acceptance of hypothesis 2. 
3. Preliminary evidence for the passive function items, that the sub-scale 
scores form a measurement system, capable (following further 
evaluation) of providing a single summary statistic has been provided.  
However, hypothesis 3 cannot be fully accepted on the current evidence 
and requires further evaluation particularly of the active function sub-
scale. 
4. In the cohort study, the ArmA has been used to demonstrate 
improvement in passive function following treatment of upper limb 
spasticity using BTX and PT intervention leading to acceptance of 
hypothesis 4. 
  
In conclusion, the ability to measure function following focal upper limb spasticity 
intervention has been expanded following the development and preliminary testing of 
the ArmA.  The measurement properties of the ArmA now require further evaluation, 
with particular emphasis on a more complete evaluation of the active function sub-scale 
and establishing interval level scaling in both sub-scales.   
 
Further understanding of the effects of spasticity management on function has also been 
developed.  Physical interventions may both contribute to the initial achievement of 
functional goals and maintain these improvements in the longer term.  The exact 
duration and process of maintenance require further investigation.  This work has raised 
questions about the possible mechanisms of functional change, and raises new questions 
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